<SEC-DOCUMENT>0001178913-24-002671.txt : 20240819
<SEC-HEADER>0001178913-24-002671.hdr.sgml : 20240819
<ACCEPTANCE-DATETIME>20240819060143
ACCESSION NUMBER:		0001178913-24-002671
CONFORMED SUBMISSION TYPE:	6-K/A
PUBLIC DOCUMENT COUNT:		49
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240819
DATE AS OF CHANGE:		20240819

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38367
		FILM NUMBER:		241218157

	BUSINESS ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K/A
<SEQUENCE>1
<FILENAME>zk2431880.htm
<DESCRIPTION>6-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:slgl="http://www.sol-gel.co/20240630" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Sol-Gel Technologies Ltd. - 1684693 - 2024</title></head><body style="font-size:10pt;font-family:Times New Roman;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20240630" id="FFact_322">0001684693</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20240101to20240630" id="FFact_323">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20240630" id="FFact_324">true</ix:nonNumeric><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="C_20240101to20240630" id="FFact_326">2024-06-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20240101to20240630" id="Fdei_DocumentFiscalPeriodFocus20220718125411444">Q2</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="slgl-20240630.xsd"/>
        </ix:references></ix:header></div><div>
  <div>
    <div>
      <div>
        <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
        <div>
          <div>
            <div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold">
                  <p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span><span style="font-size:14pt">UNITED STATES</span></span></span>
                </div>
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>SECURITIES AND EXCHANGE COMMISSION</span></span></div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>Washington, D.C. 20549</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;font-size:14pt">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>FORM <ix:nonNumeric id="F20220718063032973_0" name="dei:DocumentType" contextRef="C_20240101to20240630">6-K/A</ix:nonNumeric></span></span></div>
              </div>
              <div style="line-height:1.25">
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>Report of Foreign Private Issuer</span></span></div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>Pursuant to Rule 13a-16 or 15d-16</span></span></div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>Under the Securities Exchange Act of 1934</span></span>
                  <p style="margin:0pt">&#160;</p>
                </div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span>For the month of August <ix:nonNumeric id="F20220718063032973_1" name="dei:DocumentFiscalYearFocus" contextRef="C_20240101to20240630">2024</ix:nonNumeric></span></span></div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold">
                  <p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span>Commission File Number 001-38367</span></span>
                </div>
              </div>
              <div style="line-height:1.25">
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="F20220718063032974_2" name="dei:EntityRegistrantName" contextRef="C_20240101to20240630">SOL-GEL TECHNOLOGIES LTD.</ix:nonNumeric></span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span>(Translation of registrant&#8217;s name into English)</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="F20220718063032974_3" name="dei:EntityAddressAddressLine1" contextRef="C_20240101to20240630">7 Golda Meir Street</ix:nonNumeric></span></span></div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="F20220718063032974_4" name="dei:EntityAddressCityOrTown" contextRef="C_20240101to20240630">Ness Ziona</ix:nonNumeric>&#160;<ix:nonNumeric id="F20220718063032975_5" name="dei:EntityAddressPostalZipCode" contextRef="C_20240101to20240630">7403650</ix:nonNumeric>, <ix:nonNumeric id="F20220718063032975_6" name="dei:EntityAddressCountry" contextRef="C_20240101to20240630" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span>(Address of principal executive offices)</span></span>
                  <p style="margin:0pt">&#160;</p>
                </div>
              </div>
              <div style="line-height:1.25">
                <div style="text-indent:24.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</span></span></div>
              </div>
              <div style="line-height:1.25">
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span>Form 20-F &#9746;</span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Times New Roman,Times,serif"><span>Form 40-F &#9744;</span></span></div>
              </div>
              <div style="line-height:1.25">
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="line-height:1.25">
                <div style="text-indent:24.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;<span></span></span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25">
                <div style="text-indent:24.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</span></span></div>
              </div>
            </div>
          </div>
          <div style="line-height:1.25">
            <div style="line-height:1.25">&#160;</div>
            <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
              <div style="page-break-after:always">
                <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
              </div>
            </div>
          </div>
          <div>
            <div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold">
                  <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Explanatory Note</span></div>
                </div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <ix:nonNumeric id="Fxbrl_20240819085853731" name="dei:AmendmentDescription" contextRef="C_20240101to20240630">
                <div>
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Sol-Gel Technologies Ltd. (the &#8220;Company&#8221;) is amending its Report on Form 6-K furnished to the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) on August 16, 2024 (the &#8220;Original Form 6-K&#8221;) solely to (i) revise Exhibit 99.1 of the Original 6-K to correct typographical errors; and</span><br/>&#160;</div>
                    </div>
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">(ii) revise the incorporation by reference language included in the Explanatory Note of the Form 6-K. Other than as set forth below, the information contained in the Original Form 6-K remains unchanged.</span></div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">The press release attached hereto as Exhibit 99.1 was reissued on August 17, 2024 to correct typographical errors.</span></div>
                    </div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">The incorporation by reference paragraph in the Original Form 6-K is hereby amended and restated as follows:</span><br/>&#160;</div>
                    <div>
                      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                          <tr style="vertical-align:top">
                            <td style="text-align:right;vertical-align:top;width:72pt">
                              <div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_99-1.htm"><span>Exhibit 99.1</span></a></span></div>
                            </td>
                            <td style="text-align:left;vertical-align:top;width:auto">
                              <div style="line-height:1.25">
                                <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_99-1.htm">Press release dated August 17, 2024 (reissued)</a></span></div>
                              </div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="line-height:1.25">
                      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%">

                          <tr style="vertical-align:top">
                            <td style="text-align:right;vertical-align:top;width:72pt">
                              <div style="text-align:left;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_99-2.htm">Exhibit 99.2</a></span></div>
                            </td>
                            <td style="text-align:left;vertical-align:top;width:auto">
                              <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_99-2.htm">Unaudited condensed consolidated financial statements as of June 30, 2024 and for the three and six months then ended.</a></span></div>
                            </td>
                          </tr>

                      </table>
                    </div>
                  </div>
                  <div style="line-height:1.25">
                    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><br/><span style="font-family:Times New Roman,Times,serif">Exhibit 99.1 (other than the paragraph immediately preceding the heading &#8220;Financial Results for the Second Quarter 2024&#8221;) and 99.2 are hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No 333-264190).</span></div>
                      </div>
                    </div>
                  </div>
                </div>
              </ix:nonNumeric>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25">
                <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                  <div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">2</span></span></div>
                  <div style="page-break-after:always">
                    <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                  </div>
                </div>
              </div>
              <div style="line-height:1.25">
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">SIGNATURES</span></div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <div style="line-height:1.25">
                <div style="text-indent:24.5pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div>
                <div style="line-height:1.25">&#160;</div>
              </div>
              <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:50%;vertical-align:top">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td colspan="2" style="vertical-align:top">
                      <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:50%;vertical-align:middle">&#160;</td>
                    <td style="width:4%;vertical-align:middle">&#160;</td>
                    <td style="width:46%;vertical-align:middle">
                      <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:1.25">&#160;</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:50%;vertical-align:top">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Date: August 19, 2024</span></div>
                    </td>
                    <td style="width:4%;vertical-align:top">
                      <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">By:</span></div>
                    </td>
                    <td style="width:46%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)"><span style="font-family:Times New Roman,Times,serif">/s/ Eyal Ben-Or</span></td>
                  </tr>
                  <tr>
                    <td style="width:50%;vertical-align:top">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:4%;vertical-align:top">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:46%;vertical-align:top">
                      <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Eyal Ben-Or</span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width:50%;vertical-align:top">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:4%;vertical-align:top">
                      <div style="line-height:1.25">&#160;</div>
                    </td>
                    <td style="width:46%;vertical-align:top">
                      <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif">Chief Financial Officer</span></div>
                    </td>
                  </tr>

              </table>
              <div style="line-height:1.25">
                <div style="line-height:1.25;text-align:center"><br/><span style="font-family:Times New Roman,Times,serif">&#160;<span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">3</span></span></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div>
      <div style="page-break-after:always;margin-top:5pt">
        <hr style="border:none;border-bottom:4px solid #000000;border-top:1px solid #000000;height:10px;width:100%;color:#000000;text-align:center;text-align:center"/>
      </div>
    </div>
  </div>
</div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<img width="329" height="67" src="image0.jpg"></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">Sol-Gel Reports Second Quarter 2024 Financial </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold; font-size: 12pt;">Results and Provides Corporate Updates</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z7d008dbe040b4ca292857a8c0cd644ac" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Following recent transactions and cost-cutting efforts, Sol-Gel&#8217;s cash runway is expected to extend into the first quarter of 2026</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdbd54ada09274dce87a60f0f768506a2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top;">
                <div>SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;">
        <div> </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4161334e09f346a6b7ed1a20879ca59d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve&#174; Cream (roflumilast cream 0.3%)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z25d9b0916a934735a0c81f455318f418" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Following management realignment, Mr. Mori Arkin, the Company&#8217;s executive chairman and controlling shareholder to be appointed as Company&#8217;s interim CEO as of January 1, 2025, subject to shareholders approval</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z7432560691a64fb5b23a351628ad6042" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">NESS ZIONA, Israel, August 17, 2024 (GLOBE NEWSWIRE) - <font style="font-weight: bold;">Sol-Gel Technologies, Ltd.</font>&#160;(NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin
          conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO&#174; and EPSOLAY&#174;, today announced financial results for the second quarter ended
          June 30, 2024, and provided a corporate update.</div>
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Q2 2024 and Recent Corporate Developments</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z815d480ec35f4996b6047b0082017fb4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 14.2pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>On August 15, 2024, Sol-Gel signed a new agreement with Padagis, which replaces the parties&#8217; prior collaborative agreement for the development and commercialization of a drug product generic to Zoryve&#174;&#160;Cream (roflumilast cream 0.3%).&#160;Under
              this new agreement,&#160;Sol-Gel&#160;is to unconditionally receive&#160;quarterly payments which will be paid over 24 months and low single digit royalties from gross profits from sales of roflumilast cream for a period of five years, in lieu of its 50%
              share in future gross profits from such sales. In addition,&#160;Sol-Gel&#160;will cease paying any outstanding and future costs related to this prior collaborative agreement. The amount to be received by Padagis together with the elimination of future
              expected expenses related to this asset is expected to enhance our cash position by approximately $6 million. Recognizing that TWYNEO and EPSOLAY have a significant commercial potential also outside the U.S., during July 2024, Sol-Gel has
              successfully signed six initial license agreements with key partners covering most European countries and South Africa. Sol-Gel expects to sign additional agreements covering the majority of Latin American countries, Australia, New Zealand,
              South Korea, Spain, Italy and Portugal. These already signed agreements together with agreements we anticipate to sign in the future, are expected to provide upfront and regulatory milestone payments of up to $3.7 million, which we expect to
              utilize on adapting TWYNEO and EPSOLAY to the regulatory requirements of these new territories. Based on the forecasts received from Sol-Gel&#8217;s current and potential partners, Sol-Gel expects that TWYNEO and EPSOLAY will launch in the majority
              of these new territories in 2027 and 2026 respectively, and following launch these transactions are anticipated to provide Sol-Gel with an annual royalty revenue stream starting with approximately $1 million to $2 million in 2026 and growing
              gradually to approximately up to $10 million for the year 2030 and further.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <table cellspacing="0" cellpadding="0" id="zaaf232acac8a49cabae1dc68cd9e167c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 14.2pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Phase 3 study in Sol-Gel&#8217;s key asset SGT-610 in approximately 140 subjects (with 100 subjects required to complete the Study), at about 42 experienced clinical centers is ongoing. To date, Sol-Gel has signed agreements with 39 centers
              in multiple countries, including the&#160;U.S.,&#160;Germany,&#160;Italy,&#160;France, and the UK, and approximately 29 of these enters have been activated. Top line results are anticipated in Q2 2026. SGT-610 is a topically applied patidegib, a hedgehog
              signaling pathway blocker 2% gel If approved, SGT-610 is expected to be the first approved product for the prevention of new BCC lesions in Gorlin syndrome patients and is targeting a market exceeding $300 million annually.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdc3850b05b42469a83a312feb667a56d">

            <tr>
              <td style="width: 14.2pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Sol-Gel&#8217;s proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease is ongoing. Darier disease is a significant unmet medical need, with a market potential estimated between $200 million to $300 million. If
                  we successfully complete this proof-of-concept study and&#160; the required pre-clinical studies, we anticipate filing for a Phase 2 IND in Q2 2025. SGT-210 is currently being used in a compassionate use treatment of a pediatric patient
                  suffering from a rare disease, and given the preliminary highly encouraging response, we are cautiously optimistic about the potential for success in other viable keratoderma indications, recognizing that further research and clinical
                  studies are necessary to validate any broader applications of our therapy.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za43b934ebf0e4645a7444ad1ed15fa03">

            <tr>
              <td style="width: 14.2pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Subject to shareholder approval, Mr. Arkin, the Company&#8217;s Executive Chairman and controlling shareholder, who has several decades of experience in leading positions in the pharmaceutical industry and in the dermatological space in
                  particular, will assume the role of interim CEO as of January 1, 2025. During his tenure as interim CEO, Mr. Arkin plans to transition away from the majority of his other business activities in order to dedicate himself to his new
                  full-time position as interim CEO of the Company. Mr. Arkin will not be entitled to any compensation for assuming this position. <font style="font-style: italic;">On July 15, 2024, Sol-Gel announced management realignment </font>whereby
                  pending shareholder approval our CEO Dr. Alon Seri-Levy will step down as CEO and Board Member, effective December 31, 2024, and will then continue to serve the Company as a consultant to our new CEO and management team for at least one
                  year.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zfd02b2bd6dca4921a5a8b6da6b7946b2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.2pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Effective July 12, 2024, Mr. Eyal Ben-Or, the Company's previous Director of Finance, assumed the role of Chief Financial Officer (CFO). Prior to his employment in Sol-Gel Mr. Ben-Or worked at Mobileye and KPMG Israel. Mr. Ben-Or, is a
                certified public accountant, holds an MBA and a BA in accounting from the College of Management in Israel. Mr. Ben-Or replaces the Company&#8217;s previous CFO, Mr. Gilad Mamlok, who will facilitate the transition through December 31, 2024.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Mr. Mori Arkin, Executive Chairman of Sol-Gel, stated: "</font>We are encouraged by Sol-Gel&#8217;s financial results for the second quarter of 2024 and our ability to extend our cash runway
        into the first quarter of 2026. We will continue to explore opportunities for non-dilutive funding to potentially further extend our runway through topline results. In our pipeline, we continue to conduct the pivotal Phase 3 clinical trial of
        SGT-610 for preventing new basal cell carcinomas in Gorlin Syndrome patients, targeting a market exceeding $300 million, with top line results anticipated in the second quarter of 2026 along with our proof-of-concept study for SGT-210 (topical
        erlotinib) in Darier disease patients targeting a market of between $200 million to $300 million. These two rare disease projects reflect the huge growth potential of a company of our size. The Sol-Gel management team and I are committed to spare
        no effort to realize this potential".</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Financial Results for the Second Quarter 2024</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Total revenue in the second quarter was&#160;$5.4 million, which primarily consisted of licensing revenue from Beimei, Galderma and Searchlight, compared to $0.6 million revenues for the same period
          in 2023.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Research and development expenses were&#8239;$2.4 million&#8239;compared to&#8239;$5.3 million&#8239;for the same period in 2023. The decrease of&#8239;$2.9 million&#8239;was primarily attributed to a decrease of $0.7 million in
          manufacturing expenses related to TWYNEO, a decrease of $0.7 million in clinical development expenses related to a generic product candidate, a decrease of $0.5 million in payroll expenses due to the adoption of cost saving measures initiated
          during the third quarter of 2023, a decrease of $0.5 million related to R&amp;D expenses, a decrease of&#8239;$0.3 million in clinical trial expenses related to SGT-610 and a decrease of $0.2 million in clinical expenses related to SGT-210.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">General and administrative expenses were&#160;$1.4 million compared to&#160;$1.8 million&#160;for the same period in 2023. The decrease of&#160;$0.4 million&#160;was mainly attributed to a decrease in professional
        expenses.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Sol-Gel&#160;reported a net income of&#160;$1.9 million&#160;for the second quarter of 2024 and earnings of&#160;$0.07&#160;per basic and diluted share, compared to a net loss of&#160;$6.0 million&#160;and a loss of&#160;$0.22&#160;per basic
        and diluted share for the same period in 2023.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">As of&#160;June 30, 2024,&#160;Sol-Gel&#160;had&#160;$15.6 million&#160;in cash, cash equivalents, and deposits and&#160;$14.9 million&#160;in marketable securities for a total balance of&#160;$30.5 million. The Company expects its cash
        resources to fund cash requirements into the first quarter of 2026.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About TWYNEO and EPSOLAY</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">TWYNEO is a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, cream for the treatment of acne vulgaris in adults and pediatric patients 9 years of age
      and older. TWYNEO is the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin. Tretinoin and benzoyl peroxide are widely prescribed separately for acne vulgaris; however, benzoyl peroxide causes degradation of
      the tretinoin molecule, thereby potentially reducing its effectiveness if used at the same time or combined in the same formulation. TWYNEO uses silica (silicon dioxide) core shell structures to separately micro-encapsulate tretinoin crystals and
      benzoyl peroxide crystals enabling inclusion of the two active ingredients in the cream.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">EPSOLAY is a topical cream containing benzoyl peroxide (BPO), 5%, for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults.&#160;EPSOLAY utilizes a proprietary, patented
      technology to encapsulate BPO within silica-based microcapsules to create a barrier between the medication and the skin. The silica-based shell is designed to slowly release BPO over time to provide a tolerable and effective treatment.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Gorlin Syndrome and SGT-610</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for prevention of BCCs in Gorlin syndrome patients, if approved. Gorlin syndrome, an autosomal dominant
      genetic disorder affecting approximately 1 in 27,000-31,000 people in the&#160;U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1) gene. Normally, the PTCH1 gene blocks the smoothened, frizzle
      class receptor (SMO) gene, turning off the hedgehog signaling pathway when it is not needed. Mutations in the PTCH1 gene may cause a loss of PTCH1 function, release of SMO, and may allow BCC tumor cells to divide uncontrollably. Patidegib, the active
      substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Darier Disease and SGT-210</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="text-align: justify; line-height: 1.25;">SGT-210 is a topical erlotinib drug candidate that is formulated for the treatment of Darier Disease and other hyperkeratosis-related indications. Erlotinib is a tyrosine kinase receptor inhibitor
        that acts on the epidermal growth factor receptor, a protein present on cell surfaces that plays a key role in promoting cell growth and division. Darier Disease is a rare, genetic keratinization disorder which is classically characterized
        scaly&#160;crusted&#160;papules&#160;in a&#160;seborrheic distribution&#160;and in skin folds.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Sol-Gel Technologies</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Sol-Gel Technologies, Ltd.&#160;is a dermatology company focused on identifying, developing and commercializing or partnering drug products to treat skin diseases.&#160;Sol-Gel&#160;developed TWYNEO which is
      approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s pipeline also includes Phase 3 clinical trial of Orphan and breakthrough drug candidate SGT-610, which is a new topical hedgehog inhibitor being developed to prevent the new basal cell
      carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment of&#160;rare hyper keratinization
      disorders.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">For additional information, please visit our new website: &#160;www.sol-gel.com</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate
      to matters of historical fact should be considered forward-looking statements, including, but not limited to the amounts to be received under our current and future licensing agreements and our agreement with Padagis with respect to the generic drug
      product to Zoryve<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;Cream (roflumilast cream, 0.3%), the out-licensing Twyneo and Epsolay in additional territories, our expected cash runway, the expected royalties amounts to be received from Galderma, the potential of Sol-Gel&#8217;s assets
      including Twyneo, Epsolay, SGT-610, and SGT-210, the timeline for advancing SGT-610 and SGT-210, and the size of SGT-610&#8217;s market.&#160; In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
      &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our
      management&#8217;s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could
      cause such differences include, but are not limited to, our ability to enter into further collaborations, lower than anticipated annual revenue income from new collaborations, a delay in the timing of our clinical trials, the success of our clinical
      trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the
      adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain
      regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory
      approval is obtained; (v) our collaborators&#8217; ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators&#8217; ability to manufacture our
      product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators&#8217; ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare
      professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to
      our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and
      personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in&#160;the United States,&#160;China, Europe&#160;or&#160;Israel; and (xv) loss or retirement of key executives and
      research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and,&#160; (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional
      conflict involving&#160;Israel&#160;with other parties. These factors and other important factors discussed in the Company's Annual Report on Form 20-F filed with the&#160;Securities and Exchange Commission&#160;(&#8220;SEC&#8221;) on March 13, 2024, and our other reports filed
      with the&#160;SEC,&#160;could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this
      press release.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Sol-Gel Contact:</div>
    <div style="line-height: 1.25;">Eyal Ben-Or</div>
    <div style="line-height: 1.25;">Chief Financial Officer</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><u>info@sol-gel.com</u></div>
    </div>
    <div style="line-height: 1.25;">+972-8-9313429</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><img width="198" height="40" src="image1.jpg"></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Source: Sol-Gel Technologies Ltd.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">CONDENSED CONSOLIDATED BALANCE SHEETS</div>
    <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share data)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">(Unaudited)</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" class="cfttable" id="z56d28d20dc5248fabffb4481746aaf53" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2023</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2024</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">A s s e t s</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">CURRENT ASSETS</font>:</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Cash and cash equivalents</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">7,513</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">11,549</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Bank deposits</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">10,012</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">4,012</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Marketable securities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">20,471</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">14,912</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Accounts receivables</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">377</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">6,059</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Prepaid expenses and other current assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">2,794</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">1,750</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL&#160; CURRENT ASSETS</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">41,167</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">38,282</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">NON-CURRENT ASSETS:</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Restricted long-term deposits and cash equivalents</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">1,284</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">1,273</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Property and equipment, net</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">434</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">305</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Operating lease right-of-use assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">1,721</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">1,507</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Other long-term assets</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">55</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">34</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Funds in respect of employee rights upon retirement</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">626</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">604</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL&#160; NON-CURRENT ASSETS</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">4,120</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">3,723</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL&#160; ASSETS</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">45,287</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">42,005</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Liabilities and shareholders' equity</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CURRENT LIABILITIES:</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Accounts payable</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">154</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">679</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Other accounts payable</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">3,921</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">4,147</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Current maturities of operating leases</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">447</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">376</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL&#160; CURRENT LIABILITIES</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">4,522</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">5,202</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">LONG-TERM LIABILITIES</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Operating leases liabilities</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">1,206</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">1,018</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Liability for employee rights upon retirement</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">915</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">883</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL&#160; LONG-TERM LIABILITIES</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">2,121</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">1,901</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL&#160; LIABILITIES</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">6,643</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">7,103</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -16.149pt; margin-left: 16.149pt; line-height: 1.25; font-weight: bold;">SHAREHOLDERS' EQUITY:</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="text-align: justify; text-indent: -7.05pt; margin-left: 22.9pt; line-height: 1.25;">Ordinary Shares, NIS 0.1 par value &#8211; authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of
              December 31, 2023 and June 30, 2024.</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">774</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">774</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Additional paid-in capital</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">258,173</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">258,799</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; text-indent: 14.2pt; line-height: 1.25;">Accumulated deficit</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(220,303</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(224,671</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -20.35pt; margin-left: 20.35pt; line-height: 1.25; font-weight: bold;">TOTAL SHAREHOLDERS' EQUITY</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">38,644</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">34,902</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
            <div style="line-height: 1.25; font-weight: bold;">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">45,287</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">42,005</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</div>
    <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share data)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">(Unaudited)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <table cellspacing="0" cellpadding="0" class="cfttable" id="zb6bdff3df18748cfb65db84d9a56aeaa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">Six months ended</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">June 30</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">Three months ended</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">June 30</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;"> 2023</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">2024</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">2023</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">2024</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">REVENUE</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">894</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">5,899</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">594</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">5,433</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">RESEARCH AND DEVELOPMENT EXPENSES</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">14,698</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">7,783</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">5,312</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">2,438</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">GENERAL AND ADMINISTRATIVE EXPENSES</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">3,786</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">3,203</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">1,809</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">1,371</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div style="text-align: justify; text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">OPERATING INCOME (LOSS)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">(17,590</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">(5,087</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">(6,527</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">1,624</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25;"><font style="font-weight: bold;">FINANCIAL INCOME, </font>net</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">899</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">719</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">557</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">352</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
            <div style="text-align: justify; text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">NET INCOME (LOSS) FOR THE PERIOD</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(16,691</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(4,368</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(5,970</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">1,976</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">BASIC AND DILUTED EARNINGS (LOSS) PER ORDINARY SHARE</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(0.63</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(0.16</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(0.22</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">0.07</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">26,306,484</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">27,857,620</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">27,660,326</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
              <div style="line-height: 1.25;">27,857,620</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25; text-align: center;"><br>
      <font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">7</font><br style="line-height: 1.25;">
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit_99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:slgl="http://www.sol-gel.co/20240630" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Sol-Gel Technologies Ltd. - 1684693 - 2024</title></head><body style="font-size:10pt;font-family:Times New Roman;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:footnote id="FN20230803170759609" xml:lang="en-US">Investments in Corporate bonds rated A or higher.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="slgl-20240630.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20240101to20240630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtTitleOfIndividualAxis_srtDirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240131_srtTitleOfIndividualAxis_srtDirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240131_srtTitleOfIndividualAxis_srtDirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtProductOrServiceAxis_usgaapLicenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtProductOrServiceAxis_usgaapLicenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_srtProductOrServiceAxis_usgaapLicenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_srtProductOrServiceAxis_usgaapLicenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_srtProductOrServiceAxis_usgaapServiceMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_srtProductOrServiceAxis_usgaapServiceMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtProductOrServiceAxis_usgaapServiceMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtProductOrServiceAxis_usgaapServiceMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20070101to20071231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2007-01-01</xbrli:startDate>
        <xbrli:endDate>2007-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20070101to20071231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2007-01-01</xbrli:startDate>
        <xbrli:endDate>2007-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211101"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-01</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230401to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="slgl:MilestonePaymentsAxis">slgl:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">slgl:PellepharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230130to20230130_slglMilestonePaymentsAxis_slglDevelopmentAndNdaAcceptanceMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="slgl:MilestonePaymentsAxis">slgl:DevelopmentAndNdaAcceptanceMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">slgl:PellepharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-30</xbrli:startDate>
        <xbrli:endDate>2023-01-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240301to20240331_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="slgl:MilestonePaymentsAxis">slgl:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">slgl:PellepharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slgl:OtherForeignGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231231_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240630_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slgl:OtherForeignGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230601to20230606_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithSearchlightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-06</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithSearchlightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithSearchlightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithBeimeiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:GeneralPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="Agreement"><xbrli:measure>slgl:Agreement</xbrli:measure></xbrli:unit>
<xbrli:unit id="Candidate"><xbrli:measure>slgl:Candidate</xbrli:measure></xbrli:unit>
<xbrli:unit id="ILSPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Program"><xbrli:measure>slgl:Program</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="FFact_257" toRefs="FN20230803170759609"/><ix:relationship fromRefs="FFact_258" toRefs="FN20230803170759609"/></ix:resources></ix:header></div><div><div><hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/><div style="text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;text-decoration:underline">Exhibit 99.2</span></span></span></div><div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></span></div><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF JUNE 30, 2024</span></span></div></div>&#160;<div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div><div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED CONDENSED</span></span></div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED FINANCIAL STATEMENTS</span></span></div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS OF JUNE 30, 2024</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TABLE OF CONTENTS</span></span></div><div style="line-height:1.25">&#160;</div><table border="0" cellpadding="2" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"><tr><td style="width:86.63%;vertical-align:top">&#160;</td><td style="width:13.37%;vertical-align:top"><div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div></td></tr><tr><td style="width:86.63%;vertical-align:top"><div style="text-indent:-14pt;margin-right:17pt;margin-left:14pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:</span></span></div></td><td style="width:13.37%;vertical-align:top">&#160;</td></tr><tr><td style="width:86.63%;vertical-align:top"><div style="text-indent:6.35pt;margin-right:17pt;margin-left:7.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_integixAnchor">Balance Sheets</a></span></span></div></td><td style="width:13.37%;vertical-align:top"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 2</span></span></div></td></tr><tr><td style="width:86.63%;vertical-align:top"><div style="text-indent:6.35pt;margin-right:17pt;margin-left:7.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS_integixAnchor">Statements of Operations</a></span></span></div></td><td style="width:13.37%;vertical-align:top"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 3</span></span></div></td></tr><tr><td style="width:86.63%;vertical-align:top"><div style="text-indent:6.35pt;margin-right:17pt;margin-left:7.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONDENSEDCONSOLIDATEDSTAT_integixAnchor">Statements of Changes in Shareholders' Equity</a></span></span></div></td><td style="width:13.37%;vertical-align:top"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 4 - F - 5</span></span></div></td></tr><tr><td style="width:86.63%;vertical-align:top"><div style="text-indent:6.35pt;margin-right:17pt;margin-left:7.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS_integixAnchor">Statements of Cash Flows</a></span></span></div></td><td style="width:13.37%;vertical-align:top"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 6</span></span></div></td></tr><tr><td style="width:86.63%;vertical-align:top"><div style="text-indent:6.35pt;margin-right:17pt;margin-left:7.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS_integixAnchor">Notes to the Financial Statements</a></span></span></div></td><td style="width:13.37%;vertical-align:top"><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 7 - F - 13</span></span></div></td></tr></table><div style="line-height:1.25"><div>&#160;</div></div><div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">_______________________________</span></span></div><div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">_____________________________________________</span></span></div><div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">_______________________________</span></span></div><div style="line-height:1.25">&#160;</div><div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The amounts are stated in U.S. dollars in thousands, except share and per share data</span></span></div><div style="line-height:1.25">&#160;</div><div style="clear:both;margin-top:10pt;margin-bottom:10pt"><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div></div></div>
  <div>
    <div>
      <div>
        <div>
          <div>
            <div>
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:center;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="CONDENSEDCONSOLIDATEDBALANCESHEETS_integixAnchor"></span>CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></div>
              <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S. dollars in thousands, except share and per share data)</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>
              <div style="line-height:1.25">&#160;</div>
            </div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A s s e t s</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">CURRENT ASSETS</span>:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,513</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank deposits</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_3" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,012</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_4" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,012</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_5" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,471</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_6" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,912</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts receivables</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812183418752" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812183423585" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,059</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses and other current assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,794</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_10" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,750</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL CURRENT ASSETS</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_11" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,167</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_12" name="us-gaap:AssetsCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,282</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT ASSETS:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted long-term deposits and cash equivalents</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_13" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,284</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_14" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_15" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">434</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_16" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">305</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_17" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,721</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_18" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,507</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other long-term assets</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731160858778_Fact_17" name="us-gaap:AccountsReceivableNetNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731160858778_Fact_18" name="us-gaap:AccountsReceivableNetNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Funds in respect of employee rights upon retirement</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_19" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_20" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">604</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL NON-CURRENT ASSETS</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_21" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,120</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_22" name="us-gaap:AssetsNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,723</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL ASSETS</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_23" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,287</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_24" name="us-gaap:Assets" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,005</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;vertical-align:bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities and shareholders' equity</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT LIABILITIES:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts payable</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_25" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_26" name="us-gaap:AccountsPayableCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">679</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other accounts payable</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_27" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,921</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_28" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,147</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current maturities of operating leases</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_29" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">447</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_30" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">376</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL CURRENT LIABILITIES</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_31" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,522</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_32" name="us-gaap:LiabilitiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,202</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LONG-TERM LIABILITIES</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating leases liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_33" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,206</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_34" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,018</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liability for employee rights upon retirement</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_35" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">915</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_36" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">883</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL LONG-TERM LIABILITIES</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_37" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,121</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_38" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,901</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL LIABILITIES</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_39" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,643</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_40" name="us-gaap:Liabilities" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,103</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:-16.149pt;margin-left:16.149pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SHAREHOLDERS' EQUITY:</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:-7.05pt;margin-left:22.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary Shares, NIS <ix:nonFraction id="Fxbrl_20220721225320013" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="ILSPerShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_42" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630" unitRef="ILSPerShare" decimals="INF" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction> par value &#8211; authorized: <ix:nonFraction id="Fxbrl_20220721225341350" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_44" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction> as of December 31, 2023 and June 30, 2024; issued and outstanding: <ix:nonFraction id="Fxbrl_20240812183220415" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20240812183204882" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220721225424766" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_46" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> as of December 31, 2023 and June 30, 2024.</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_49" name="us-gaap:CommonStockValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_50" name="us-gaap:CommonStockValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_51" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,173</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_52" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,799</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                    <div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_53" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">220,303</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_54" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">224,671</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="text-align:justify;text-indent:-20.35pt;margin-left:20.35pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL SHAREHOLDERS' EQUITY</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_55" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,644</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_56" name="us-gaap:StockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,902</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom">
                    <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_57" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,287</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_58" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,005</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></span></div>
          </div>
        </div>
        <div style="line-height:1.25;font-weight:bold">&#160;</div>
      </div>
    </div>
    <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
      <div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span><span style="font-family:Times New Roman,Times,serif"><span><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 2</span></span></span></span></span></span></span></div>
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS_integixAnchor"></span>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></span></div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S. dollars in thousands, except share and per share data)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>
          <div style="line-height:1.25">&#160;</div>
        </div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three months ended</span></span></div>
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REVENUE</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721161146624" name="us-gaap:Revenues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721161139299" name="us-gaap:Revenues" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,899</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721161133008" name="us-gaap:Revenues" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">594</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721161123723" name="us-gaap:Revenues" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,433</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RESEARCH AND DEVELOPMENT EXPENSES</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_63" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,698</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_64" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,783</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_65" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,312</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_66" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,438</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">GENERAL AND ADMINISTRATIVE EXPENSES</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_67" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,786</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_68" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,203</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_69" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,809</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_70" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,371</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
                <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OPERATING INCOME (LOSS)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_71" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">17,590</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_72" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,087</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_73" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,527</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_74" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,624</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">FINANCIAL INCOME, </span>net</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_75" name="slgl:FinancialIncomeExpensesNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">899</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_76" name="slgl:FinancialIncomeExpensesNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_77" name="slgl:FinancialIncomeExpensesNet" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">557</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_78" name="slgl:FinancialIncomeExpensesNet" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                <div style="text-align:justify;text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NET INCOME (LOSS) FOR THE PERIOD</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_79" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">16,691</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_80" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,368</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_81" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,970</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_82" name="us-gaap:NetIncomeLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,976</ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BASIC AND DILUTED EARNINGS (LOSS) PER ORDINARY SHARE</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220721234223951" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_83" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.63</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220721234245557" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_84" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.16</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220721234258686" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_85" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.22</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721234313495" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_86" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240401to20240630" unitRef="USD_per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom">
                <div style="text-indent:-14.2pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721234332813" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_87" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">26,306,484</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721234354066" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_88" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721234405451" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230401to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_89" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230401to20230630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,660,326</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721234419394" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240401to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_90" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240401to20240630" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></ix:nonFraction></span></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></span></strong></div>
        <div style="clear:both;margin-top:10pt;margin-bottom:5pt">
          <div style="text-align:center;margin-top:20pt"><span style="font-size:10pt"><span><span><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 3</span></span></span></span></span></div>
        </div>
      </div>
    </div>
    <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:center;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="CONDENSEDCONSOLIDATEDSTAT_integixAnchor"></span>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></span></div>
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S. dollars in thousands, except share and per share data)</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional</span></span></div>
                        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">paid-in</span>&#160;<span style="font-weight:bold">capital</span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-13.8pt;margin-left:13.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AS OF JANUARY 1, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203312766_Fact_121" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">23,129,469</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203312766_Fact_122" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">638</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203312766_Fact_123" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">234,640</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203312766_Fact_124" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">193,065</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203312766_Fact_125" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,213</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-16.1pt;margin-left:16.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss for the period</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203243985_Fact_126" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">16,691</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203243985_Fact_127" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">16,691</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares and warrants through public offering, net of issuance costs</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165232354" name="slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,560,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165255304" name="slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165306136" name="slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,468</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165308803" name="slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,542</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares and warrants through private placement from the controlling shareholder</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165314251" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165323696" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165338826" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,944</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165341127" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243988_Fact_131" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">116,485</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203425221" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243988_Fact_133" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">177</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243988_Fact_134" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243992_Fact_135" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,052</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243992_Fact_136" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,052</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-15.9pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AT JUNE 30, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243995_Fact_137" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,805,954</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243995_Fact_138" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">771</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243995_Fact_139" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,281</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203243995_Fact_140" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">209,756</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203243995_Fact_141" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,296</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-13.8pt;margin-left:13.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AS OF JANUARY 1, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_121" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_122" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_123" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,173</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_124" name="us-gaap:StockholdersEquity" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">220,303</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_125" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,644</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-16.1pt;margin-left:16.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss for the period</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185624392" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185621393" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731162137076_xbrl_20220802203243985_Fact_126" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,368</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731162137076_xbrl_20220802203243985_Fact_127" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,368</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185640102" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185635670" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731162201964_xbrl_20220802203243992_Fact_135" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731162201964_xbrl_20220802203243992_Fact_136" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-15.9pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AT JUNE 30, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_137" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_138" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_139" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,799</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_140" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">224,671</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_141" name="us-gaap:StockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,902</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
                <div style="text-align:center"><span style="font-size:10pt"><span><span><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F - 4</span></span></span></span></span></div>
                <div style="page-break-after:always">
                  <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
                </div>
              </div>
              <div style="line-height:1.25">
                <div>
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></span></div>
                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S. dollars in thousands, except share and per share data)</span></span></div>
                  <div style="line-height:1.25">&#160;</div>
                  <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>
                </div>
              </div>
              <div style="line-height:1.25">&#160;</div>
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional</span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">paid-in</span>&#160;<span style="font-weight:bold">capital</span></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of shares</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-13.8pt;margin-left:13.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AS OF APRIL 1, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203522391_Fact_168" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">25,702,237</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203522391_Fact_169" name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203522391_Fact_170" name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">246,678</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203522391_Fact_171" name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">203,786</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203522391_Fact_172" name="us-gaap:StockholdersEquity" contextRef="C_20230331" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,604</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-16.1pt;margin-left:16.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHANGES DURING THE THREE MONTHS ENDED JUNE 30, 2023:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss for the period</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203512165_Fact_173" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,970</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203512165_Fact_174" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,970</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares and warrants through private placement from the controlling shareholder</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165403635" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165351160" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165357152" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,944</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731165400531" name="slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163821363" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">103,717</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163828939" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163842514" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163939372" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203512178_Fact_179" name="us-gaap:ShareBasedCompensation" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">498</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203512178_Fact_180" name="us-gaap:ShareBasedCompensation" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">498</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-15.9pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AT JUNE 30, 2023</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203512181_Fact_181" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,805,954</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203512181_Fact_182" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">771</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203512181_Fact_183" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,281</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20220802203512181_Fact_184" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">209,756</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220802203512181_Fact_185" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,296</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-13.8pt;margin-left:13.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AS OF APRIL 1, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_168" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_169" name="us-gaap:StockholdersEquity" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_170" name="us-gaap:StockholdersEquity" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,524</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_171" name="us-gaap:StockholdersEquity" contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">226,647</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_172" name="us-gaap:StockholdersEquity" contextRef="C_20240331" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,651</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-16.1pt;margin-left:16.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHANGES DURING THE THREE MONTHS ENDED JUNE 30, 2024:</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income for the period</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185914982" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185910830" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163734539_xbrl_20220802203512165_Fact_173" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,976</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163734539_xbrl_20220802203512165_Fact_174" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,976</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
                      <div style="text-align:justify;text-indent:-14.45pt;margin-left:31.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185927735" name="us-gaap:ShareBasedCompensation" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812185923525" name="us-gaap:ShareBasedCompensation" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163954949_xbrl_20220802203512178_Fact_179" name="us-gaap:ShareBasedCompensation" contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163954949_xbrl_20220802203512178_Fact_180" name="us-gaap:ShareBasedCompensation" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="text-indent:-15.9pt;margin-left:15.9pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE AT JUNE 30, 2024</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_181" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">27,857,620</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_182" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">774</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_183" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,799</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_184" name="us-gaap:StockholdersEquity" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">224,671</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                      <div style="line-height:1.25">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_185" name="us-gaap:StockholdersEquity" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,902</ix:nonFraction></span></span></div>
                      </div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                  </tr>

              </table>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">* </span>less than $1 thousand.</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements</span></span></div>
            </div>
          </div>
          <div style="clear:both;margin-top:0pt;margin-bottom:10pt">
            <div style="text-align:center">&#160;</div>
            <div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">F - 5</span></span></span></span></span></div>
            <div style="page-break-after:always">
              <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div>
      <div>
        <div>
          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS_integixAnchor"></span>CONDENSED CONSOLIDATED<span style="font-weight:bold">&#160;</span>STATEMENTS OF CASH FLOWS</span></div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt">(U.S. dollars in thousands, except share and per share data)</span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:center;line-height:1.25"><span style="font-size:10pt">(Unaudited)</span></div>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt">Six months ended</span></div>
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt">June 30</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt">2023</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt">2024</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Loss for the period</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">$</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20220721165859137" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">16,691</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">$</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20220721165911882" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,368</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Adjustments required to reconcile loss to net cash used in operating activities:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt">Depreciation</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_188" name="us-gaap:Depreciation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-weight:normal"><ix:nonFraction id="Fxbrl_20240812194344420" name="us-gaap:Depreciation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt">Changes in accrued liability for employee rights upon retirement, net</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_190" name="slgl:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_191" name="slgl:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt">Share-based compensation expenses</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_192" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,052</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_193" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt">Financial expenses (income), net</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20230731170354691" name="slgl:FinanceExpensesNet" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20220721165945170" name="slgl:FinanceExpensesNet" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="text-indent:8.95pt;line-height:1.25"><span style="font-size:10pt">Net changes in operating leases</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_196" name="slgl:NetChangesInOperatingLeases" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-weight:normal">(<ix:nonFraction id="FFact_197" name="slgl:NetChangesInOperatingLeases" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:8.95pt;line-height:1.25"><span style="font-size:10pt">Changes in fair value of marketable securities</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20220721165926561" name="slgl:ChangesInFairValueOfMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20230731170401785" name="slgl:ChangesInFairValueOfMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Changes in operating asset and liabilities:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:-7.1pt;margin-left:16.05pt;line-height:1.25"><span style="font-size:10pt">Receivables from collaborative and licensing arrangements</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_200" name="us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,653</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_201" name="us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="text-indent:-7.1pt;margin-left:16.05pt;line-height:1.25"><span style="font-size:10pt">Accounts receivables</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20240812194236884_Fact_200" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20240812194236884_Fact_201" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,682</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-indent:8.95pt;line-height:1.25"><span style="font-size:10pt">Prepaid expenses and other current assets</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_202" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,063</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_203" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,065</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                <div style="text-indent:8.95pt;line-height:1.25"><span style="font-size:10pt">Accounts payable, accrued expenses and other</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721170010362" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,623</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721170023162" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">751</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Net cash used in operating activities</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_206" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,335</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_207" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,627</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Purchase of property and equipment</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_208" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_209" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Proceeds from sale of property and equipment</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20240812194936354_Fact_208" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20240812194936354_Fact_209" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Investment in marketable securities</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="FFact_210" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,114</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_211" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Proceeds from sales and maturity of marketable securities</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_212" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,995</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_213" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,646</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Short-term deposits</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20220721163559362" name="slgl:ProceedsFromShortTermDeposits" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,000</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731170423185" name="slgl:ProceedsFromShortTermDeposits" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Long-term deposits</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721163643329" name="slgl:ProceedsFromLongTermDeposits" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721163650650" name="slgl:ProceedsFromLongTermDeposits" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">821</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Net cash </span>provided&#160;by&#160;(used in)<span> investing activities</span></span></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20230731170434560" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,201</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">)</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721170501016" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,471</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Proceeds from exercise of options</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_220" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_221" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Proceeds from issuance of shares and warrants through placement from the controlling shareholder</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731170558344_Fact_220" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731170558344_Fact_221" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt">Proceeds from issuance of shares and warrants through public offering,</span></div>
                <div style="line-height:1.25"><span style="font-size:10pt">&#160; &#160; &#160;net of issuance costs</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731170600336_Fact_220" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,542</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731170600336_Fact_221" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Net cash provided by financing activities</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_224" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,722</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_225" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721165808265" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_227" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731170445409" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,187</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721165838498" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,846</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20220721180304367" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,598</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_231" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,863</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">$</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_232" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,785</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">$</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_233" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,709</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Cash and Cash equivalents</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_234" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,618</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,549</ix:nonFraction></span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Restricted cash</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_236" name="us-gaap:RestrictedCash" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,167</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_237" name="us-gaap:RestrictedCash" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,160</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_238" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,785</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_239" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,709</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25">&#160;</div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom"><span style="font-size:10pt">Recognition of new operating lease ROU and liabilities</span></td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt">$</span></td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731163016874" name="slgl:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230731163032579" name="slgl:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;vertical-align:bottom">
                <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt">SUPPLEMENTARY INFORMATION:</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25"><span style="font-size:10pt">Interest received</span></div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">$</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_240" name="us-gaap:ProceedsFromInterestReceived" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">590</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt">$</span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                <div style="line-height:1.25">
                  <div style="line-height:1.25"><span style="font-size:10pt"><ix:nonFraction id="FFact_241" name="us-gaap:ProceedsFromInterestReceived" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,121</ix:nonFraction></span></div>
                </div>
              </td>
              <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
            </tr>

        </table>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div>
        <div style="line-height:1.25">&#160;</div>
      </div>
      <div style="clear:both;margin-top:10pt;margin-bottom:5pt">
        <div style="text-align:center"><span style="font-size:10pt"><span><span><span style="font-weight:normal;font-style:normal">F - 6</span></span></span></span></div>
      </div>
    </div>
  </div>
  <div>
    <div>
      <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
        </div>
      </div>
    </div>
  </div>

  <div>
    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SOL-GEL TECHNOLOGIES LTD.</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:center;line-height:1.25"><span id="FINANCIALSTATEMENTS_integixAnchor"></span><span id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS_integixAnchor"><span id="NOTES_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></strong></span></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(U.S. dollars in thousands, except share and per share data)</span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>
  </div>
  <div style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</div>
  <div>
    <ix:nonNumeric id="Fxbrl_20230803164645178" name="us-gaap:NatureOfOperations" contextRef="C_20240101to20240630" escape="true">
      <div>
        <div>
          <div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1 - NATURE OF OPERATIONS</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo&#174;, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay&#174;, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo&#174; and Epsolay&#174; in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo&#174; is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay&#174; is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company&#8217;s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-&#8220;PellePharm&#8221;), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of <ix:nonNumeric id="Fxbrl_20230809125938262" name="slgl:DescriptionOfUpfrontPayment" contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember">$4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date.</ix:nonNumeric> In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $<ix:nonFraction id="Fxbrl_20230809125946725" name="slgl:SalesMilestonePayments" contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglDevelopmentAndNdaAcceptanceMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">6</ix:nonFraction> million, and up to $<ix:nonFraction id="Fxbrl_20230809125953294" name="slgl:SalesMilestonePayments" contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">64</ix:nonFraction> million in commercial milestones which amount increases to $<ix:nonFraction id="Fxbrl_20230809130002318" name="slgl:IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">89</ix:nonFraction> million when sales exceed $<ix:nonFraction id="Fxbrl_20240812200107085" name="us-gaap:Revenues" contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">500</ix:nonFraction> million as well as single digit royalties which increase to double digit royalties when sales exceed $<ix:nonFraction id="Fxbrl_20240812200129542" name="us-gaap:Revenues" contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">500</ix:nonFraction> million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $<ix:nonFraction id="Fxbrl_20240812200141030" name="slgl:ClinicalExpenses" contextRef="C_20240301to20240331_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction> as clinical expenses.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&amp;D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border and launched a series of attacks against Israel. Following these attacks, Israel&#8217;s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee</span></span></div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt">&#160;</div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 7</span></span></span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;margin-top:4pt;margin-bottom:10pt;height:2px;color:#000000;background-color:#000000"/></div></div><div style="text-align:center;line-height:1.25;margin-top:8pt;margin-bottom:0px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></span></strong></div><div style="text-align:center;line-height:1.25;color:#000000"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:'Times New Roman',Times,serif"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/>(U.S. dollars in thousands, except share and per share data)</span></span></span></p></div><div style="text-align:center;margin-top:0px;margin-bottom:10pt;line-height:1.25;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(Unaudited)</span></span></div>
              <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1 - NATURE OF OPERATIONS </span>(continued):</span></span></div>
              <div style="text-align:justify;line-height:1.25;margin-bottom:0pt">&#160;</div>
            </ix:exclude></div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk and Uncertainties</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since incorporation through June 30, 2024, the Company has an accumulated deficit of $<ix:nonFraction id="FFact_242" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">224,671</ix:nonFraction> and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.</span></span></div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240815124913284" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 2 &#8211; SIGNIFICANT ACCOUNTING POLICIES:<br/>&#160;</span></span></span></div>
        <ix:nonNumeric id="Fxbrl_20240815124928826" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">
          <div>
            <div style="line-height:1.25">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:18pt">&#160;</td>
                    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">Basis of Presentation</span></span></span></span></span><br/>&#160;</div>
                      <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="margin-left:36pt;line-height:1.25;text-align:justify">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:35.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.</span></span></span></span></div>
          </div>
        </ix:nonNumeric>
        <div style="line-height:1.25">&#160;</div>
        <ix:nonNumeric id="Fxbrl_20240815124937379" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20240630" escape="true">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Earnings (Loss) per share</span></span></span></span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted earnings per share, does not include <ix:nonFraction id="Fxbrl_20230809130130036" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">6,501,769</ix:nonFraction> options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted loss per share does not include <ix:nonFraction id="Fxbrl_20230809130146333" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20240101to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">6,993,858</ix:nonFraction> options and warrants for the six months ended June 30, 2024 and <ix:nonFraction id="Fxbrl_20240812132032517" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">5,961,999</ix:nonFraction> and <ix:nonFraction id="Fxbrl_20240812132039605" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230401to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,120,463</ix:nonFraction> options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.</span></span></span></span></div>
          </div>
        </ix:nonNumeric>
        <p style="margin:0pt">&#160;</p>
        <div style="line-height:1.25;font-weight:400;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
          <div><ix:exclude>
            <div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 8</span></span></span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;margin-top:4pt;margin-bottom:10pt;height:2px;color:#000000;background-color:#000000"/></div></div><div style="text-align:center;line-height:1.25;margin-top:8pt;margin-bottom:0px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></span></strong></div><div style="text-align:center;line-height:1.25;color:#000000"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:'Times New Roman',Times,serif"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/>(U.S. dollars in thousands, except share and per share data)</span></span></span></p></div><div style="text-align:center;margin-top:0px;margin-bottom:10pt;line-height:1.25;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(Unaudited)</span></span></div>
            </div>
            <div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">NOTE 2 &#8211; SIGNIFICANT ACCOUNTING POLICIES </span>(continued)<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">:</span></span></span></div>
            <div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
          </ix:exclude></div>
        </div>
        <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif">
          <div>
            <div>
              <div style="line-height:1.25">
                <ix:nonNumeric id="Fxbrl_20240815124948619" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20240630" escape="true">
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:18pt">&#160;</td>
                        <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div>
                            <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements, not yet adopted</span></span></div>&#160;<div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures&#8221;. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.</span></span></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                </ix:nonNumeric>
              </div>
            </div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20230803170227615" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3&#8201;-&#8201;MARKETABLE SECURITIES:</span></span></div>
        <div>
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company&#8217;s marketable securities for the indicated periods:</span></span></div>
            <div style="margin-left:36pt;line-height:1.25">&#160;</div>
            <ix:nonNumeric id="Fxbrl_20240813000956692" name="us-gaap:MarketableSecuritiesTextBlock" contextRef="C_20240101to20240630" escape="true">
              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 securities:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S government and agency bonds</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_251" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,583</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_252" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,612</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other foreign government bonds</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_255" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721171136582" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,974</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate bonds*</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_257" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,942</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_258" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,326</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731231159479" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,471</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731231211104" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,912</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Investments in Corporate bonds rated A or higher.</span></span></div>
              </div>
            </ix:nonNumeric>
            <div style="margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The table below sets forth a summary of the changes in the fair value of the Company&#8217;s marketable securities for the indicated periods:</span></span></div>
            <div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="margin-left:36pt">
              <ix:nonNumeric id="Fxbrl_20230801011136317" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" contextRef="C_20240101to20240630" escape="true">
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ended June 30, 2024</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_262" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,678</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_263" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,471</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_264" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,164</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_265" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale or maturity</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_266" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,807</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_267" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,646</ix:nonFraction></span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value during the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731163411098" name="us-gaap:IncreaseDecreaseInTradingSecurities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">436</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220721232906325" name="us-gaap:IncreaseDecreaseInTradingSecurities" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_270" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,471</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_271" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,912</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                  <p style="margin:0pt">&#160;</p>
                </div>
              </ix:nonNumeric>
            </div>
            <div><ix:exclude>
              <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                <div style="width:100%">
                  <div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 9</span></span></span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;margin-top:4pt;margin-bottom:10pt;height:2px;color:#000000;background-color:#000000"/></div></div><div style="text-align:center;line-height:1.25;margin-top:8pt;margin-bottom:0px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></span></strong></div><div style="text-align:center;line-height:1.25;color:#000000"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:'Times New Roman',Times,serif"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/>(U.S. dollars in thousands, except share and per share data)</span></span></span></p></div><div style="text-align:center;margin-top:0px;margin-bottom:10pt;line-height:1.25;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(Unaudited)</span></span></div>
                </div>
              </div>
              <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3&#8201;-&#8201;MARKETABLE SECURITIES </span>(continued)<span style="font-weight:bold">:</span></span></span></div>
              <div style="text-align:justify;line-height:1.25">&#160;</div>
            </ix:exclude></div>
            <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company&#8217;s debt securities had the following maturity dates:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt">
              <ix:nonNumeric id="Fxbrl_20230801011321820" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_20240101to20240630" escape="true">
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market value</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due within one year</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_273" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,912</ix:nonFraction></span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              </ix:nonNumeric>
            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates. In addition, due to the short-term nature and/or low-risk nature of the Company's cash and cash equivalents, restricted cash equivalents, accounts receivable, accounts payable and other payables , their carrying amounts approximates their fair value</span></span></div>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>

  <div>
    <ix:nonNumeric id="Fxbrl_20240815130102404" name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="C_20240101to20240630" escape="true">
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4&#8201;-&#8201; REVENUE:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-right:35.45pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company&#8217;s revenues for the indicated periods:</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
        <div style="line-height:1.25;margin-left:36pt">
          <ix:nonNumeric id="Fxbrl_20240815130132988" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_20240101to20240630" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three months ended</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124626943" name="us-gaap:Revenues" contextRef="C_20230101to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124633429" name="us-gaap:Revenues" contextRef="C_20240101to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124802214" name="us-gaap:Revenues" contextRef="C_20230401to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124816598" name="us-gaap:Revenues" contextRef="C_20240401to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">612</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of IP and license revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124725174" name="us-gaap:Revenues" contextRef="C_20230101to20230630_srtProductOrServiceAxis_usgaapLicenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124648933" name="us-gaap:Revenues" contextRef="C_20240101to20240630_srtProductOrServiceAxis_usgaapLicenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,800</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124805214" name="us-gaap:Revenues" contextRef="C_20230401to20230630_srtProductOrServiceAxis_usgaapLicenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124821702" name="us-gaap:Revenues" contextRef="C_20240401to20240630_srtProductOrServiceAxis_usgaapLicenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,800</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Support services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240815130928154_xbrl_20240812124725174" name="us-gaap:Revenues" contextRef="C_20230101to20230630_srtProductOrServiceAxis_usgaapServiceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240815130928154_xbrl_20240812124648933" name="us-gaap:Revenues" contextRef="C_20240101to20240630_srtProductOrServiceAxis_usgaapServiceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240815130928154_xbrl_20240812124805214" name="us-gaap:Revenues" contextRef="C_20230401to20230630_srtProductOrServiceAxis_usgaapServiceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240815130928154_xbrl_20240812124821702" name="us-gaap:Revenues" contextRef="C_20240401to20240630_srtProductOrServiceAxis_usgaapServiceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124719390" name="us-gaap:Revenues" contextRef="C_20230101to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124705933" name="us-gaap:Revenues" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,899</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124809576" name="us-gaap:Revenues" contextRef="C_20230401to20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">594</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20240812124826302" name="us-gaap:Revenues" contextRef="C_20240401to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,433</ix:nonFraction></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
  </div>

  <ix:nonNumeric id="FFact_281" name="slgl:CollaborationAgreementsTextBlock" contextRef="C_20240101to20240630" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 5 - COLLABORATION AGREEMENTS:<br/>&#160;</span></span></p>
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:20pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">a.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-family:Times New Roman,Times,serif">In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years <ix:nonNumeric id="Fxbrl_20220721155340132" name="slgl:RoyaltiesMaturity" contextRef="C_20070101to20071231_srtRangeAxis_srtMinimumMember">2016</ix:nonNumeric> to <ix:nonNumeric id="Fxbrl_20220721155348640" name="slgl:RoyaltiesMaturity" contextRef="C_20070101to20071231_srtRangeAxis_srtMaximumMember">2024</ix:nonNumeric>. Based on current sales, royalties are not material.</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:20pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">b.</span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">In 2016 through 2020, the Company entered into several collaboration agreements mainly with one third party (the "Partner") for the development, manufacturing and commercialization of several product candidates (including an agreement assumed by the Company in August 2018, following the transfer of an in-process research and development product candidate from a related party).</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:20pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">c.</span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">Under the agreements, the Partner is obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the products and prepare and file an abbreviated new drug application ("ANDA"), with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.</span></div>
                <div>&#160;</div>
                <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">Upon FDA approval, the Partner has exclusive rights and is required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to a share of the Partner's gross profits related to the sale of the products, as such term is defined in each of the agreements.</span></div>
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <div><ix:exclude>
          <div style="line-height:1.25">
            <div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 10</span></span></span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;margin-top:4pt;margin-bottom:10pt;height:2px;color:#000000;background-color:#000000"/></div></div><div style="text-align:center;line-height:1.25;margin-top:8pt;margin-bottom:0px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></span></strong></div><div style="text-align:center;line-height:1.25;color:#000000"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:'Times New Roman',Times,serif"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/>(U.S. dollars in thousands, except share and per share data)</span></span></span></p></div><div style="text-align:center;margin-top:0px;margin-bottom:10pt;line-height:1.25;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(Unaudited)</span></span></div>
          </div>
          <div style="text-align:justify;line-height:1.25"><span style="font-weight:bold">NOTE 5 - COLLABORATION AGREEMENTS </span>(continued):</div>
          <div style="text-align:justify;line-height:1.25">&#160;</div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These Agreements are considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company recognizes collaboration revenues when the related sales occur.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In November 2021, the Company entered into a new agreement ("New Agreement") with the Partner, to sell its rights to the Partner in relation to <ix:nonFraction id="Fxbrl_20230809130555941" name="slgl:NumberOfGenericCollaborativeAgreementsToSellRights" contextRef="C_20211101" unitRef="Agreement" scale="0" decimals="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> generic collaborative agreements between the parties in consideration of $<ix:nonFraction id="Fxbrl_20220721163242015" name="slgl:ExpectedRevenueReceivableOverTwentyFourMonths" contextRef="C_20211101" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,500</ix:nonFraction> which was paid over 24 months. Under the New Agreement, the Company has retained collaboration rights to <ix:nonFraction id="Fxbrl_20230809130607525" name="slgl:NumberOfGenericProgramsRetainedForCollaborationRights" contextRef="C_20211101" unitRef="Program" scale="0" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction> generic programs related to <ix:nonFraction id="Fxbrl_20230809130616870" name="slgl:NumberOfGenericDrugCandidates" contextRef="C_20211101" unitRef="Candidate" scale="0" decimals="0" format="ixt-sec:numwordsen">four</ix:nonFraction> generic drug candidates, and is no longer entitled to receive its share in profit as detailed above.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, the Company ceased paying any outstanding and future operational costs related to these collaborative agreements.</span></span></span></div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In August 15, 2024 the Company entered into a Termination Agreement with the Partner, For further details, see note 9.</span></span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both;margin-top:0pt;margin-bottom:0pt">&#160;</div>
  </div>

  <ix:nonNumeric id="FFact_285" name="slgl:LicenseAgreementsTextBlock" contextRef="C_20240101to20240630" escape="true">
    <div>
      <div style="margin-left:0px">
        <div>
          <div>
            <div style="text-align:justify;line-height:1.25;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span>&#160;<span style="font-weight:bold">6 - AGREEMENTS:</span></span></span></div>
            <div>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:36pt">&#160;</td>
                      <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                      <td style="vertical-align:top;text-align:justify;width:auto">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of two of the Company's most advanced investigational drug products (Twyneo&#174; and Epsolay&#174;) in the United States. The Company was entitled to amounts of up to $<ix:nonFraction id="Fxbrl_20230803181242436" name="slgl:RegulatoryApprovalMilestonePaymentsReceived" contextRef="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction> million per product in upfront payments and regulatory approval milestone payments assuming 2021 approval of each respective product. The Company is also eligible to receive tiered double-digit royalties ranging from mid-teen to high-teen percentage of net sales as well as up to $<ix:nonFraction id="Fxbrl_20230803181903246" name="slgl:SalesMilestonePayments" contextRef="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">9</ix:nonFraction> million in sales milestone payments.</span></span></div>
                        <div style="line-height:1.25">&#160;</div>
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to the agreement, the Company has an option to regain commercialization rights five years following first commercialization.</span></span></div>
                        <div style="line-height:1.25">&#160;</div>
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 14, 2022, the Company announced that Twyneo&#174; is available for purchase by consumers who obtain a prescription from their physician, See note 1. On June 2, 2022, the Company announced that Epsolay&#174; is available for purchase by consumers who obtain a prescription from their physician, See also note 1.<span style="font-weight:bold">&#160;</span>The Company recognized $<ix:nonFraction id="Fxbrl_20230803181330296" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20240812112622375" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">466</ix:nonFraction> during the six-month periods ended June 30, 2024 and 2023, respectively, as royalty revenue in respect of the license agreement for both products.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:36pt">&#160;</td>
                      <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 6, 2023, the Company and Searchlight Pharma Inc. (&#8220;Searchlight&#8221;), a private Canadian specialty pharmaceutical company, signed on an exclusive license agreements for Twyneo&#174; and Epsolay&#174; for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada, with support from the Company.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement, the Company will receive up to $<ix:nonFraction id="Fxbrl_20230803181302644" name="slgl:UpfrontPaymentsReceived" contextRef="C_20230601to20230606_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">11</ix:nonFraction> million in upfront payments and regulatory and sales milestones for both drugs, combined. In addition, the Company will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.</span></span></div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt">&#160;</div>
                <div><ix:exclude>
                  <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
                    <div style="width:100%">
                      <div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 11</span></span></span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;margin-top:4pt;margin-bottom:10pt;height:2px;color:#000000;background-color:#000000"/></div></div><div style="text-align:center;line-height:1.25;margin-top:8pt;margin-bottom:0px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></span></strong></div><div style="text-align:center;line-height:1.25;color:#000000"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:'Times New Roman',Times,serif"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/>(U.S. dollars in thousands, except share and per share data)</span></span></span></p></div><div style="text-align:center;margin-top:0px;margin-bottom:10pt;line-height:1.25;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(Unaudited)</span></span></div>
                    </div>
                  </div>
                  <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span>&#160;<span style="font-weight:bold">6 - AGREEMENTS </span>(continued):</span></span></div>
                  <div style="text-align:justify;line-height:1.25">&#160;</div>
                </ix:exclude></div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2023, the Company received $<ix:nonFraction id="Fxbrl_20230808134752021" name="slgl:UpfrontPaymentsReceived" contextRef="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction> as an upfront payment in connection with the license agreement and related support provided to Searchlight for obtaining the regulatory approval in the Canadian market. The Company is also required to support Searchlight during such period if needed based on agreed upon rates. The Company has identified two performance obligations in the license agreement as follows: (i) the license to market the products in Canada; and (ii) continuing support during the regulatory approval process.</span></span></div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six-month period ended June 30, 2024, the Company recognized a total amount of $<ix:nonFraction id="Fxbrl_20230808134758188" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> for continuing support. The remaining outstanding contract liability in respect of the support services, is, as of June 30, 2024 $<ix:nonFraction id="Fxbrl_20230808134805084" name="slgl:ContractLiability" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction> .</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:36pt">&#160;</td>
                      <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 15, 2024, the Company and Beimei, a private Chinese company, signed an agreement for the purchase and license by Beimei of certain rights in the intellectual property ("IP") related to Twyneo, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div>
                  <div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the agreement, Beimei will purchase and license from the Company the IP in these territories. The Company is also required to support Beimei to a certain extent during the period until obtaining regulatory approval. The Company may provide further support services to Beimei, if needed, based on agreed upon rates. In return, Sol-Gel is to receive payments of up to $<ix:nonFraction id="Fxbrl_20240812113218328" name="slgl:UpfrontPaymentsReceived" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction> million (including amounts contingent on achieving certain milestones) and up to $<ix:nonFraction id="Fxbrl_20240812113426144" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">5</ix:nonFraction> million as royalty payments on net sales.</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
                    </div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has identified multiple performance obligations in the agreement. Revenue from sale and license of IP is recognized at a point in time, upon transfer of control over the license and the IP to Beimei. Support services are recognized over time as the services are performed.</span></span></div>
                    </div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six-month period ended June 30, 2024, the Company recognized revenue for a total amount of $<ix:nonFraction id="Fxbrl_20240812113646895" name="slgl:EstimatedVariableConsiderationRevenue" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million. This amount does not include variable consideration that was determined to be constrained (not probable that would not result in a significant reversal). In addition, the Company recorded $<ix:nonFraction id="Fxbrl_20240812113656167" name="slgl:ContractLiability" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction> as a contract liability in respect of the support services.</span></span></div>
                    </div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In July 2024, the Company received $<ix:nonFraction id="Fxbrl_20240812113617559" name="slgl:SalesMilestonePayments" contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">2</ix:nonFraction> million as the first payment in connection with the agreement.</span></span></div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div style="clear:both;margin-top:0pt;margin-bottom:0pt"><div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span style="color:#000000;font-weight:normal;font-style:normal">F - 12</span></span></span></span></span></div><div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;margin-top:4pt;margin-bottom:10pt;height:2px;color:#000000;background-color:#000000"/></div></div><div style="text-align:center;line-height:1.25;margin-top:8pt;margin-bottom:0px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SOL-GEL TECHNOLOGIES LTD.</span></span></strong></div><div style="text-align:center;line-height:1.25;color:#000000"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:'Times New Roman',Times,serif"><strong>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/>(U.S. dollars in thousands, except share and per share data)</span></span></span></p></div><div style="text-align:center;margin-top:0px;margin-bottom:10pt;line-height:1.25;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif"><p style="margin:0pt">&#160;</p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(Unaudited)</span></span></div>

  <ix:nonNumeric id="Fxbrl_20230731205816709" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span>&#160;<span style="font-weight:bold">7 - SHARE BASED COMPENSATION:</span></span></span></p>
      <div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six months ended June 30, 2024, the Company granted <ix:nonFraction id="Fxbrl_20230803174227564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20240630_srtTitleOfIndividualAxis_srtDirectorMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">300,000</ix:nonFraction> options to Directors as follows:</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2024, the board of directors approved and recommended the Company's shareholders to approve a grant of <ix:nonFraction id="Fxbrl_20230803174236536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20240131_srtTitleOfIndividualAxis_srtDirectorMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">300,000</ix:nonFraction> options to the Company's Directors to purchase ordinary shares at an exercise price of $<ix:nonFraction id="Fxbrl_20230803174245540" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20240131_srtTitleOfIndividualAxis_srtDirectorMember" unitRef="USD_per_Share" scale="0" decimals="1" format="ixt:num-dot-decimal">1.2</ix:nonFraction> per share. The Company's shareholders approved the grant in February 28, 2024.</span></span></div>
          <div style="margin-left:35.45pt;line-height:1.25">&#160;</div>
          <div style="margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The options vest over a period of <ix:nonNumeric id="Fxbrl_20230803174304312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20240101to20240131_srtTitleOfIndividualAxis_srtDirectorMember" format="ixt-sec:duryear">3</ix:nonNumeric> years; one third of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following two years. The options expire on the tenth anniversary of their grant date.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of options granted in 2024 was $<ix:nonFraction id="Fxbrl_20240815132733772" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20240101to20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction>. The underlying data used for computing the fair value of the options are as follows:</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:36pt">
            <ix:nonNumeric id="Fxbrl_20230803174142717" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20240101to20240630" escape="true">
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value of one ordinary share</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230803174055527_xbrl_20230731204457117" name="us-gaap:SharePrice" contextRef="C_20240630" unitRef="USD_per_Share" scale="0" decimals="1" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230803174055529_xbrl_20230731204503117" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240101to20240630" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230803174055532_xbrl_20230731204509677" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20240630" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230803174055534_xbrl_20230731204516412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20240101to20240630" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:center;text-indent:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20240812212059837" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20240630" format="ixt-sec:duryear">4</ix:nonNumeric> years</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>

  <ix:nonNumeric id="FFact_318" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20240630" escape="true">
    <div>
      <div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 8 - RELATED PARTIES:<br/>&#160;</span></span></span></div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:18pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:18pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As to options granted to directors and executive officers, see note 7.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>

  <div>
    <div>
      <div>
        <div style="line-height:1.25">
          <ix:nonNumeric id="Fxbrl_20240815133358684" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20240630" escape="true">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9 <span style="font-weight:bold">&#8211;</span> SUBSEQUENT EVENT</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:38pt;line-height:1.25;font-family:'Palatino Linotype', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">In August 15, 2024, the Company entered into a </span><span>Termination Agreement </span><span style="color:rgb(0, 0, 0)">("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As </span><span>consideration </span><span style="color:rgb(0, 0, 0)">for the Agreement between the parties, the Partner will pay to the Company $<ix:nonFraction id="Fxbrl_20240815134553794" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,250</ix:nonFraction>, which will paid </span><span>in quarterly installments </span><span style="color:rgb(0, 0, 0)">during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel <ix:nonFraction id="Fxbrl_20240815134600435" name="slgl:RoyaltiesPercentage" contextRef="C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction>% royalties of the Partner&#8217;s Gross Profits for that Product.</span></span></span></div>
            </div>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;text-align:center"><span style="font-family:'Times New Roman',Times,serif;font-weight:normal;font-style:normal;color:rgb(0, 0, 0)">F - 13</span></div>
        <hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
      </div>
    </div>
  </div>
</div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "> P,# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 45EZSKFB^'=.N=7\0:OI
MFA:39QO->:GK%_:Z9I]K#&I>26XO;V6&VAC1%9V>21555+$@ FO@3XI_\%+_
M -GCP&)K+PG=:O\ %/6D9XUB\+V_V+0(W1@I-SXCU86\,D+C>89=&LM960H-
MWEQ2),?<R3AGB#B2M[#(\HQV9S4E&<L-0E*A2;V]OB9<N'PZ?1UJM-/N?,\2
M<9\*<'X;ZWQ/G^5Y+2<7*G'&XJG3Q%=)I-87"1<L7BI*^L,-1JR6]K'Z'U5O
M;ZRTVUFO=1N[6PL[:-Y;B[O;B*UM8(HU9Y)9IYW2**-$5G=W=5559F( )K^?
M?XC?\%2OCGXGDFMO FB^%OAOIC!EBGBM6\4>(?F^7=+J.KJFD@  .B0>'XGC
M<L'GG7;CXB\9?&7XH?$N_DOOB#X]\4>+)99?-$>K:M=3:?;L7+[;'24DBTK3
MX59BR6^GV5M!'D^7$M?M&1_1UXJQJA5SO,,NR2BTG*C3E+,\=';1TZ#I8-:7
M]Z..J6?V6KG\X<3_ $O^ \LE4H<-Y5G'$N(C)QAB*D(Y+E<U9VG&MBHULP:O
M;W9993NK^\M+_P!#?Q0_;T^ GP]66TT;7'^)&NJ[1)I_@QH;O38W4LOF7?B2
M9X]'%ON4KNTV;5;G+(XM3"WFC\U?BY^VO\6OBXMYI-O>1^!O"-S*2N@>&IIH
M[VYM0<Q0:QX@/E:AJ'RDBYBM5TO3;K(,VFL$3'YZ65]TY]._4<=#N_']1U-=
M59WGW>>.,'\N^?\ ]7TZ_L&0^$'"?##A7AA)YKF%-J2QN:.%9TYIW4L/AHQA
MA:,HNSIU/93KP:5JW5_SOQ3](7CSC:-7"SQM+(LJJWC/+,D53#>VIR7*X8K'
M2J3QN(C.+:J4E6I8:JGKA[61ZA:W0P!GITYZ=>#SCV'KCUKH+>YR!S^77_/^
M?IYQ:7F<<X/IGKU_VOQ_SFNEM;OH,_CD<?7G\OU[$?3XG"[Z;^3\M%IH_N_R
M^(P>-NHWEVUOZ=+_ -;^GT3\$?$;^'/BS\.-768PQ6_C'P_%=R@CY=.OM1@L
M-37EE7$FGW-RF&95!;YB!S7]!%?S??#:"XU?Q[X'TFU(%UJGB_PSIUL20H^T
M7NM6-K"<EEVCS)5SR .Y';^D&OYA\;*%.EF>25%;VU3!XJ%3O[.E7INDWU^*
MK6MTNGL[G]N?1HQ-:KDG$U%W>'I9G@JM+?E]K6PE2-:W2_)0P][:VY;[)(HH
MHK\2/Z8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORO_ &I/
M^"F'A#X77^H^!?@S9Z;\0?&UA-<V.K^(;R65O!/AV]AS$]M ]G+%<>*-1MI\
MK<165U9Z7;NGEG4[J=9[2'!_X*?_ +5>I_#7P[I_P+\!ZE+IWBKQYI,VH>,]
M6LY/+N](\$W#SV$6E6DRMYEO>>)YXKR&YGCVRV^D6=Q$A#:G%+#_ #Y1R$8&
M?3\>F!T_6OZ0\)?"/!9W@Z'$_%-.=7 UY2>5Y5S2I0Q5.G)Q^N8V<'&H\/*<
M9*AAX2@JJA[6K*5"<83_ (\\?/'[,N&,PQ'!7!-2G0S3#P@L[SUPA6J8&I6A
M&I'+\MIU(SH_6XTIPEBL74C4^KNI["C".)A.K1]Q^*/QP^*OQIU9=9^)?C;6
MO%,T1;['9W5P(-&TU7(+)I>B6:V^DZ=NPOF/:VD<LY1&N))74-7FB.".OT]O
M8_TK(BEZ<^W\N.GZU<1NX_$?TK^L\%AL)E^'I8/!8;#X/"T8\E'#X6C3P]"E
M'^6%*E&,(+K[L5KOO<_@;-,;F&;8NMF&9X[%YECL1)SKXS'8BMB\37D_M5J]
M>4ZDY=$Y2>BMHK6U%;L?S_QJ=&Q].WL:SDDSUZ?R_P :M(W8_A_A7HQEJD_^
M'_X/GUV?=>+4A:]UI^7]='_3V+:Y:,@$G&1CGZ=\\>O^>>ILKW[OS>G?J?IG
MKST[_6N$5L?3_/-7[>X,9']TX]..GM[?X^M8UJ"J*ZM?T_3].FWD70Q$Z$XZ
MMINU[^AZO:7GW1N^G//?'?\ +TKJ;2\SCYOUX/7IS_GZ=/*+.]SCG_Z_7\A_
M/V/-=OH4.H:Q?V6E:59W6HZEJ%S%:6-C90R7-W=W4[B*&"W@C5I)9I7(18T4
MLS$8&:^>QF&4(SE.T813E*4FHQ44KN4I/X4DKW;5E>^VOV.6XR565.%-2G4G
M*$(0@G*<Y2:C",(I-N3;45&*N[V6I]Y_L3^#;GQO\=?#-W]F\_2O!4=SXNU6
M61<PP/81^1HWS%E4W)UVYT^6VC!,I6VFN!&\=K-C]Y*^3?V0_P!G]O@;\.\Z
M]#"WC[Q:T&I>*)HG,PL((E?^RO#\,FU%*Z9%-++>.BGS=3N[P":>VAL_+^LJ
M_A7Q.XDP_$?%&(JX&:JY=E]*.78.K'X,0J4ZDZ^)CJTXU:]2:I27QT*=&5DW
M9?ZC>"?!V+X-X&P>'S.DZ&;YM7GG&8T)+]YA9XBG2IX;!U+I.-3#X6C1]O3?
M\+%5,1!-I791117YX?K@4444 %%%% !1110 45P?Q/\ B;X&^#7@#Q7\3_B5
MXBL/"G@?P7H]UKGB'7=2DV06EE:)NV11KNFO+Z[E,=GIVG6D<U[J5_/;V-E!
M/=7$,3_Q3?MZ_P#!;']H']I/7=:\&? C7?$'P)^!2?VII4-KH-U%IWQ"\?:;
M<ND*:EXO\26?F:CH23VL<JQ^&?"NIV=E';ZA=VNM7WB%A;2VH!_6S\?_ -O7
M]D+]F&-T^,_QX\#^&M75_+'A/3;R?Q?XW+%M@:3P7X/M]=\36MN7RAOKW3+:
MP1U<272;'V_FG\0_^#A[]B3PL[VW@GPO\;?B?<8E\J[TKPGHGAC0R4V[!+=^
M+?$NEZU&)BWR&/PY/M5',@1O+23^87]D+_@G!^U3^VM++??"+P/'8>!K25X+
M_P")_C>YG\-^ H;B*8P3V5AJAM+R]\1:C!(LBW-CX;T[5I;%TVZD;$/&S_O?
M\)_^#;+X>6NE6T_QQ_:-\8ZWKDJ))=Z9\+/#FC>&M'L9"H\RU@UCQ7'XHOM7
M17R4OGT70V=2 ;",@E@#E=6_X.7[$3SKH?[(%V]LLKK:S:M\:H8IYH1*XCEG
MMK/X8S1V\LD.QW@CN[I(92\:W$Z*)6QO^(E_4O\ HT"Q_P##UW'_ ,["OT+\
M'_\ ! C_ ()Z^&K>.+6_#WQ4^(4J$E[KQ;\3=3L)9<^9\K)X#L_!<"HOF+L"
M1+)B&(/)(3,TW>G_ ((;?\$TR"/^%%ZV/<?%_P",&1[C/C<C(]P1ZB@#X"\%
M?\'*WPPO+IX_B+^RYX]\.6(:+9>>"OB#X>\:W3JQD\[?IVNZ%X!AC:)1$8@-
M5E$Y>0.;81J9?O/X6?\ !<?_ ()X_$R[TK3;WXG>)/A;JFKRPP0VGQ3\$:SH
MMI:3SXQ'JOB30/\ A)_!^E11L=LU]?\ B*#38<%WO1%^\/D7C3_@WJ_82\1N
M9O#6J_&_X>R!-J6^@^.M)UG3MVU%\R6'QAX6\0ZB[91GQ'JT*;I9!LV")(_S
MK^/_ /P;@_$?0XIM6_9K^-^A>.X55G'@_P"*.F-X/UQ0BL1'9>*=$.KZ'JEQ
M,P"JM_H_ABWB)R]TXR5 /ZP_"/C7P=X_T2T\2^!/%GAKQIX=OXTFLM>\*:YI
MGB+1KN*5%DCDMM3TBZN[*='C975HYF!5@1P:Z:O\WC3=>_;5_P"";OQ?O[*R
MO/B;^SC\2TCC34],E7R-(\6:797<Z6TEW87"ZCX-^(/AM;H7#6%XT6NZ*TK2
M3V$_F'S*_J+_ ."&W[5'QW_:TN/VL?B%\=_'VI>,]:3Q+\-8-'L6CM]-\-^%
M].FTWQ8_]E^&/#FFQ6VDZ/9A8X$GD@MCJ&I-;Q76L7VHWP>Z< _?RBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJK?7UEIEE=ZCJ5Y:Z?I]A;37E]?WUQ%:6=E:6T;3
M7%U=W4[QP6]O!$CRS3S.D<4:L[LJJ2 "U5+4-2T_2+.?4=5O[+3-/M4,ES?:
MA=065G;1CK)/=7+QP0H.[2.JCUK^=W]M_P#X+^?#+X47^K?#S]DK0M+^,WC3
M3[C4-,U/XD>(/[0MOA9HM_:M+:G^P;:TDL=7^(#0W<;DWEE>:+X;N(%ANM+U
MO6[>XS'_ "\?M"?MD_M._M47T=U\>/C)XP\>V=O<M>6'ANYNX=)\&Z5<DOMG
MTSP9H4&F>&+*Z2.0P"^ATH7[P!8YKJ0"@#^YWXS?\%9?V /@9J<FA>*_VA_#
M'B#7XEF,NC_#.SUGXG2020%5DMKW5/!.GZSX>TR]5V"?8M4UFRN\[LPA8Y"G
MP'\0?^#C;]D[0?MEO\//A+\;OB#=P*?LMSJEIX2\#Z#>R[F "WL_B+Q!KD$)
M4!O,G\,K*"VW[.<9K^<3]E7_ ()C_MA?M?+:ZM\-/AG<Z%X#NHQ.GQ.^(DD_
MA#P-/ W"2Z/>W5K/JGB=9#N16\+:3K4,;J1=2VR@N/W7^#O_  ;:>!+;2K6Z
M^/W[1'BO6==E$4EWHOPET'2?#^C:>VQ?-M(O$/BZV\17^M+O#E+\^'?#[%&5
M38 J7< XZ\_X.8&+_P#$O_8]5(]S9^V?' R/MXV#,'PKB7=][<<8/& .:KQ?
M\',%Z)%\_P#8_M3%SO$7QLE60\'&UG^%[*/FQG*GC/?FOTC\'_\ !![_ ()R
M^&K.WMM;^&_CGXA3PI&LNH>+OBMXWL;N[9%*L\\?@+4_!-BAE8[W%M9VZA@!
M&$7*GJM2_P""'W_!,Z^@,5K^S[J.C2%9%^TZ;\8OC9+."Z@*X75_B'JMMNB(
MW1@VY0L3YJ2+A0 ?#_@+_@Y+^ .I^2GQ-_9W^+O@YW?9+)X*UWP?\0K>(%RJ
MRL=9N/AQ.4"[))5C@DD0%TC6X9%,OW;\,?\ @M5_P3K^)NHZ=HZ_&Z3P#JNI
MG;#;_$[PCXF\(:=;R;68QZCXIFTZ[\&:8 %/[^^\1P6A;:BW!=T5OEKQO_P;
MJ?L:Z]+>7/@WXA?'7P')<9:WLE\0>%?$^CV#;0%6&#5_"4>L30;AO=+K7IYF
M+.%N(U*!/RZ^/_\ P;O?M0> 8]4U?X%^/_ _QUT6TAEN;71+U'^&WCZZ">8_
MV*VTW5[W5?"5U<*@2..>3QGIWVR3<5L[4E(6 /['/"GC;P;X\TN'7/ _BWPS
MXRT6X1)(-8\*:]I7B+2YXY5WQR0ZAI%W>6DJ2+\R,DS*Z\J2.:Z:O\S"TU']
MIG]C/XHRK:77Q8_9U^+&CQ(MS"C^(/ GB)]/DG+)'=VY^Q_VQH-[-:DB*XCO
MM%U'R3E;A$./U#^"_P#P6S_X*&:_??#?X+W7Q%\%:G>^*/B/X)T!OB7JWPZ\
M.S^/X],UCQ/IFGSZ0TL=J/!DUG<6UP]I/J%WX&OO$(@D>:'5EOECN5 /[C**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH _CW_:W\?W?Q'_:6^,_B>[NC=QMX[UK1--D$GFQ)HWA:X/AK1X[=EPGV<:=
MI-NT90 .6:5BTDCNWS_')V/^??\ ^M46NM=)K^MB^+_;!J^I"[\P@R?:A>S_
M &CS",AG,V_>0<;LD&J\<F<<^F#Z?_6]#_3I_I3E&'I8#+,NP-"RHX+ X3"T
MU%6C[+#T*=&#BK[<L%U?G?<_QKXBQ5;-L[SC-,3S/$9CFF/QU=S;<_;8K%5:
M\U)OJI5&E>VUK6-F.3&/3U]O3Z>_;Z5H12_Y_I_@?_KUAQR=C_GWZ?I5Q)",
M>GK[>G^>E>U"?W?EY/\ K3T/F:E*U]/5=_EW7]:FXK=Q^(JU&X(YZ?R__73K
M'0];O+.74H=.N1IENC23ZI<*+32X(T^^T^I79@L8HT_B:2X4)QN([?77[/W[
M$WQ8_:)T2Q\7^"M1\&_\(3>75Y9?\)8GB33-7TN&\T^<V][9N-%N;V::Y@E7
M:T5JD^,H[M'')'(W!F?$.2Y'AI8K.,TP67X>$N1U,37A#WW%R5.,;N<ZDHQ;
MA3A&4Y6M&+/3R;A#B3B?%PP/#^1YEFV*J0=2-+!X6I4M24HPE4J5+*E3H1E.
M"E6J3C3AS+FDD]?DU7['IV-:6GV-_J5REGIUE=7]U*0([:S@DN)W)( VQQ([
MGD@=,9(YK]U?AE_P2E^'6B-#>?$WQEJ_BV=!&QTK1(UT;31,O+F6[E$]U<P,
M>%@%O;%=N7FF#%!]0^#+C]DCX'_$BW^#'AO3O"'A#QS]@L+R"YO+2-I[F]U2
M0K:Z,WB?4/->+7;F(V]W;Z2;FW\VWO;=;&-GE\@?AW&'TGO#[A6G05/$+%3Q
MF-H9;@<1F&)HY'EV*S'$J;PV"HXG'N->OBJSIS5&A2PLIUE":IN5D?OO#/T2
MN-<R]A7XKS3*>$<%5G&#HSJQS3,W*3]V$:&&JPP49S2DXJ>8<\=$Z3=XK\:_
M@[^P+^T+\2Y+:[O?#Z^ M E596U7Q>9+"8Q-M91;Z4J2:E.TJ,6C(MUB7!$T
MD1*JW[.?LZ?L;_#7]G](M7A5_%OCMH52;Q5JT$0^PLRD31Z#8C?'IL;YV-.7
MFO)$7'GQ(\D1^O**_#.,?%SB[C&G5PF(KTLLRNK=3R[+(SHPK0_DQ6(G.>(Q
M$7]JFYPH2W=&ZN?UYX>> ' 'AW6HYAA,+B,ZSRC9T\WSJ<,15P]16_>8+"4X
M4\'A)IZPK1I3Q4-5'$6;"BBBOR\_;@HHHH **** "BBB@ HHHH _E-_X../V
MF-9@U3X/?LG>']7N[31[G0S\8?B/86S&.WUAKC5M0\/^ -/OI4&Z>+39]#\3
MZO)ISOY'VB?1=0FA>:WL)8/P(_8D^ ]I^TW^U?\  OX&:G))'HGCWQS:6WB5
MH)I+>X/A/1;.\\3>+([6XB_>07DOAO1=4BM)4*M'<O$P=,;U_1__ (.#;&_M
M/V_8KB\21;?5/@;\.+[2B[,5DL(]2\7Z9(\(/"QC5-.U*,JOR^:DK?>9J_+#
M]F#XX:I^S9^T'\(?CKI%O+>W'PS\;Z/XCN].@DCAFU?1(Y3:>)-$CFE5HX6U
MOP]=:II(F=2(OMGF?PT ?Z6O@[P=X6^'OA7P_P"!_!&@Z9X7\(^%=*L]#\.^
M'M&M8[+2]'TFPB6"TL;*VB 2.&&-0.[NQ:21GD=F/25X-^SK^TM\&?VJ?AQI
M?Q/^"GC32_%OA^^@M/[2L[>Y@&O>%-5N;2.[D\.^+M&662[T'7K-9-L]E>*H
ME"_:;*6ZLI(;F7WF@ HHHH **** /E3]L']C[X0_MI?"+6?A7\5=%MY)VMKN
M?P7XTM[2W?Q/\/O$DL:"V\0>'+Z5#) WFP6\>J:?O%EK6GK)IVH1R02#9^07
M_!!OX->,_P!GGQ;^WA\%?B#9_8_%OPY^)WP_\.:IL5A;7R6VF^+9--UK3RWS
M2:5KVES66MZ3,V&FTV_M96"LY4?T45YYX<^%7@/PGX]^(?Q-\/Z&NG^-/BJO
MA5?'FKI>ZA*NNGP7ID^C>')'L)KJ33K.:QTVXDM7FL+6UEO%$;7K7$D4;J >
MAT444 %%(2 "20  22>  .223P !U-?S"_\ !3'_ (+F?\(;J>O_  )_8LU3
M3=1U^Q>^T;QG\=S;P:II6DW?E-;7.E_#*WN!)9:GJEC<-+'<^+KZWN](MYX-
MNA6VI,Z:K:@'[J_M)_MJ?LR?LD:,^J_'?XK^'O"-Z]JMWIOA*%YM<\=ZY'+*
M8+<Z-X-T:.]U^[@FN!Y)U%[*'2+3#SZAJ%G:PSW$7X%?'G_@Y&L;>[FTO]FO
MX RZC:HKJOC#XP:R;$RRAF53:^"O"DMQ(;<J%E2YO/%\$[AC')ID!7>?YB9;
MCXE_'+XCVXNKKQ9\3_BE\1O$-AIT$M]=ZAXE\6^+?$FL7$&G:=:?:+N6YO\
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M(G5XGA\%BZB9O#OAC8%O8%36M?-Q=7%EIFA_IU_P<%?MK:I\// OAC]C_P
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M33X=)\,>!/"N@>$/#^F6ZA8;'1O#FE6NDZ=:QX R(;2TB0N1ND8%W)9B3U]
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M>YE::ZGL]-:YMKWP[?S3.]P]_P"&M0TF:XN6,FH"^C:6"0 _T8J*_FV^"/\
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M?UU_81_X(0?&CXSW^C?$#]JJ+5/@C\*H[F.Z/@:1$A^+/C.T2,2+ ;*02P^
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M]VX?_A&OVC?A%JY!_=C7/#OC+P[N7>@RYL8/$VP^67;:HD&]53=AS(G]@]%
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M1_Q#>_LF?]%M_:)_\&'PU_\ G=U_0_10!_/!_P 0WO[)G_1;?VB?_!A\-?\
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M<Q^&_A7K/B)P-P\U()=3\9^%U)V9"2O" &P6A(&#][?##_@WI_8C\'PV\GQ
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M:B^D:I]B\!VEY_9VI+;&ROOLEU;77V::7[/<0R[)%_?VB@!  H"J     !@
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M.;;E.3<I2;W;;NVPHHHKT"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !@ =8# 2(  A$! Q$!_\0
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MJ&H:9I?B31/",-[=.#-/_9'AG2[19&(M;2VA"1( 26W_  6V_P""9=S,D/\
MPT?+;F1T17N?@_\ '2*'<YVC?*/AHZ1(#C?)*4C0'<[J@9E^JOA9^W7^QO\
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MJ%GK6A:[I,MW;7EK%J_A_7M-TW6M+DN;2ZMEOK"#[1;7$'F0O_&#\/O^"_\
M_P %!O!D<B>)-5^$/Q:+QK&LWC_X:0Z9+"RMEIXO^%6:Q\-8?.<?*1-#-
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MYGV;R)?(V?:)MW[R?\.(_P#@G!_T2WQG_P"'8^('_P NZ_-[_@V7_P";V/\
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MM?AOXSTR75/"_A_[5--+=W']@:WI'C&UL%FV6^F^'9- T/3DCLM*BAB^5_\
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MBBBO7)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>slgl-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:slgl="http://www.sol-gel.co/20240630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" targetNamespace="http://www.sol-gel.co/20240630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <import namespace="http://fasb.org/us-gaap-ebp/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.sol-gel.co/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" id="CondensedConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>0007 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/MarketableSecurities" id="MarketableSecurities">
        <link:definition>0009 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/REVENUE" id="REVENUE">
        <link:definition>0010 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CollaborationAgreements" id="CollaborationAgreements">
        <link:definition>0011 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/LicenseAgreements" id="LicenseAgreements">
        <link:definition>0012 - Disclosure - AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/ShareCapital" id="ShareCapital">
        <link:definition>0013 - Disclosure - SHARE BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/RelatedParties" id="RelatedParties">
        <link:definition>0014 - Disclosure - RELATED PARTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0015 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
        <link:definition>0017 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/REVENUETables" id="REVENUETables">
        <link:definition>0018 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>0019 - Disclosure - SHARE BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/NatureOfOperationsDetails" id="NatureOfOperationsDetails">
        <link:definition>0020 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails" id="SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" id="MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails">
        <link:definition>0022 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" id="MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails">
        <link:definition>0023 - Disclosure - MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" id="MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails">
        <link:definition>0024 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/REVENUEDetails" id="REVENUEDetails">
        <link:definition>0025 - Disclosure - REVENUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/CollaborationAgreementsDetails" id="CollaborationAgreementsDetails">
        <link:definition>0026 - Disclosure - COLLABORATION AGREEMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/LicenseAgreementsDetails" id="LicenseAgreementsDetails">
        <link:definition>0027 - Disclosure - AGREEMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>0028 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" id="ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails">
        <link:definition>0029 - Disclosure - SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails" id="SUBSEQUENTEVENTNarrativeDetails">
        <link:definition>0030 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="slgl-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="slgl-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="slgl-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="slgl-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AdditionalRevenueContingentOnAchievingCertainMilestones" id="slgl_AdditionalRevenueContingentOnAchievingCertainMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateOfferingPrice" id="slgl_AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AgreementSigningAmount" id="slgl_AgreementSigningAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AssetPurchaseAgreementMember" id="slgl_AssetPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" id="slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows" id="slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" id="slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ChangesInFairValueOfMarketableSecurities" id="slgl_ChangesInFairValueOfMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ClinicalExpenses" id="slgl_ClinicalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CollaborationAgreementsAbstract" id="slgl_CollaborationAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborationAgreementsTextBlock" id="slgl_CollaborationAgreementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollabrationsMember" id="slgl_CollabrationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommercialMilestonesMember" id="slgl_CommercialMilestonesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContractLiability" id="slgl_ContractLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DescriptionOfUpfrontPayment" id="slgl_DescriptionOfUpfrontPayment" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DevelopmentAndNdaAcceptanceMilestonesMember" id="slgl_DevelopmentAndNdaAcceptanceMilestonesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DocumentAndEntityInformation" id="slgl_DocumentAndEntityInformation" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesAndExecutiveOfficersMember" id="slgl_EmployeesAndExecutiveOfficersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesMember" id="slgl_EmployeesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EpsolayMember" id="slgl_EpsolayMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedVariableConsiderationRevenue" id="slgl_EstimatedVariableConsiderationRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ExpectedRevenueReceivableOverTwentyFourMonths" id="slgl_ExpectedRevenueReceivableOverTwentyFourMonths" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FinanceExpensesNet" id="slgl_FinanceExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FinancialIncomeExpensesNet" id="slgl_FinancialIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseInOperatingLeaseRouAssetsAndLiabilities" id="slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" id="slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IntellectualPropertyRelatedToTwyneoMember" id="slgl_IntellectualPropertyRelatedToTwyneoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InvestorWarrantsMember" id="slgl_InvestorWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesAndWarrantsThroughPrivatePlacement" id="slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" id="slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" id="slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares" id="slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" id="slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" id="slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="JefferiesLlcMember" id="slgl_JefferiesLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementsAbstract" id="slgl_LicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementsTextBlock" id="slgl_LicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementsWithBeimeiMember" id="slgl_LicenseAgreementsWithBeimeiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementsWithGaldermaMember" id="slgl_LicenseAgreementsWithGaldermaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementsWithSearchlightMember" id="slgl_LicenseAgreementsWithSearchlightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LongTermDeposits" id="slgl_LongTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MilestonePaymentsAxis" id="slgl_MilestonePaymentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MilestonePaymentsDomain" id="slgl_MilestonePaymentsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetChangesInOperatingLeases" id="slgl_NetChangesInOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NumberOfApprovedGenericDrugProducts" id="slgl_NumberOfApprovedGenericDrugProducts" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfEqualQuarterlyInstalments" id="slgl_NumberOfEqualQuarterlyInstalments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfGenericCollaborativeAgreementsToSellRights" id="slgl_NumberOfGenericCollaborativeAgreementsToSellRights" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfGenericDrugCandidates" id="slgl_NumberOfGenericDrugCandidates" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfGenericProgramsRetainedForCollaborationRights" id="slgl_NumberOfGenericProgramsRetainedForCollaborationRights" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfUnapprovedGenericPrograms" id="slgl_NumberOfUnapprovedGenericPrograms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherForeignGovernmentBondsMember" id="slgl_OtherForeignGovernmentBondsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OutstandingPrincipalAmount" id="slgl_OutstandingPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaidUpfrontAmount" id="slgl_PaidUpfrontAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentReceivableInInstalments" id="slgl_PaymentReceivableInInstalments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PellepharmMember" id="slgl_PellepharmMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfGrossProceedsFromSaleOfShares" id="slgl_PercentageOfGrossProceedsFromSaleOfShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfGrossProfitsRelatedToSaleProducts" id="slgl_PercentageOfGrossProfitsRelatedToSaleProducts" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromLongTermDeposits" id="slgl_ProceedsFromLongTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromShortTermDeposits" id="slgl_ProceedsFromShortTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProductAndService" id="slgl_ProductAndService" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseAgreementAxis" id="slgl_PurchaseAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="PurchaseAgreementDomain" id="slgl_PurchaseAgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PurchaseAgreementWithArmisticeCapitalMember" id="slgl_PurchaseAgreementWithArmisticeCapitalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReceiveFromThirdPartyUpfrontPayment" id="slgl_ReceiveFromThirdPartyUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" id="slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RefundableUpfrontPayment" id="slgl_RefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RefundUpFrontPayment" id="slgl_RefundUpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RefundUpfrontPayment" id="slgl_RefundUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RegulatoryApprovalMilestonePaymentsReceived" id="slgl_RegulatoryApprovalMilestonePaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltiesCompanyIsEligibleToReceive" id="slgl_RoyaltiesCompanyIsEligibleToReceive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltiesMaturity" id="slgl_RoyaltiesMaturity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltiesPercentage" id="slgl_RoyaltiesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfAssetsAndLicenseRevenue" id="slgl_SaleOfAssetsAndLicenseRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SalesMilestonePayments" id="slgl_SalesMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ShortTermDeposits" id="slgl_ShortTermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SubscriptionAgreementMArkinDermatologyLtdMember" id="slgl_SubscriptionAgreementMArkinDermatologyLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows" id="slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwyneoAndEpsolayMember" id="slgl_TwyneoAndEpsolayMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwyneoMember" id="slgl_TwyneoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwrittenPublicOfferingMember" id="slgl_UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UpfrontPaymentReceived" id="slgl_UpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="UpfrontPaymentsReceived" id="slgl_UpfrontPaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>slgl-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_Liabilities_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_15" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_17" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_19" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_19" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14" xlink:to="loc_us-gaap_StockholdersEquity_24" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24" xlink:to="loc_us-gaap_CommonStockValue_24" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_24" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_slgl_FinancialIncomeExpensesNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_Revenues_4" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinanceExpensesNet" xlink:label="loc_slgl_FinanceExpensesNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_slgl_ChangesInFairValueOfMarketableSecurities_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NetChangesInOperatingLeases" xlink:label="loc_slgl_NetChangesInOperatingLeases_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_16"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromShortTermDeposits" xlink:label="loc_slgl_ProceedsFromShortTermDeposits_17"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_18"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ShortTermDeposits" xlink:label="loc_slgl_ShortTermDeposits_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_25"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProfitLoss_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_slgl_FinanceExpensesNet_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_slgl_ChangesInFairValueOfMarketableSecurities_10" order="90" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_slgl_NetChangesInOperatingLeases_11" order="100" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_14" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_15" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_16" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_slgl_ProceedsFromShortTermDeposits_17" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_slgl_ProceedsFromLongTermDeposits_18" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13" xlink:to="loc_slgl_ShortTermDeposits_19" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_25" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>slgl-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#NatureOfOperationsDetails" roleURI="http://www.sol-gel.co/role/NatureOfOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" roleURI="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CollaborationAgreementsDetails" roleURI="http://www.sol-gel.co/role/CollaborationAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#LicenseAgreementsDetails" roleURI="http://www.sol-gel.co/role/LicenseAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" roleURI="http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#REVENUEDetails" roleURI="http://www.sol-gel.co/role/REVENUEDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Revenues_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_FinancialIncomeExpensesNet_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_11"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_12"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_13"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_17" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/NatureOfOperationsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PellepharmMember" xlink:label="loc_slgl_PellepharmMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AssetPurchaseAgreementMember" xlink:label="loc_slgl_AssetPurchaseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsAxis" xlink:label="loc_slgl_MilestonePaymentsAxis_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsDomain" xlink:label="loc_slgl_MilestonePaymentsDomain_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DevelopmentAndNdaAcceptanceMilestonesMember" xlink:label="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CommercialMilestonesMember" xlink:label="loc_slgl_CommercialMilestonesMember_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsDomain" xlink:label="loc_slgl_MilestonePaymentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaidUpfrontAmount" xlink:label="loc_slgl_PaidUpfrontAmount_15"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OutstandingPrincipalAmount" xlink:label="loc_slgl_OutstandingPrincipalAmount_16"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_17"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DescriptionOfUpfrontPayment" xlink:label="loc_slgl_DescriptionOfUpfrontPayment_18"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" xlink:label="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_21"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ClinicalExpenses" xlink:label="loc_slgl_ClinicalExpenses_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1" xlink:to="loc_slgl_PellepharmMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_slgl_AssetPurchaseAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_slgl_MilestonePaymentsAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_slgl_MilestonePaymentsAxis_9" xlink:to="loc_slgl_MilestonePaymentsDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_slgl_MilestonePaymentsDomain_9" xlink:to="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_slgl_MilestonePaymentsDomain_9" xlink:to="loc_slgl_CommercialMilestonesMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_slgl_MilestonePaymentsAxis_9" xlink:to="loc_slgl_MilestonePaymentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_PaidUpfrontAmount_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_OutstandingPrincipalAmount_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_SalesMilestonePayments_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_DescriptionOfUpfrontPayment_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_Revenues_21" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_ClinicalExpenses_22" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_2"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OtherForeignGovernmentBondsMember" xlink:label="loc_slgl_OtherForeignGovernmentBondsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_InvestmentTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_slgl_OtherForeignGovernmentBondsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_MarketableSecuritiesAbstract_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_9" order="0" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CollaborationAgreementsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesMaturity" xlink:label="loc_slgl_RoyaltiesMaturity_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericCollaborativeAgreementsToSellRights" xlink:label="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericProgramsRetainedForCollaborationRights" xlink:label="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericDrugCandidates" xlink:label="loc_slgl_NumberOfGenericDrugCandidates_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ExpectedRevenueReceivableOverTwentyFourMonths" xlink:label="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_11"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfApprovedGenericDrugProducts" xlink:label="loc_slgl_NumberOfApprovedGenericDrugProducts_12"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfUnapprovedGenericPrograms" xlink:label="loc_slgl_NumberOfUnapprovedGenericPrograms_13"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentReceived" xlink:label="loc_slgl_UpfrontPaymentReceived_14"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaymentReceivableInInstalments" xlink:label="loc_slgl_PaymentReceivableInInstalments_15"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfEqualQuarterlyInstalments" xlink:label="loc_slgl_NumberOfEqualQuarterlyInstalments_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_RoyaltiesMaturity_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_NumberOfGenericDrugCandidates_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_NumberOfApprovedGenericDrugProducts_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_NumberOfUnapprovedGenericPrograms_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_UpfrontPaymentReceived_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_PaymentReceivableInInstalments_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_slgl_NumberOfEqualQuarterlyInstalments_16" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/LicenseAgreementsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoMember" xlink:label="loc_slgl_TwyneoMember_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EpsolayMember" xlink:label="loc_slgl_EpsolayMember_2"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoAndEpsolayMember" xlink:label="loc_slgl_TwyneoAndEpsolayMember_3"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IntellectualPropertyRelatedToTwyneoMember" xlink:label="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithGaldermaMember" xlink:label="loc_slgl_LicenseAgreementsWithGaldermaMember_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithSearchlightMember" xlink:label="loc_slgl_LicenseAgreementsWithSearchlightMember_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithBeimeiMember" xlink:label="loc_slgl_LicenseAgreementsWithBeimeiMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RegulatoryApprovalMilestonePaymentsReceived" xlink:label="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_15"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_16"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentsReceived" xlink:label="loc_slgl_UpfrontPaymentsReceived_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ContractLiability" xlink:label="loc_slgl_ContractLiability_19"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AdditionalRevenueContingentOnAchievingCertainMilestones" xlink:label="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_20"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EstimatedVariableConsiderationRevenue" xlink:label="loc_slgl_EstimatedVariableConsiderationRevenue_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_srt_ProductOrServiceAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_TwyneoMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_EpsolayMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_TwyneoAndEpsolayMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8" xlink:to="loc_slgl_LicenseAgreementsWithGaldermaMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8" xlink:to="loc_slgl_LicenseAgreementsWithSearchlightMember_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8" xlink:to="loc_slgl_LicenseAgreementsWithBeimeiMember_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_SalesMilestonePayments_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_UpfrontPaymentsReceived_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_ContractLiability_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xlink:to="loc_slgl_EstimatedVariableConsiderationRevenue_21" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_DirectorMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/REVENUEDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_ProductOrServiceAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_us-gaap_RoyaltyMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_us-gaap_LicenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_us-gaap_ServiceMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Revenues_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralPartnerMember" xlink:label="loc_us-gaap_GeneralPartnerMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesPercentage" xlink:label="loc_slgl_RoyaltiesPercentage_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_5" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_5" xlink:to="loc_us-gaap_GeneralPartnerMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_5" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_slgl_RoyaltiesPercentage_11" order="20" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>slgl-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_15"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AdditionalRevenueContingentOnAchievingCertainMilestones" xlink:label="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_16"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AdditionalRevenueContingentOnAchievingCertainMilestones" xlink:label="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_17"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AdditionalRevenueContingentOnAchievingCertainMilestones" xlink:label="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_18"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AggregateOfferingPrice" xlink:label="loc_slgl_AggregateOfferingPrice_19"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AggregateOfferingPrice" xlink:label="loc_slgl_AggregateOfferingPrice_20"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AggregateOfferingPrice" xlink:label="loc_slgl_AggregateOfferingPrice_21"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AgreementSigningAmount" xlink:label="loc_slgl_AgreementSigningAmount_22"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AgreementSigningAmount" xlink:label="loc_slgl_AgreementSigningAmount_23"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AgreementSigningAmount" xlink:label="loc_slgl_AgreementSigningAmount_24"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AssetPurchaseAgreementMember" xlink:label="loc_slgl_AssetPurchaseAgreementMember_25"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AssetPurchaseAgreementMember" xlink:label="loc_slgl_AssetPurchaseAgreementMember_26"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_27"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_28"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_29"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows" xlink:label="loc_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_30"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows" xlink:label="loc_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_31"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_32"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_33"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_34"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_slgl_ChangesInFairValueOfMarketableSecurities_35"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_slgl_ChangesInFairValueOfMarketableSecurities_36"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_slgl_ChangesInFairValueOfMarketableSecurities_37"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_slgl_ChangesInFairValueOfMarketableSecurities_38"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ClinicalExpenses" xlink:label="loc_slgl_ClinicalExpenses_39"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ClinicalExpenses" xlink:label="loc_slgl_ClinicalExpenses_40"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ClinicalExpenses" xlink:label="loc_slgl_ClinicalExpenses_41"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollaborationAgreementsAbstract" xlink:label="loc_slgl_CollaborationAgreementsAbstract_42"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollaborationAgreementsTextBlock" xlink:label="loc_slgl_CollaborationAgreementsTextBlock_43"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollaborationAgreementsTextBlock" xlink:label="loc_slgl_CollaborationAgreementsTextBlock_44"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollaborationAgreementsTextBlock" xlink:label="loc_slgl_CollaborationAgreementsTextBlock_45"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollabrationsMember" xlink:label="loc_slgl_CollabrationsMember_46"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollabrationsMember" xlink:label="loc_slgl_CollabrationsMember_47"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollabrationsMember" xlink:label="loc_slgl_CollabrationsMember_48"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CommercialMilestonesMember" xlink:label="loc_slgl_CommercialMilestonesMember_49"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CommercialMilestonesMember" xlink:label="loc_slgl_CommercialMilestonesMember_50"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ContractLiability" xlink:label="loc_slgl_ContractLiability_51"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ContractLiability" xlink:label="loc_slgl_ContractLiability_52"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ContractLiability" xlink:label="loc_slgl_ContractLiability_53"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DescriptionOfUpfrontPayment" xlink:label="loc_slgl_DescriptionOfUpfrontPayment_54"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DescriptionOfUpfrontPayment" xlink:label="loc_slgl_DescriptionOfUpfrontPayment_55"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DescriptionOfUpfrontPayment" xlink:label="loc_slgl_DescriptionOfUpfrontPayment_56"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DevelopmentAndNdaAcceptanceMilestonesMember" xlink:label="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_57"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DevelopmentAndNdaAcceptanceMilestonesMember" xlink:label="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_58"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DocumentAndEntityInformation" xlink:label="loc_slgl_DocumentAndEntityInformation_59"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EmployeesAndExecutiveOfficersMember" xlink:label="loc_slgl_EmployeesAndExecutiveOfficersMember_60"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EmployeesAndExecutiveOfficersMember" xlink:label="loc_slgl_EmployeesAndExecutiveOfficersMember_61"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EmployeesAndExecutiveOfficersMember" xlink:label="loc_slgl_EmployeesAndExecutiveOfficersMember_62"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EmployeesAndExecutiveOfficersMember" xlink:label="loc_slgl_EmployeesAndExecutiveOfficersMember_63"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EmployeesMember" xlink:label="loc_slgl_EmployeesMember_64"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EmployeesMember" xlink:label="loc_slgl_EmployeesMember_65"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EpsolayMember" xlink:label="loc_slgl_EpsolayMember_66"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EpsolayMember" xlink:label="loc_slgl_EpsolayMember_67"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EstimatedVariableConsiderationRevenue" xlink:label="loc_slgl_EstimatedVariableConsiderationRevenue_68"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EstimatedVariableConsiderationRevenue" xlink:label="loc_slgl_EstimatedVariableConsiderationRevenue_69"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EstimatedVariableConsiderationRevenue" xlink:label="loc_slgl_EstimatedVariableConsiderationRevenue_70"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ExpectedRevenueReceivableOverTwentyFourMonths" xlink:label="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_71"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ExpectedRevenueReceivableOverTwentyFourMonths" xlink:label="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_72"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ExpectedRevenueReceivableOverTwentyFourMonths" xlink:label="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_73"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinanceExpensesNet" xlink:label="loc_slgl_FinanceExpensesNet_74"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinanceExpensesNet" xlink:label="loc_slgl_FinanceExpensesNet_75"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinanceExpensesNet" xlink:label="loc_slgl_FinanceExpensesNet_76"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_77"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_78"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_79"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_80"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:label="loc_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_81"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:label="loc_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_82"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" xlink:label="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_83"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" xlink:label="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_84"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" xlink:label="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_85"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IntellectualPropertyRelatedToTwyneoMember" xlink:label="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_86"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IntellectualPropertyRelatedToTwyneoMember" xlink:label="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_87"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_InvestorWarrantsMember" xlink:label="loc_slgl_InvestorWarrantsMember_88"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_InvestorWarrantsMember" xlink:label="loc_slgl_InvestorWarrantsMember_89"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_90"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_91"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_92"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_93"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_94"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_95"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_96"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_97"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_98"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_99"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_100"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_101"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_102"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_103"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_104"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_105"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_106"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_107"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_JefferiesLlcMember" xlink:label="loc_slgl_JefferiesLlcMember_108"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_JefferiesLlcMember" xlink:label="loc_slgl_JefferiesLlcMember_109"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsAbstract" xlink:label="loc_slgl_LicenseAgreementsAbstract_110"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsTextBlock" xlink:label="loc_slgl_LicenseAgreementsTextBlock_111"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsTextBlock" xlink:label="loc_slgl_LicenseAgreementsTextBlock_112"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsTextBlock" xlink:label="loc_slgl_LicenseAgreementsTextBlock_113"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithBeimeiMember" xlink:label="loc_slgl_LicenseAgreementsWithBeimeiMember_114"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithBeimeiMember" xlink:label="loc_slgl_LicenseAgreementsWithBeimeiMember_115"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithGaldermaMember" xlink:label="loc_slgl_LicenseAgreementsWithGaldermaMember_116"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithGaldermaMember" xlink:label="loc_slgl_LicenseAgreementsWithGaldermaMember_117"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithSearchlightMember" xlink:label="loc_slgl_LicenseAgreementsWithSearchlightMember_118"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithSearchlightMember" xlink:label="loc_slgl_LicenseAgreementsWithSearchlightMember_119"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LongTermDeposits" xlink:label="loc_slgl_LongTermDeposits_120"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LongTermDeposits" xlink:label="loc_slgl_LongTermDeposits_121"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LongTermDeposits" xlink:label="loc_slgl_LongTermDeposits_122"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsAxis" xlink:label="loc_slgl_MilestonePaymentsAxis_123"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsAxis" xlink:label="loc_slgl_MilestonePaymentsAxis_124"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsDomain" xlink:label="loc_slgl_MilestonePaymentsDomain_125"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsDomain" xlink:label="loc_slgl_MilestonePaymentsDomain_126"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NetChangesInOperatingLeases" xlink:label="loc_slgl_NetChangesInOperatingLeases_127"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NetChangesInOperatingLeases" xlink:label="loc_slgl_NetChangesInOperatingLeases_128"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NetChangesInOperatingLeases" xlink:label="loc_slgl_NetChangesInOperatingLeases_129"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfApprovedGenericDrugProducts" xlink:label="loc_slgl_NumberOfApprovedGenericDrugProducts_130"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfApprovedGenericDrugProducts" xlink:label="loc_slgl_NumberOfApprovedGenericDrugProducts_131"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfApprovedGenericDrugProducts" xlink:label="loc_slgl_NumberOfApprovedGenericDrugProducts_132"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfEqualQuarterlyInstalments" xlink:label="loc_slgl_NumberOfEqualQuarterlyInstalments_133"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfEqualQuarterlyInstalments" xlink:label="loc_slgl_NumberOfEqualQuarterlyInstalments_134"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfEqualQuarterlyInstalments" xlink:label="loc_slgl_NumberOfEqualQuarterlyInstalments_135"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericCollaborativeAgreementsToSellRights" xlink:label="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_136"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericCollaborativeAgreementsToSellRights" xlink:label="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_137"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericCollaborativeAgreementsToSellRights" xlink:label="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_138"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericDrugCandidates" xlink:label="loc_slgl_NumberOfGenericDrugCandidates_139"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericDrugCandidates" xlink:label="loc_slgl_NumberOfGenericDrugCandidates_140"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericDrugCandidates" xlink:label="loc_slgl_NumberOfGenericDrugCandidates_141"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericProgramsRetainedForCollaborationRights" xlink:label="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_142"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericProgramsRetainedForCollaborationRights" xlink:label="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_143"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericProgramsRetainedForCollaborationRights" xlink:label="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_144"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfUnapprovedGenericPrograms" xlink:label="loc_slgl_NumberOfUnapprovedGenericPrograms_145"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfUnapprovedGenericPrograms" xlink:label="loc_slgl_NumberOfUnapprovedGenericPrograms_146"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfUnapprovedGenericPrograms" xlink:label="loc_slgl_NumberOfUnapprovedGenericPrograms_147"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OtherForeignGovernmentBondsMember" xlink:label="loc_slgl_OtherForeignGovernmentBondsMember_148"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OtherForeignGovernmentBondsMember" xlink:label="loc_slgl_OtherForeignGovernmentBondsMember_149"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OutstandingPrincipalAmount" xlink:label="loc_slgl_OutstandingPrincipalAmount_150"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OutstandingPrincipalAmount" xlink:label="loc_slgl_OutstandingPrincipalAmount_151"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OutstandingPrincipalAmount" xlink:label="loc_slgl_OutstandingPrincipalAmount_152"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaidUpfrontAmount" xlink:label="loc_slgl_PaidUpfrontAmount_153"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaidUpfrontAmount" xlink:label="loc_slgl_PaidUpfrontAmount_154"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaidUpfrontAmount" xlink:label="loc_slgl_PaidUpfrontAmount_155"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaymentReceivableInInstalments" xlink:label="loc_slgl_PaymentReceivableInInstalments_156"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaymentReceivableInInstalments" xlink:label="loc_slgl_PaymentReceivableInInstalments_157"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaymentReceivableInInstalments" xlink:label="loc_slgl_PaymentReceivableInInstalments_158"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PellepharmMember" xlink:label="loc_slgl_PellepharmMember_159"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PellepharmMember" xlink:label="loc_slgl_PellepharmMember_160"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PellepharmMember" xlink:label="loc_slgl_PellepharmMember_161"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PercentageOfGrossProceedsFromSaleOfShares" xlink:label="loc_slgl_PercentageOfGrossProceedsFromSaleOfShares_162"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PercentageOfGrossProceedsFromSaleOfShares" xlink:label="loc_slgl_PercentageOfGrossProceedsFromSaleOfShares_163"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PercentageOfGrossProceedsFromSaleOfShares" xlink:label="loc_slgl_PercentageOfGrossProceedsFromSaleOfShares_164"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:label="loc_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_165"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:label="loc_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_166"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_167"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_168"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_169"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_170"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_171"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromShortTermDeposits" xlink:label="loc_slgl_ProceedsFromShortTermDeposits_172"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromShortTermDeposits" xlink:label="loc_slgl_ProceedsFromShortTermDeposits_173"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromShortTermDeposits" xlink:label="loc_slgl_ProceedsFromShortTermDeposits_174"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromShortTermDeposits" xlink:label="loc_slgl_ProceedsFromShortTermDeposits_175"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProductAndService" xlink:label="loc_slgl_ProductAndService_176"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProductAndService" xlink:label="loc_slgl_ProductAndService_177"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PurchaseAgreementAxis" xlink:label="loc_slgl_PurchaseAgreementAxis_178"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PurchaseAgreementDomain" xlink:label="loc_slgl_PurchaseAgreementDomain_179"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PurchaseAgreementWithArmisticeCapitalMember" xlink:label="loc_slgl_PurchaseAgreementWithArmisticeCapitalMember_180"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PurchaseAgreementWithArmisticeCapitalMember" xlink:label="loc_slgl_PurchaseAgreementWithArmisticeCapitalMember_181"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ReceiveFromThirdPartyUpfrontPayment" xlink:label="loc_slgl_ReceiveFromThirdPartyUpfrontPayment_182"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ReceiveFromThirdPartyUpfrontPayment" xlink:label="loc_slgl_ReceiveFromThirdPartyUpfrontPayment_183"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_184"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_185"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_186"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RefundableUpfrontPayment" xlink:label="loc_slgl_RefundableUpfrontPayment_187"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RefundableUpfrontPayment" xlink:label="loc_slgl_RefundableUpfrontPayment_188"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RefundableUpfrontPayment" xlink:label="loc_slgl_RefundableUpfrontPayment_189"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RefundUpFrontPayment" xlink:label="loc_slgl_RefundUpFrontPayment_190"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RefundUpFrontPayment" xlink:label="loc_slgl_RefundUpFrontPayment_191"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RefundUpFrontPayment" xlink:label="loc_slgl_RefundUpFrontPayment_192"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RegulatoryApprovalMilestonePaymentsReceived" xlink:label="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_193"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RegulatoryApprovalMilestonePaymentsReceived" xlink:label="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_194"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RegulatoryApprovalMilestonePaymentsReceived" xlink:label="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_195"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesCompanyIsEligibleToReceive" xlink:label="loc_slgl_RoyaltiesCompanyIsEligibleToReceive_196"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesCompanyIsEligibleToReceive" xlink:label="loc_slgl_RoyaltiesCompanyIsEligibleToReceive_197"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesMaturity" xlink:label="loc_slgl_RoyaltiesMaturity_198"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesMaturity" xlink:label="loc_slgl_RoyaltiesMaturity_199"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesMaturity" xlink:label="loc_slgl_RoyaltiesMaturity_200"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesPercentage" xlink:label="loc_slgl_RoyaltiesPercentage_201"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesPercentage" xlink:label="loc_slgl_RoyaltiesPercentage_202"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesPercentage" xlink:label="loc_slgl_RoyaltiesPercentage_203"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SaleOfAssetsAndLicenseRevenue" xlink:label="loc_slgl_SaleOfAssetsAndLicenseRevenue_204"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SaleOfAssetsAndLicenseRevenue" xlink:label="loc_slgl_SaleOfAssetsAndLicenseRevenue_205"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SaleOfAssetsAndLicenseRevenue" xlink:label="loc_slgl_SaleOfAssetsAndLicenseRevenue_206"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_207"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_208"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_209"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ShortTermDeposits" xlink:label="loc_slgl_ShortTermDeposits_210"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ShortTermDeposits" xlink:label="loc_slgl_ShortTermDeposits_211"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ShortTermDeposits" xlink:label="loc_slgl_ShortTermDeposits_212"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SubscriptionAgreementMArkinDermatologyLtdMember" xlink:label="loc_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_213"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SubscriptionAgreementMArkinDermatologyLtdMember" xlink:label="loc_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_214"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows" xlink:label="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_215"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows" xlink:label="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_216"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows" xlink:label="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_217"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows" xlink:label="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_218"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoAndEpsolayMember" xlink:label="loc_slgl_TwyneoAndEpsolayMember_219"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoAndEpsolayMember" xlink:label="loc_slgl_TwyneoAndEpsolayMember_220"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoMember" xlink:label="loc_slgl_TwyneoMember_221"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoMember" xlink:label="loc_slgl_TwyneoMember_222"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UnderwrittenPublicOfferingMember" xlink:label="loc_slgl_UnderwrittenPublicOfferingMember_223"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UnderwrittenPublicOfferingMember" xlink:label="loc_slgl_UnderwrittenPublicOfferingMember_224"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentReceived" xlink:label="loc_slgl_UpfrontPaymentReceived_225"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentReceived" xlink:label="loc_slgl_UpfrontPaymentReceived_226"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentReceived" xlink:label="loc_slgl_UpfrontPaymentReceived_227"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentsReceived" xlink:label="loc_slgl_UpfrontPaymentsReceived_228"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentsReceived" xlink:label="loc_slgl_UpfrontPaymentsReceived_229"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentsReceived" xlink:label="loc_slgl_UpfrontPaymentsReceived_230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralPartnerMember" xlink:label="loc_us-gaap_GeneralPartnerMember_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralPartnerMember" xlink:label="loc_us-gaap_GeneralPartnerMember_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTradingSecurities" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTradingSecurities" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTradingSecurities" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTradingSecurities" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_497"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_0" xml:lang="en-US">Additional Revenue Contingent On Achieving Certain Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_1" xml:lang="en-US">Represents the amount of additional revenue contingent on achieving certain milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_2" xml:lang="en-US">Additional revenue contingent on achieving certain milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_AggregateOfferingPrice_0" xml:lang="en-US">Represents the amount of aggregate offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_AggregateOfferingPrice_1" xml:lang="en-US">Aggregate Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_AggregateOfferingPrice_2" xml:lang="en-US">Aggregate offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_AgreementSigningAmount_0" xml:lang="en-US">Represents the amount of agreement signing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_AgreementSigningAmount_1" xml:lang="en-US">Agreement Signing Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_AgreementSigningAmount_2" xml:lang="en-US">Agreement signing amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_AssetPurchaseAgreementMember_0" xml:lang="en-US">The member stands for Asset Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_AssetPurchaseAgreementMember_1" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_0" xml:lang="en-US">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in two fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_1" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_2" xml:lang="en-US">Between 1-2 years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_0" xml:lang="en-US">Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_1" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash Shown In Statement Of Cash Flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_0" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_1" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_2" xml:lang="en-US">Changes In Accrued Liability For Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ChangesInFairValueOfMarketableSecurities_0" xml:lang="en-US">Cash inflow from changes in fair value of marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_slgl_ChangesInFairValueOfMarketableSecurities_1" xml:lang="en-US">Changes in fair value of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ChangesInFairValueOfMarketableSecurities_2" xml:lang="en-US">Changes In Fair Value Of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_ChangesInFairValueOfMarketableSecurities_3" xml:lang="en-US">Change in fair value during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ClinicalExpenses_0" xml:lang="en-US">Clinical Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ClinicalExpenses_1" xml:lang="en-US">The amount of clinical expenses during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_ClinicalExpenses_2" xml:lang="en-US">Clinical expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_CollaborationAgreementsAbstract_0" xml:lang="en-US">Collaboration Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_CollaborationAgreementsTextBlock_0" xml:lang="en-US">Collaboration Agreements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_CollaborationAgreementsTextBlock_1" xml:lang="en-US">The entire disclosure of collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_CollaborationAgreementsTextBlock_2" xml:lang="en-US">COLLABORATION AGREEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_CollabrationsMember_0" xml:lang="en-US">This member stands for collabrations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_CollabrationsMember_1" xml:lang="en-US">Collabrations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_CollabrationsMember_2" xml:lang="en-US">COLLABORATION REVENUES [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_CommercialMilestonesMember_0" xml:lang="en-US">Commercial Milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_CommercialMilestonesMember_1" xml:lang="en-US">Commercial Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ContractLiability_0" xml:lang="en-US">Information about contract liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ContractLiability_1" xml:lang="en-US">Contract Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_ContractLiability_2" xml:lang="en-US">Contract liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_DescriptionOfUpfrontPayment_0" xml:lang="en-US">Description of upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_DescriptionOfUpfrontPayment_1" xml:lang="en-US">Description Of Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_DescriptionOfUpfrontPayment_2" xml:lang="en-US">Description of upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_0" xml:lang="en-US">Development And Nda Acceptance Milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_1" xml:lang="en-US">Development And Nda Acceptance Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_DocumentAndEntityInformation_0" xml:lang="en-US">Document And Entity Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_EmployeesAndExecutiveOfficersMember_0" xml:lang="en-US">Employees And Executive Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_EmployeesAndExecutiveOfficersMember_1" xml:lang="en-US">Employees And Executive Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_EmployeesAndExecutiveOfficersMember_2" xml:lang="en-US">Employees and Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_EmployeesAndExecutiveOfficersMember_3" xml:lang="en-US">Employees And Executive Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_EmployeesMember_0" xml:lang="en-US">Employees Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_EmployeesMember_1" xml:lang="en-US">Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_EpsolayMember_0" xml:lang="en-US">Epsolay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_EpsolayMember_1" xml:lang="en-US">Epsolay [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_EstimatedVariableConsiderationRevenue_0" xml:lang="en-US">Estimated Variable Consideration Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_EstimatedVariableConsiderationRevenue_1" xml:lang="en-US">Represents the amount of revenue that is estimated variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_EstimatedVariableConsiderationRevenue_2" xml:lang="en-US">Estimated variable consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_0" xml:lang="en-US">Represents the value of expected revenue receivable over twenty four months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_1" xml:lang="en-US">Expected Revenue Receivable Over Twenty Four Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_2" xml:lang="en-US">Expected revenue receivable over twenty four months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_FinanceExpensesNet_0" xml:lang="en-US">Finance expenses, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_FinanceExpensesNet_1" xml:lang="en-US">Finance Expenses Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_FinanceExpensesNet_2" xml:lang="en-US">Financial expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_FinancialIncomeExpensesNet_0" xml:lang="en-US">Financial expenses (income), net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_slgl_FinancialIncomeExpensesNet_1" xml:lang="en-US">FINANCIAL INCOME, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_FinancialIncomeExpensesNet_2" xml:lang="en-US">Financial Income Expenses Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_FinancialIncomeExpensesNet_3" xml:lang="en-US">FINANCIAL INCOME, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_0" xml:lang="en-US">Increase in Operating lease ROU assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_1" xml:lang="en-US">Increase in Operating lease ROU assets and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_0" xml:lang="en-US">Represents the Increase in Sales Milestone amount due to sales exceed dollar 500 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_1" xml:lang="en-US">Increase In Sales Milestone Amount Due To Sales Exceed Dollar 500 Million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_2" xml:lang="en-US">Increase in sales milestone amount due to sales exceed dollar 500 million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IntellectualPropertyRelatedToTwyneoMember_0" xml:lang="en-US">Intellectual Property Related To Twyneo [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IntellectualPropertyRelatedToTwyneoMember_1" xml:lang="en-US">This member stands for Intellectual Property Related To Twyneo.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_InvestorWarrantsMember_0" xml:lang="en-US">This member stands for Investor Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_InvestorWarrantsMember_1" xml:lang="en-US">Investor Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_0" xml:lang="en-US">Issuance of shares and warrants throught private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_1" xml:lang="en-US">Issuance Of Shares And Warrants Through Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_2" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_0" xml:lang="en-US">Represents amount of issuance of shares and warrants through private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_1" xml:lang="en-US">Issuance Of Shares And Warrants Through Private Placement From Controlling Shareholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_2" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_0" xml:lang="en-US">Represents amount of issuance of shares and warrants through private placement, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_1" xml:lang="en-US">Issuance Of Shares And Warrants Through Private Placement From Controlling Shareholder Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_2" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_0" xml:lang="en-US">Number of issuance of shares and warrants throught private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_1" xml:lang="en-US">Issuance Of Shares And Warrants Through Private Placement Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_2" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_0" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_1" xml:lang="en-US">Issuance Of Shares And Warrants Through Public Offering Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_0" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_JefferiesLlcMember_0" xml:lang="en-US">Jefferies Llc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_JefferiesLlcMember_1" xml:lang="en-US">Jefferies Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_LicenseAgreementsAbstract_0" xml:lang="en-US">License Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_LicenseAgreementsTextBlock_0" xml:lang="en-US">The entire disclosure for license agreements information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_LicenseAgreementsTextBlock_1" xml:lang="en-US">License Agreements Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_LicenseAgreementsTextBlock_2" xml:lang="en-US">AGREEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_LicenseAgreementsWithBeimeiMember_0" xml:lang="en-US">License Agreements With Beimei [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_LicenseAgreementsWithBeimeiMember_1" xml:lang="en-US">This member stands for License Agreements with Beimei.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_LicenseAgreementsWithGaldermaMember_0" xml:lang="en-US">License Agreements With Galderma</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_LicenseAgreementsWithGaldermaMember_1" xml:lang="en-US">License Agreements With Galderma [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_LicenseAgreementsWithSearchlightMember_0" xml:lang="en-US">This member stands for License Agreements with Searchlight.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_LicenseAgreementsWithSearchlightMember_1" xml:lang="en-US">License Agreements With Searchlight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_LongTermDeposits_0" xml:lang="en-US">Long-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_slgl_LongTermDeposits_1" xml:lang="en-US">Long-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_LongTermDeposits_2" xml:lang="en-US">Long Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_MilestonePaymentsAxis_0" xml:lang="en-US">Milestone Payments Axis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_MilestonePaymentsAxis_1" xml:lang="en-US">Milestone Payments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_MilestonePaymentsDomain_0" xml:lang="en-US">Milestone Payments domain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_MilestonePaymentsDomain_1" xml:lang="en-US">Milestone Payments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NetChangesInOperatingLeases_0" xml:lang="en-US">Net changes in operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_slgl_NetChangesInOperatingLeases_1" xml:lang="en-US">Net changes in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NetChangesInOperatingLeases_2" xml:lang="en-US">Net Changes In Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NumberOfApprovedGenericDrugProducts_0" xml:lang="en-US">Represents the number of approved generic drug products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NumberOfApprovedGenericDrugProducts_1" xml:lang="en-US">Number Of Approved Generic Drug Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_NumberOfApprovedGenericDrugProducts_2" xml:lang="en-US">Number of approved generic drug products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NumberOfEqualQuarterlyInstalments_0" xml:lang="en-US">Represents the number of equal quarterly instalments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NumberOfEqualQuarterlyInstalments_1" xml:lang="en-US">Number Of Equal Quarterly Instalments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_NumberOfEqualQuarterlyInstalments_2" xml:lang="en-US">Number of equal quarterly instalments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_0" xml:lang="en-US">Number of generic collaborative agreements to sell the rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_1" xml:lang="en-US">Number Of Generic Collaborative Agreements To Sell Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_2" xml:lang="en-US">Number of generic collaborative agreements to sell rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NumberOfGenericDrugCandidates_0" xml:lang="en-US">Number of generic drug candidates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NumberOfGenericDrugCandidates_1" xml:lang="en-US">Number Of Generic Drug Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_NumberOfGenericDrugCandidates_2" xml:lang="en-US">Number of generic drug candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_0" xml:lang="en-US">Number of generic programs retained for collaboration rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_1" xml:lang="en-US">Number Of Generic Programs Retained For Collaboration Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_2" xml:lang="en-US">Number of generic programs retained for collaboration rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_NumberOfUnapprovedGenericPrograms_0" xml:lang="en-US">Represents the number of unapproved generic programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_NumberOfUnapprovedGenericPrograms_1" xml:lang="en-US">Number Of Unapproved Generic Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_NumberOfUnapprovedGenericPrograms_2" xml:lang="en-US">Number of unapproved generic programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_OtherForeignGovernmentBondsMember_0" xml:lang="en-US">Other foreign government bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_OtherForeignGovernmentBondsMember_1" xml:lang="en-US">Other foreign government bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_OutstandingPrincipalAmount_0" xml:lang="en-US">Represents the amount of outstanding principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_OutstandingPrincipalAmount_1" xml:lang="en-US">Outstanding Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_OutstandingPrincipalAmount_2" xml:lang="en-US">Outstanding principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_PaidUpfrontAmount_0" xml:lang="en-US">Represent amount of upfront payment done.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PaidUpfrontAmount_1" xml:lang="en-US">Paid Upfront Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_PaidUpfrontAmount_2" xml:lang="en-US">Upfront payment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_PaymentReceivableInInstalments_0" xml:lang="en-US">Represents the value of payment receivable in instalments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PaymentReceivableInInstalments_1" xml:lang="en-US">Payment Receivable In Instalments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_PaymentReceivableInInstalments_2" xml:lang="en-US">Payment receivable in instalments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_PellepharmMember_0" xml:lang="en-US">The member stands for Pellepharm.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PellepharmMember_1" xml:lang="en-US">Pellepharm [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_PellepharmMember_2" xml:lang="en-US">PellePharm, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_PercentageOfGrossProceedsFromSaleOfShares_0" xml:lang="en-US">Represents the of Percentage of gross proceeds from sale of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PercentageOfGrossProceedsFromSaleOfShares_1" xml:lang="en-US">Percentage Of Gross Proceeds From Sale Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_PercentageOfGrossProceedsFromSaleOfShares_2" xml:lang="en-US">Percentage of gross proceeds from sale of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_0" xml:lang="en-US">Percentage of gross profits related to sale products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_1" xml:lang="en-US">Percentage of gross profits related to sale products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ProceedsFromLongTermDeposits_0" xml:lang="en-US">Represents the amount of proceeds from long-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ProceedsFromLongTermDeposits_1" xml:lang="en-US">Proceeds From Long Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_ProceedsFromLongTermDeposits_2" xml:lang="en-US">Proceeds from long-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_ProceedsFromLongTermDeposits_3" xml:lang="en-US">Restricted long-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_slgl_ProceedsFromLongTermDeposits_4" xml:lang="en-US">Long-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ProceedsFromShortTermDeposits_0" xml:lang="en-US">Represents the amount of proceeds from short term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ProceedsFromShortTermDeposits_1" xml:lang="en-US">Proceeds From Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_ProceedsFromShortTermDeposits_2" xml:lang="en-US">Proceeds from short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_ProceedsFromShortTermDeposits_3" xml:lang="en-US">Short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ProductAndService_0" xml:lang="en-US">Information by product and service, or group of similar products and similar services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ProductAndService_1" xml:lang="en-US">Product And Service</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PurchaseAgreementAxis_0" xml:lang="en-US">Purchase Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PurchaseAgreementDomain_0" xml:lang="en-US">Purchase Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_PurchaseAgreementWithArmisticeCapitalMember_0" xml:lang="en-US">This member stands for Purchase Agreement with Armistice Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_PurchaseAgreementWithArmisticeCapitalMember_1" xml:lang="en-US">Purchase Agreement With Armistice Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ReceiveFromThirdPartyUpfrontPayment_0" xml:lang="en-US">Receive from third party upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ReceiveFromThirdPartyUpfrontPayment_1" xml:lang="en-US">Receive from third party upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_0" xml:lang="en-US">The amount represents recognition ofoperating lease right of use assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_1" xml:lang="en-US">Recognition Of Operating Lease Right Of Use Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_2" xml:lang="en-US">Recognition of new operating lease ROU and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RefundableUpfrontPayment_0" xml:lang="en-US">Represent the amount of refundable upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RefundableUpfrontPayment_1" xml:lang="en-US">Refundable Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_RefundableUpfrontPayment_2" xml:lang="en-US">Refundable upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RefundUpFrontPayment_0" xml:lang="en-US">The amount of refund upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RefundUpFrontPayment_1" xml:lang="en-US">Refund Up Front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_RefundUpFrontPayment_2" xml:lang="en-US">Refunded Upfront Payment To Galderma</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RegulatoryApprovalMilestonePaymentsReceived_0" xml:lang="en-US">Regulatory approval milestone payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RegulatoryApprovalMilestonePaymentsReceived_1" xml:lang="en-US">Regulatory Approval Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_RegulatoryApprovalMilestonePaymentsReceived_2" xml:lang="en-US">Regulatory approval milestone payments received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RoyaltiesCompanyIsEligibleToReceive_0" xml:lang="en-US">Royalties company is eligible to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RoyaltiesCompanyIsEligibleToReceive_1" xml:lang="en-US">Royalties company is eligible to receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RoyaltiesMaturity_0" xml:lang="en-US">Royalties Maturity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RoyaltiesMaturity_1" xml:lang="en-US">Royalties Maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_RoyaltiesMaturity_2" xml:lang="en-US">Royalties maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_RoyaltiesPercentage_0" xml:lang="en-US">Royalties Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_RoyaltiesPercentage_1" xml:lang="en-US">The information about the royalties percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_RoyaltiesPercentage_2" xml:lang="en-US">Royalties percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_SaleOfAssetsAndLicenseRevenue_0" xml:lang="en-US">Sale Of Assets And License Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_SaleOfAssetsAndLicenseRevenue_1" xml:lang="en-US">Represents the amount of revenue from the sale of assets and license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_SaleOfAssetsAndLicenseRevenue_2" xml:lang="en-US">Sale of assets and license revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_SalesMilestonePayments_0" xml:lang="en-US">Represent of amount the sales milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_SalesMilestonePayments_1" xml:lang="en-US">Sales Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_SalesMilestonePayments_2" xml:lang="en-US">Sales milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_ShortTermDeposits_0" xml:lang="en-US">Short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_slgl_ShortTermDeposits_1" xml:lang="en-US">short-term deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_ShortTermDeposits_2" xml:lang="en-US">Short Term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_0" xml:lang="en-US">This member stands for Subscription Agreement M. Arkin Dermatology Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_1" xml:lang="en-US">Subscription Agreement M Arkin Dermatology Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_0" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_1" xml:lang="en-US">Supplementary Information On Investing And Financing Activities Not Involving Cash Flows:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_2" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_3" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_TwyneoAndEpsolayMember_0" xml:lang="en-US">This member stands for Twyneo and Epsolay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_TwyneoAndEpsolayMember_1" xml:lang="en-US">Twyneo And Epsolay [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_TwyneoMember_0" xml:lang="en-US">Twyneo</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_TwyneoMember_1" xml:lang="en-US">Twyneo [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_UnderwrittenPublicOfferingMember_0" xml:lang="en-US">Underwritten Public Offering Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_UnderwrittenPublicOfferingMember_1" xml:lang="en-US">Underwritten Public Offering [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_UpfrontPaymentReceived_0" xml:lang="en-US">Represents the value of upfront payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_UpfrontPaymentReceived_1" xml:lang="en-US">Upfront Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_UpfrontPaymentReceived_2" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_slgl_UpfrontPaymentsReceived_0" xml:lang="en-US">Upfront payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_slgl_UpfrontPaymentsReceived_1" xml:lang="en-US">Upfront Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_slgl_UpfrontPaymentsReceived_2" xml:lang="en-US">Upfront payments received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis_0" xml:lang="en-US">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain_0" xml:lang="en-US">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title and Position [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title and Position [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US">Accounts receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent_0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent_1" xml:lang="en-US">Other long-term receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent_2" xml:lang="en-US">Other long-term assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember_0" xml:lang="en-US">Corporate bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Anti-dilutive shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Anti-dilutive securities excluded from computation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis_0" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain_0" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0" xml:lang="en-US">Due within one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1" xml:lang="en-US">Due within one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and Cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary Shares, NIS 0.1 par value - authorized: 50,000,000 as of December 31, 2021 and June 30, 2022; issued and outstanding: 23,000,782 and 23,029,951 as of December 31, 2021 and June 30, 2022, respectively.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary Shares, NIS 0.1 par value &#8211; authorized: 50,000,000 as of December 31, 2022 and June 30, 2023; issued and outstanding: 23,129,469 and 27,805,954 as of December 31, 2022 and June 30, 2023, respectively.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_2" xml:lang="en-US">Ordinary Shares, NIS 0.1 par value &#8211; authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_0" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent_0" xml:lang="en-US">Bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1" xml:lang="en-US">Schedule of Components of Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">BASIC LOSS PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">BASIC EARNINGS (LOSS) PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">BASIC AND DILUTED LOSS PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">DILUTED LOSS PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2" xml:lang="en-US">DILUTED EARNINGS (LOSS) PER ORDINARY SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Earnings (Loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember_0" xml:lang="en-US">Canada government bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralPartnerMember_0" xml:lang="en-US">General Partner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralPartnerMember_1" xml:lang="en-US">Partner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Accounts receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Accounts payable, accrued expenses and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_0" xml:lang="en-US">Receivables from collaborative and licensing arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_1" xml:lang="en-US">Increase (Decrease) in Long-Term Receivables, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0" xml:lang="en-US">Changes in operating asset and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInTradingSecurities_0" xml:lang="en-US">Changes in fair value of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInTradingSecurities_1" xml:lang="en-US">Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInTradingSecurities_2" xml:lang="en-US">Changes in fair value during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInTradingSecurities_3" xml:lang="en-US">Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0" xml:lang="en-US">Schedule of Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0" xml:lang="en-US">MARKETABLE SECURITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis_0" xml:lang="en-US">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_0" xml:lang="en-US">Investments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">TOTAL LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">LONG-TERM LIABILITIES -</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">LONG-TERM LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember_0" xml:lang="en-US">License [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember_1" xml:lang="en-US">Sale of IP and license revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract_0" xml:lang="en-US">Level 2 securities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_0" xml:lang="en-US">Balance at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_1" xml:lang="en-US">Balance at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_2" xml:lang="en-US">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_3" xml:lang="en-US">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_0" xml:lang="en-US">Schedule of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturities of operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating leases liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Other accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0" xml:lang="en-US">Partner Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_0" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0" xml:lang="en-US">Investment in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1" xml:lang="en-US">Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2" xml:lang="en-US">Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_0" xml:lang="en-US">Interest received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1" xml:lang="en-US">Proceeds from issuance of shares and warrants through public offering, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US">Proceeds from issuance of shares and warrants through placement from the controlling shareholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0" xml:lang="en-US">Sale or maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1" xml:lang="en-US">Proceeds from sales and maturity of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceed from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1" xml:lang="en-US">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_3" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1" xml:lang="en-US">Consideration for agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">RELATED PARTIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCash_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash_1" xml:lang="en-US">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0" xml:lang="en-US">Restricted long-term deposits and cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_1" xml:lang="en-US">Restricted long-term deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1" xml:lang="en-US">REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_0" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" xml:lang="en-US">Royalties revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_2" xml:lang="en-US">Sales amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_Revenues_3" xml:lang="en-US">REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyMember_0" xml:lang="en-US">Royalty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyMember_1" xml:lang="en-US">Royalties revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_0" xml:lang="en-US">Summary of Changes in Fair Value of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_1" xml:lang="en-US">Schedule of Summary of Changes in Fair Value of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServiceMember_0" xml:lang="en-US">Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServiceMember_1" xml:lang="en-US">Support services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Option vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US">Option vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Option grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Option grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US">Fair value of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Value of one ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">SHARE CAPITAL:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">SHARE BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Exercise of options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">SUPPLEMENTARY INFORMATION:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0" xml:lang="en-US">U.S government and agency bonds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Options and Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_1" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_2" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_3" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_4" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_5" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_6" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_7" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_8" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_9" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_10" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_11" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_12" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_13" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_14" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_15" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_16" xlink:to="lab_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_17" xlink:to="lab_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_18" xlink:to="lab_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AggregateOfferingPrice_19" xlink:to="lab_slgl_AggregateOfferingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AggregateOfferingPrice_20" xlink:to="lab_slgl_AggregateOfferingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AggregateOfferingPrice_21" xlink:to="lab_slgl_AggregateOfferingPrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AgreementSigningAmount_22" xlink:to="lab_slgl_AgreementSigningAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AgreementSigningAmount_23" xlink:to="lab_slgl_AgreementSigningAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AgreementSigningAmount_24" xlink:to="lab_slgl_AgreementSigningAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AssetPurchaseAgreementMember_25" xlink:to="lab_slgl_AssetPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AssetPurchaseAgreementMember_26" xlink:to="lab_slgl_AssetPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_27" xlink:to="lab_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_28" xlink:to="lab_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_29" xlink:to="lab_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_30" xlink:to="lab_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_31" xlink:to="lab_slgl_CashAndCashEquivalentsAndRestrictedCashShownInStatementOfCashFlows_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_32" xlink:to="lab_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_33" xlink:to="lab_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_34" xlink:to="lab_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInFairValueOfMarketableSecurities_35" xlink:to="lab_slgl_ChangesInFairValueOfMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInFairValueOfMarketableSecurities_36" xlink:to="lab_slgl_ChangesInFairValueOfMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInFairValueOfMarketableSecurities_37" xlink:to="lab_slgl_ChangesInFairValueOfMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ChangesInFairValueOfMarketableSecurities_38" xlink:to="lab_slgl_ChangesInFairValueOfMarketableSecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ClinicalExpenses_39" xlink:to="lab_slgl_ClinicalExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ClinicalExpenses_40" xlink:to="lab_slgl_ClinicalExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ClinicalExpenses_41" xlink:to="lab_slgl_ClinicalExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollaborationAgreementsAbstract_42" xlink:to="lab_slgl_CollaborationAgreementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollaborationAgreementsTextBlock_43" xlink:to="lab_slgl_CollaborationAgreementsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollaborationAgreementsTextBlock_44" xlink:to="lab_slgl_CollaborationAgreementsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollaborationAgreementsTextBlock_45" xlink:to="lab_slgl_CollaborationAgreementsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollabrationsMember_46" xlink:to="lab_slgl_CollabrationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollabrationsMember_47" xlink:to="lab_slgl_CollabrationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CollabrationsMember_48" xlink:to="lab_slgl_CollabrationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CommercialMilestonesMember_49" xlink:to="lab_slgl_CommercialMilestonesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_CommercialMilestonesMember_50" xlink:to="lab_slgl_CommercialMilestonesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ContractLiability_51" xlink:to="lab_slgl_ContractLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ContractLiability_52" xlink:to="lab_slgl_ContractLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ContractLiability_53" xlink:to="lab_slgl_ContractLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_DescriptionOfUpfrontPayment_54" xlink:to="lab_slgl_DescriptionOfUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_DescriptionOfUpfrontPayment_55" xlink:to="lab_slgl_DescriptionOfUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_DescriptionOfUpfrontPayment_56" xlink:to="lab_slgl_DescriptionOfUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_57" xlink:to="lab_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_58" xlink:to="lab_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_DocumentAndEntityInformation_59" xlink:to="lab_slgl_DocumentAndEntityInformation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EmployeesAndExecutiveOfficersMember_60" xlink:to="lab_slgl_EmployeesAndExecutiveOfficersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EmployeesAndExecutiveOfficersMember_61" xlink:to="lab_slgl_EmployeesAndExecutiveOfficersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EmployeesAndExecutiveOfficersMember_62" xlink:to="lab_slgl_EmployeesAndExecutiveOfficersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EmployeesAndExecutiveOfficersMember_63" xlink:to="lab_slgl_EmployeesAndExecutiveOfficersMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EmployeesMember_64" xlink:to="lab_slgl_EmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EmployeesMember_65" xlink:to="lab_slgl_EmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EpsolayMember_66" xlink:to="lab_slgl_EpsolayMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EpsolayMember_67" xlink:to="lab_slgl_EpsolayMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EstimatedVariableConsiderationRevenue_68" xlink:to="lab_slgl_EstimatedVariableConsiderationRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EstimatedVariableConsiderationRevenue_69" xlink:to="lab_slgl_EstimatedVariableConsiderationRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_EstimatedVariableConsiderationRevenue_70" xlink:to="lab_slgl_EstimatedVariableConsiderationRevenue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_71" xlink:to="lab_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_72" xlink:to="lab_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_73" xlink:to="lab_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinanceExpensesNet_74" xlink:to="lab_slgl_FinanceExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinanceExpensesNet_75" xlink:to="lab_slgl_FinanceExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinanceExpensesNet_76" xlink:to="lab_slgl_FinanceExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinancialIncomeExpensesNet_77" xlink:to="lab_slgl_FinancialIncomeExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinancialIncomeExpensesNet_78" xlink:to="lab_slgl_FinancialIncomeExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinancialIncomeExpensesNet_79" xlink:to="lab_slgl_FinancialIncomeExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_FinancialIncomeExpensesNet_80" xlink:to="lab_slgl_FinancialIncomeExpensesNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_81" xlink:to="lab_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_82" xlink:to="lab_slgl_IncreaseInOperatingLeaseRouAssetsAndLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_83" xlink:to="lab_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_84" xlink:to="lab_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_85" xlink:to="lab_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_86" xlink:to="lab_slgl_IntellectualPropertyRelatedToTwyneoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_87" xlink:to="lab_slgl_IntellectualPropertyRelatedToTwyneoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_InvestorWarrantsMember_88" xlink:to="lab_slgl_InvestorWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_InvestorWarrantsMember_89" xlink:to="lab_slgl_InvestorWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_90" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_91" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_92" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_93" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_94" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_95" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_96" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_97" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_98" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_99" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_100" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_101" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_102" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_103" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_104" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_105" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_106" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_107" xlink:to="lab_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_JefferiesLlcMember_108" xlink:to="lab_slgl_JefferiesLlcMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_JefferiesLlcMember_109" xlink:to="lab_slgl_JefferiesLlcMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsAbstract_110" xlink:to="lab_slgl_LicenseAgreementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsTextBlock_111" xlink:to="lab_slgl_LicenseAgreementsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsTextBlock_112" xlink:to="lab_slgl_LicenseAgreementsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsTextBlock_113" xlink:to="lab_slgl_LicenseAgreementsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsWithBeimeiMember_114" xlink:to="lab_slgl_LicenseAgreementsWithBeimeiMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsWithBeimeiMember_115" xlink:to="lab_slgl_LicenseAgreementsWithBeimeiMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsWithGaldermaMember_116" xlink:to="lab_slgl_LicenseAgreementsWithGaldermaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsWithGaldermaMember_117" xlink:to="lab_slgl_LicenseAgreementsWithGaldermaMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsWithSearchlightMember_118" xlink:to="lab_slgl_LicenseAgreementsWithSearchlightMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LicenseAgreementsWithSearchlightMember_119" xlink:to="lab_slgl_LicenseAgreementsWithSearchlightMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LongTermDeposits_120" xlink:to="lab_slgl_LongTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LongTermDeposits_121" xlink:to="lab_slgl_LongTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_LongTermDeposits_122" xlink:to="lab_slgl_LongTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_MilestonePaymentsAxis_123" xlink:to="lab_slgl_MilestonePaymentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_MilestonePaymentsAxis_124" xlink:to="lab_slgl_MilestonePaymentsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_MilestonePaymentsDomain_125" xlink:to="lab_slgl_MilestonePaymentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_MilestonePaymentsDomain_126" xlink:to="lab_slgl_MilestonePaymentsDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NetChangesInOperatingLeases_127" xlink:to="lab_slgl_NetChangesInOperatingLeases_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NetChangesInOperatingLeases_128" xlink:to="lab_slgl_NetChangesInOperatingLeases_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NetChangesInOperatingLeases_129" xlink:to="lab_slgl_NetChangesInOperatingLeases_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfApprovedGenericDrugProducts_130" xlink:to="lab_slgl_NumberOfApprovedGenericDrugProducts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfApprovedGenericDrugProducts_131" xlink:to="lab_slgl_NumberOfApprovedGenericDrugProducts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfApprovedGenericDrugProducts_132" xlink:to="lab_slgl_NumberOfApprovedGenericDrugProducts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfEqualQuarterlyInstalments_133" xlink:to="lab_slgl_NumberOfEqualQuarterlyInstalments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfEqualQuarterlyInstalments_134" xlink:to="lab_slgl_NumberOfEqualQuarterlyInstalments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfEqualQuarterlyInstalments_135" xlink:to="lab_slgl_NumberOfEqualQuarterlyInstalments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_136" xlink:to="lab_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_137" xlink:to="lab_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_138" xlink:to="lab_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericDrugCandidates_139" xlink:to="lab_slgl_NumberOfGenericDrugCandidates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericDrugCandidates_140" xlink:to="lab_slgl_NumberOfGenericDrugCandidates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericDrugCandidates_141" xlink:to="lab_slgl_NumberOfGenericDrugCandidates_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_142" xlink:to="lab_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_143" xlink:to="lab_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_144" xlink:to="lab_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfUnapprovedGenericPrograms_145" xlink:to="lab_slgl_NumberOfUnapprovedGenericPrograms_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfUnapprovedGenericPrograms_146" xlink:to="lab_slgl_NumberOfUnapprovedGenericPrograms_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_NumberOfUnapprovedGenericPrograms_147" xlink:to="lab_slgl_NumberOfUnapprovedGenericPrograms_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_OtherForeignGovernmentBondsMember_148" xlink:to="lab_slgl_OtherForeignGovernmentBondsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_OtherForeignGovernmentBondsMember_149" xlink:to="lab_slgl_OtherForeignGovernmentBondsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_OutstandingPrincipalAmount_150" xlink:to="lab_slgl_OutstandingPrincipalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_OutstandingPrincipalAmount_151" xlink:to="lab_slgl_OutstandingPrincipalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_OutstandingPrincipalAmount_152" xlink:to="lab_slgl_OutstandingPrincipalAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PaidUpfrontAmount_153" xlink:to="lab_slgl_PaidUpfrontAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PaidUpfrontAmount_154" xlink:to="lab_slgl_PaidUpfrontAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PaidUpfrontAmount_155" xlink:to="lab_slgl_PaidUpfrontAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PaymentReceivableInInstalments_156" xlink:to="lab_slgl_PaymentReceivableInInstalments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PaymentReceivableInInstalments_157" xlink:to="lab_slgl_PaymentReceivableInInstalments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PaymentReceivableInInstalments_158" xlink:to="lab_slgl_PaymentReceivableInInstalments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PellepharmMember_159" xlink:to="lab_slgl_PellepharmMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PellepharmMember_160" xlink:to="lab_slgl_PellepharmMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PellepharmMember_161" xlink:to="lab_slgl_PellepharmMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PercentageOfGrossProceedsFromSaleOfShares_162" xlink:to="lab_slgl_PercentageOfGrossProceedsFromSaleOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PercentageOfGrossProceedsFromSaleOfShares_163" xlink:to="lab_slgl_PercentageOfGrossProceedsFromSaleOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PercentageOfGrossProceedsFromSaleOfShares_164" xlink:to="lab_slgl_PercentageOfGrossProceedsFromSaleOfShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_165" xlink:to="lab_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_166" xlink:to="lab_slgl_PercentageOfGrossProfitsRelatedToSaleProducts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromLongTermDeposits_167" xlink:to="lab_slgl_ProceedsFromLongTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromLongTermDeposits_168" xlink:to="lab_slgl_ProceedsFromLongTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromLongTermDeposits_169" xlink:to="lab_slgl_ProceedsFromLongTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromLongTermDeposits_170" xlink:to="lab_slgl_ProceedsFromLongTermDeposits_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromLongTermDeposits_171" xlink:to="lab_slgl_ProceedsFromLongTermDeposits_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromShortTermDeposits_172" xlink:to="lab_slgl_ProceedsFromShortTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromShortTermDeposits_173" xlink:to="lab_slgl_ProceedsFromShortTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromShortTermDeposits_174" xlink:to="lab_slgl_ProceedsFromShortTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProceedsFromShortTermDeposits_175" xlink:to="lab_slgl_ProceedsFromShortTermDeposits_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProductAndService_176" xlink:to="lab_slgl_ProductAndService_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ProductAndService_177" xlink:to="lab_slgl_ProductAndService_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PurchaseAgreementAxis_178" xlink:to="lab_slgl_PurchaseAgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PurchaseAgreementDomain_179" xlink:to="lab_slgl_PurchaseAgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PurchaseAgreementWithArmisticeCapitalMember_180" xlink:to="lab_slgl_PurchaseAgreementWithArmisticeCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_PurchaseAgreementWithArmisticeCapitalMember_181" xlink:to="lab_slgl_PurchaseAgreementWithArmisticeCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ReceiveFromThirdPartyUpfrontPayment_182" xlink:to="lab_slgl_ReceiveFromThirdPartyUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ReceiveFromThirdPartyUpfrontPayment_183" xlink:to="lab_slgl_ReceiveFromThirdPartyUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_184" xlink:to="lab_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_185" xlink:to="lab_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_186" xlink:to="lab_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RefundableUpfrontPayment_187" xlink:to="lab_slgl_RefundableUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RefundableUpfrontPayment_188" xlink:to="lab_slgl_RefundableUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RefundableUpfrontPayment_189" xlink:to="lab_slgl_RefundableUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RefundUpFrontPayment_190" xlink:to="lab_slgl_RefundUpFrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RefundUpFrontPayment_191" xlink:to="lab_slgl_RefundUpFrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RefundUpFrontPayment_192" xlink:to="lab_slgl_RefundUpFrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_193" xlink:to="lab_slgl_RegulatoryApprovalMilestonePaymentsReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_194" xlink:to="lab_slgl_RegulatoryApprovalMilestonePaymentsReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_195" xlink:to="lab_slgl_RegulatoryApprovalMilestonePaymentsReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesCompanyIsEligibleToReceive_196" xlink:to="lab_slgl_RoyaltiesCompanyIsEligibleToReceive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesCompanyIsEligibleToReceive_197" xlink:to="lab_slgl_RoyaltiesCompanyIsEligibleToReceive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesMaturity_198" xlink:to="lab_slgl_RoyaltiesMaturity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesMaturity_199" xlink:to="lab_slgl_RoyaltiesMaturity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesMaturity_200" xlink:to="lab_slgl_RoyaltiesMaturity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesPercentage_201" xlink:to="lab_slgl_RoyaltiesPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesPercentage_202" xlink:to="lab_slgl_RoyaltiesPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_RoyaltiesPercentage_203" xlink:to="lab_slgl_RoyaltiesPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SaleOfAssetsAndLicenseRevenue_204" xlink:to="lab_slgl_SaleOfAssetsAndLicenseRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SaleOfAssetsAndLicenseRevenue_205" xlink:to="lab_slgl_SaleOfAssetsAndLicenseRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SaleOfAssetsAndLicenseRevenue_206" xlink:to="lab_slgl_SaleOfAssetsAndLicenseRevenue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SalesMilestonePayments_207" xlink:to="lab_slgl_SalesMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SalesMilestonePayments_208" xlink:to="lab_slgl_SalesMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SalesMilestonePayments_209" xlink:to="lab_slgl_SalesMilestonePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ShortTermDeposits_210" xlink:to="lab_slgl_ShortTermDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ShortTermDeposits_211" xlink:to="lab_slgl_ShortTermDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_ShortTermDeposits_212" xlink:to="lab_slgl_ShortTermDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_213" xlink:to="lab_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_214" xlink:to="lab_slgl_SubscriptionAgreementMArkinDermatologyLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_215" xlink:to="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_216" xlink:to="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_217" xlink:to="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_218" xlink:to="lab_slgl_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlows_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_TwyneoAndEpsolayMember_219" xlink:to="lab_slgl_TwyneoAndEpsolayMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_TwyneoAndEpsolayMember_220" xlink:to="lab_slgl_TwyneoAndEpsolayMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_TwyneoMember_221" xlink:to="lab_slgl_TwyneoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_TwyneoMember_222" xlink:to="lab_slgl_TwyneoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UnderwrittenPublicOfferingMember_223" xlink:to="lab_slgl_UnderwrittenPublicOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UnderwrittenPublicOfferingMember_224" xlink:to="lab_slgl_UnderwrittenPublicOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UpfrontPaymentReceived_225" xlink:to="lab_slgl_UpfrontPaymentReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UpfrontPaymentReceived_226" xlink:to="lab_slgl_UpfrontPaymentReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UpfrontPaymentReceived_227" xlink:to="lab_slgl_UpfrontPaymentReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UpfrontPaymentsReceived_228" xlink:to="lab_slgl_UpfrontPaymentsReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UpfrontPaymentsReceived_229" xlink:to="lab_slgl_UpfrontPaymentsReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_slgl_UpfrontPaymentsReceived_230" xlink:to="lab_slgl_UpfrontPaymentsReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_231" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_232" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_233" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_234" xlink:to="lab_srt_ProductOrServiceAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_235" xlink:to="lab_srt_ProductsAndServicesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_236" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_237" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_238" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_239" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_240" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_241" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_242" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_243" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent_244" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent_245" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent_246" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_247" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_248" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_249" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_250" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherCorporateBondsMember_251" xlink:to="lab_us-gaap_AllOtherCorporateBondsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_252" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_253" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_254" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_255" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_256" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_257" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis_258" xlink:to="lab_us-gaap_AssetAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain_259" xlink:to="lab_us-gaap_AssetAcquisitionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_260" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_261" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_262" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_263" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_264" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_265" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_266" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_267" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_268" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_269" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_270" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_271" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_272" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_273" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_274" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_275" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_276" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_277" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_278" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_279" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_280" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_281" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_282" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_283" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_284" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_285" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_287" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_288" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_289" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_290" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_291" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_292" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_293" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_294" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_295" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_296" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_297" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_298" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_299" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_300" xlink:to="lab_us-gaap_CommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_301" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_302" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent_303" xlink:to="lab_us-gaap_DepositsAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_304" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_305" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_306" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_307" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_308" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_309" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_310" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_311" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_312" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_313" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_314" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_315" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_316" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtMember_317" xlink:to="lab_us-gaap_ForeignGovernmentDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_318" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_319" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralPartnerMember_320" xlink:to="lab_us-gaap_GeneralPartnerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralPartnerMember_321" xlink:to="lab_us-gaap_GeneralPartnerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_322" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_323" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_324" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_325" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_326" xlink:to="lab_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_327" xlink:to="lab_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_328" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_329" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_330" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTradingSecurities_331" xlink:to="lab_us-gaap_IncreaseDecreaseInTradingSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTradingSecurities_332" xlink:to="lab_us-gaap_IncreaseDecreaseInTradingSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTradingSecurities_333" xlink:to="lab_us-gaap_IncreaseDecreaseInTradingSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTradingSecurities_334" xlink:to="lab_us-gaap_IncreaseDecreaseInTradingSecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_335" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_336" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_337" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_338" xlink:to="lab_us-gaap_InvestmentTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_339" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_340" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_341" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_342" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_343" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_344" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_345" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_346" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_347" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_348" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_349" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_350" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_351" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_352" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_353" xlink:to="lab_us-gaap_LicenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_354" xlink:to="lab_us-gaap_LicenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_355" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_356" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_357" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_358" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_359" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_360" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_361" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_362" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_363" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_364" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_365" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_366" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_367" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_368" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_369" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_370" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_371" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_372" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_373" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_374" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_375" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_376" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_377" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_378" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_379" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_380" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_381" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_382" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_383" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_384" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_385" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_386" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_387" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_388" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_389" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_390" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_391" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_392" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_393" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_394" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_395" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_396" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_397" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_398" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_399" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_400" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_401" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_402" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_403" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_404" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_405" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_406" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_407" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_408" xlink:to="lab_us-gaap_ProfitLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_409" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_410" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_411" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_412" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_413" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_414" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_415" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_416" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_417" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_418" xlink:to="lab_us-gaap_RestrictedCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_419" xlink:to="lab_us-gaap_RestrictedCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_420" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_421" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_423" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_424" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_425" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_426" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_427" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_428" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_429" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_430" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_431" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_432" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_433" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_434" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_435" xlink:to="lab_us-gaap_Revenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_436" xlink:to="lab_us-gaap_Revenues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_437" xlink:to="lab_us-gaap_RoyaltyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_438" xlink:to="lab_us-gaap_RoyaltyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_439" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_440" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_441" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_442" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_443" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_444" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_445" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_446" xlink:to="lab_us-gaap_ServiceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_447" xlink:to="lab_us-gaap_ServiceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_448" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_449" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_450" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_451" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_452" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_453" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_454" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_455" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_456" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_457" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_458" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_459" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_460" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_461" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_462" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_463" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_464" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_465" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_466" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_468" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_469" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_470" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_471" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_472" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_473" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_474" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_475" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_476" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_477" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_478" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_479" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_480" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_481" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_482" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_483" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_484" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_485" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_486" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_487" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_488" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_489" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_490" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_491" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_492" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_493" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_494" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_495" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_496" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_497" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>slgl-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#DocumentAndEntityInformation" roleURI="http://www.sol-gel.co/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#NatureOfOperations" roleURI="http://www.sol-gel.co/role/NatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SignificantAccountingPolicies" roleURI="http://www.sol-gel.co/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#MarketableSecurities" roleURI="http://www.sol-gel.co/role/MarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CollaborationAgreements" roleURI="http://www.sol-gel.co/role/CollaborationAgreements"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#LicenseAgreements" roleURI="http://www.sol-gel.co/role/LicenseAgreements"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#ShareCapital" roleURI="http://www.sol-gel.co/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#RelatedParties" roleURI="http://www.sol-gel.co/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#MarketableSecuritiesTables" roleURI="http://www.sol-gel.co/role/MarketableSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#ShareCapitalTables" roleURI="http://www.sol-gel.co/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#NatureOfOperationsDetails" roleURI="http://www.sol-gel.co/role/NatureOfOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" roleURI="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" roleURI="http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" roleURI="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CollaborationAgreementsDetails" roleURI="http://www.sol-gel.co/role/CollaborationAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#LicenseAgreementsDetails" roleURI="http://www.sol-gel.co/role/LicenseAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" roleURI="http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SUBSEQUENTEVENTS" roleURI="http://www.sol-gel.co/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#REVENUE" roleURI="http://www.sol-gel.co/role/REVENUE"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#REVENUEDetails" roleURI="http://www.sol-gel.co/role/REVENUEDetails"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#REVENUETables" roleURI="http://www.sol-gel.co/role/REVENUETables"/>
  <roleRef xlink:type="simple" xlink:href="slgl-20240630.xsd#SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentDescription_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFileNumber_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCountry_14" order="130" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8" xlink:to="loc_us-gaap_AssetsNoncurrent_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableCurrent_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_18" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrent_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_23" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_22" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_Liabilities_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquityAbstract_27" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_CommonStockValue_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquity_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinancialIncomeExpensesNet" xlink:label="loc_slgl_FinancialIncomeExpensesNet_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_slgl_FinancialIncomeExpensesNet_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_NetIncomeLoss_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_EarningsPerShareBasic_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_11"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_ProfitLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_13" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensation_15" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/NatureOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/MarketableSecurities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CollaborationAgreements">
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollaborationAgreementsAbstract" xlink:label="loc_slgl_CollaborationAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CollaborationAgreementsTextBlock" xlink:label="loc_slgl_CollaborationAgreementsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_slgl_CollaborationAgreementsAbstract_0" xlink:to="loc_slgl_CollaborationAgreementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/LicenseAgreements">
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsAbstract" xlink:label="loc_slgl_LicenseAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsTextBlock" xlink:label="loc_slgl_LicenseAgreementsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_slgl_LicenseAgreementsAbstract_0" xlink:to="loc_slgl_LicenseAgreementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/RelatedParties">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/MarketableSecuritiesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_3" order="20" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/NatureOfOperationsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PellepharmMember" xlink:label="loc_slgl_PellepharmMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AssetPurchaseAgreementMember" xlink:label="loc_slgl_AssetPurchaseAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsAxis" xlink:label="loc_slgl_MilestonePaymentsAxis_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_MilestonePaymentsDomain" xlink:label="loc_slgl_MilestonePaymentsDomain_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DevelopmentAndNdaAcceptanceMilestonesMember" xlink:label="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_CommercialMilestonesMember" xlink:label="loc_slgl_CommercialMilestonesMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaidUpfrontAmount" xlink:label="loc_slgl_PaidUpfrontAmount_11"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OutstandingPrincipalAmount" xlink:label="loc_slgl_OutstandingPrincipalAmount_12"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_13"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_DescriptionOfUpfrontPayment" xlink:label="loc_slgl_DescriptionOfUpfrontPayment_14"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million" xlink:label="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_17"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ClinicalExpenses" xlink:label="loc_slgl_ClinicalExpenses_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1" xlink:to="loc_slgl_PellepharmMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_slgl_AssetPurchaseAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_slgl_MilestonePaymentsAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_slgl_MilestonePaymentsAxis_7" xlink:to="loc_slgl_MilestonePaymentsDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_slgl_MilestonePaymentsDomain_7" xlink:to="loc_slgl_DevelopmentAndNdaAcceptanceMilestonesMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_slgl_MilestonePaymentsDomain_7" xlink:to="loc_slgl_CommercialMilestonesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_slgl_PaidUpfrontAmount_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_slgl_OutstandingPrincipalAmount_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_slgl_SalesMilestonePayments_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_slgl_DescriptionOfUpfrontPayment_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_us-gaap_Revenues_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11" xlink:to="loc_slgl_ClinicalExpenses_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_2"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_OtherForeignGovernmentBondsMember" xlink:label="loc_slgl_OtherForeignGovernmentBondsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_InvestmentTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_slgl_OtherForeignGovernmentBondsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_MarketableSecuritiesAbstract_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_7" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTradingSecurities" xlink:label="loc_us-gaap_IncreaseDecreaseInTradingSecurities_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInTradingSecurities_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0" xlink:to="loc_slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CollaborationAgreementsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesMaturity" xlink:label="loc_slgl_RoyaltiesMaturity_5"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericCollaborativeAgreementsToSellRights" xlink:label="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_6"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericProgramsRetainedForCollaborationRights" xlink:label="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfGenericDrugCandidates" xlink:label="loc_slgl_NumberOfGenericDrugCandidates_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ExpectedRevenueReceivableOverTwentyFourMonths" xlink:label="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_9"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfApprovedGenericDrugProducts" xlink:label="loc_slgl_NumberOfApprovedGenericDrugProducts_10"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfUnapprovedGenericPrograms" xlink:label="loc_slgl_NumberOfUnapprovedGenericPrograms_11"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentReceived" xlink:label="loc_slgl_UpfrontPaymentReceived_12"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_PaymentReceivableInInstalments" xlink:label="loc_slgl_PaymentReceivableInInstalments_13"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NumberOfEqualQuarterlyInstalments" xlink:label="loc_slgl_NumberOfEqualQuarterlyInstalments_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_RoyaltiesMaturity_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_NumberOfGenericCollaborativeAgreementsToSellRights_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_NumberOfGenericProgramsRetainedForCollaborationRights_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_NumberOfGenericDrugCandidates_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_ExpectedRevenueReceivableOverTwentyFourMonths_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_NumberOfApprovedGenericDrugProducts_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_NumberOfUnapprovedGenericPrograms_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_UpfrontPaymentReceived_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_PaymentReceivableInInstalments_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_slgl_NumberOfEqualQuarterlyInstalments_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/LicenseAgreementsDetails">
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsAbstract" xlink:label="loc_slgl_LicenseAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoMember" xlink:label="loc_slgl_TwyneoMember_1"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EpsolayMember" xlink:label="loc_slgl_EpsolayMember_2"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_TwyneoAndEpsolayMember" xlink:label="loc_slgl_TwyneoAndEpsolayMember_3"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_IntellectualPropertyRelatedToTwyneoMember" xlink:label="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithGaldermaMember" xlink:label="loc_slgl_LicenseAgreementsWithGaldermaMember_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithSearchlightMember" xlink:label="loc_slgl_LicenseAgreementsWithSearchlightMember_8"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_LicenseAgreementsWithBeimeiMember" xlink:label="loc_slgl_LicenseAgreementsWithBeimeiMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RegulatoryApprovalMilestonePaymentsReceived" xlink:label="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_12"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_SalesMilestonePayments" xlink:label="loc_slgl_SalesMilestonePayments_13"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_UpfrontPaymentsReceived" xlink:label="loc_slgl_UpfrontPaymentsReceived_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_15"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ContractLiability" xlink:label="loc_slgl_ContractLiability_16"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_AdditionalRevenueContingentOnAchievingCertainMilestones" xlink:label="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_17"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_EstimatedVariableConsiderationRevenue" xlink:label="loc_slgl_EstimatedVariableConsiderationRevenue_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_slgl_LicenseAgreementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_srt_ProductOrServiceAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_TwyneoMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_EpsolayMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_TwyneoAndEpsolayMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_slgl_IntellectualPropertyRelatedToTwyneoMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" xlink:to="loc_slgl_LicenseAgreementsWithGaldermaMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" xlink:to="loc_slgl_LicenseAgreementsWithSearchlightMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" xlink:to="loc_slgl_LicenseAgreementsWithBeimeiMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_slgl_RegulatoryApprovalMilestonePaymentsReceived_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_slgl_SalesMilestonePayments_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_slgl_UpfrontPaymentsReceived_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_slgl_ContractLiability_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_slgl_AdditionalRevenueContingentOnAchievingCertainMilestones_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12" xlink:to="loc_slgl_EstimatedVariableConsiderationRevenue_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_DirectorMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharePrice_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="40" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_FinanceExpensesNet" xlink:label="loc_slgl_FinanceExpensesNet_5"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_NetChangesInOperatingLeases" xlink:label="loc_slgl_NetChangesInOperatingLeases_6"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_slgl_ChangesInFairValueOfMarketableSecurities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_19"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromShortTermDeposits" xlink:label="loc_slgl_ProceedsFromShortTermDeposits_20"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_ProceedsFromLongTermDeposits" xlink:label="loc_slgl_ProceedsFromLongTermDeposits_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_38"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_slgl_FinanceExpensesNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_slgl_NetChangesInOperatingLeases_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_slgl_ChangesInFairValueOfMarketableSecurities_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_19" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_slgl_ProceedsFromShortTermDeposits_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_slgl_ProceedsFromLongTermDeposits_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_29" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_RestrictedCash_34" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_36" xlink:to="loc_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_38" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_38" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_38" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/REVENUE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/REVENUEDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_ProductOrServiceAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_us-gaap_RoyaltyMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_us-gaap_LicenseMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_us-gaap_ServiceMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_Revenues_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/REVENUETables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralPartnerMember" xlink:label="loc_us-gaap_GeneralPartnerMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_7"/>
    <loc xlink:type="locator" xlink:href="slgl-20240630.xsd#slgl_RoyaltiesPercentage" xlink:label="loc_slgl_RoyaltiesPercentage_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_4" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_4" xlink:to="loc_us-gaap_GeneralPartnerMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_slgl_RoyaltiesPercentage_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603778944432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001684693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">



                      Sol-Gel Technologies Ltd. (the &#8220;Company&#8221;) is amending its Report on Form 6-K furnished to the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) on August 16, 2024 (the &#8220;Original Form 6-K&#8221;) solely to (i) revise Exhibit 99.1 of the Original 6-K to correct typographical errors; and&#160;

                    (ii) revise the incorporation by reference language included in the Explanatory Note of the Form 6-K. Other than as set forth below, the information contained in the Original Form 6-K remains unchanged.
                    &#160;

                      The press release attached hereto as Exhibit 99.1 was reissued on August 17, 2024 to correct typographical errors.

                    &#160;
                    The incorporation by reference paragraph in the Original Form 6-K is hereby amended and restated as follows:&#160;





                              Exhibit 99.1



                                Press release dated August 17, 2024 (reissued)






                    &#160;





                              Exhibit 99.2


                              Unaudited condensed consolidated financial statements as of June 30, 2024 and for the three and six months then ended.









                        Exhibit 99.1 (other than the paragraph immediately preceding the heading &#8220;Financial Results for the Second Quarter 2024&#8221;) and 99.2 are hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No 333-264190).




              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SOL-GEL TECHNOLOGIES LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Golda Meir Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ness Ziona<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7403650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603672322976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,549<span></span>
</td>
<td class="nump">$ 7,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Bank deposits</a></td>
<td class="nump">4,012<span></span>
</td>
<td class="nump">10,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">14,912<span></span>
</td>
<td class="nump">20,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">6,059<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">38,282<span></span>
</td>
<td class="nump">41,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted long-term deposits and cash equivalents</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">42,005<span></span>
</td>
<td class="nump">45,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accounts payable</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="nump">3,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">5,202<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating leases liabilities</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">2,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">7,103<span></span>
</td>
<td class="nump">6,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares, NIS 0.1 par value &#8211; authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">258,799<span></span>
</td>
<td class="nump">258,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(224,671)<span></span>
</td>
<td class="num">(220,303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">34,902<span></span>
</td>
<td class="nump">38,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 42,005<span></span>
</td>
<td class="nump">$ 45,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603778922480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603672288288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="nump">$ 5,433<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 5,899<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">5,312<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
<td class="nump">14,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">3,203<span></span>
</td>
<td class="nump">3,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">1,624<span></span>
</td>
<td class="num">(6,527)<span></span>
</td>
<td class="num">(5,087)<span></span>
</td>
<td class="num">(17,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_FinancialIncomeExpensesNet', window );">FINANCIAL INCOME, net</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="nump">$ 1,976<span></span>
</td>
<td class="num">$ (5,970)<span></span>
</td>
<td class="num">$ (4,368)<span></span>
</td>
<td class="num">$ (16,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC EARNINGS (LOSS) PER ORDINARY SHARE</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED EARNINGS (LOSS) PER ORDINARY SHARE</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="nump">27,660,326<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
<td class="nump">26,306,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="nump">27,660,326<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
<td class="nump">26,306,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_FinancialIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses (income), net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_FinancialIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603667930544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 234,640<span></span>
</td>
<td class="num">$ (193,065)<span></span>
</td>
<td class="nump">$ 42,213<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">23,129,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,691)<span></span>
</td>
<td class="num">(16,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts', window );">Issuance of shares and warrants through public offering, net of issuance costs</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">11,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares', window );">Issuance of shares and warrants through public offering, net of issuance costs Shares</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder', window );">Issuance of shares and warrants through private placement from the controlling shareholder</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">9,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares', window );">Issuance of shares and warrants through private placement from the controlling shareholder Shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="nump">116,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">257,281<span></span>
</td>
<td class="num">(209,756)<span></span>
</td>
<td class="nump">48,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">27,805,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">246,678<span></span>
</td>
<td class="num">(203,786)<span></span>
</td>
<td class="nump">43,604<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">25,702,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,970)<span></span>
</td>
<td class="num">(5,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder', window );">Issuance of shares and warrants through private placement from the controlling shareholder</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">9,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares', window );">Issuance of shares and warrants through private placement from the controlling shareholder Shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="nump">103,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">257,281<span></span>
</td>
<td class="num">(209,756)<span></span>
</td>
<td class="nump">48,296<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">27,805,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">258,173<span></span>
</td>
<td class="num">(220,303)<span></span>
</td>
<td class="nump">$ 38,644<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,368)<span></span>
</td>
<td class="num">$ (4,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">258,799<span></span>
</td>
<td class="num">(224,671)<span></span>
</td>
<td class="nump">$ 34,902<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">258,524<span></span>
</td>
<td class="num">(226,647)<span></span>
</td>
<td class="nump">$ 32,651<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">$ 258,799<span></span>
</td>
<td class="num">$ (224,671)<span></span>
</td>
<td class="nump">$ 34,902<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">27,857,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,857,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of issuance of shares and warrants through private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of issuance of shares and warrants through private placement, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants through public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants through public offering, net of issuance costs, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603671829184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the period</a></td>
<td class="nump">$ 1,976<span></span>
</td>
<td class="num">$ (5,970)<span></span>
</td>
<td class="num">$ (4,368)<span></span>
</td>
<td class="num">$ (16,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement', window );">Changes in accrued liability for employee rights upon retirement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expenses</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_FinanceExpensesNet', window );">Financial expenses (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_NetChangesInOperatingLeases', window );">Net changes in operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ChangesInFairValueOfMarketableSecurities', window );">Changes in fair value of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating asset and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent', window );">Receivables from collaborative and licensing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,682)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,627)<span></span>
</td>
<td class="num">(8,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,114)<span></span>
</td>
<td class="num">$ (23,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturity of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,646<span></span>
</td>
<td class="nump">7,995<span></span>
</td>
<td class="nump">11,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ProceedsFromShortTermDeposits', window );">Short-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ProceedsFromLongTermDeposits', window );">Long-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,471<span></span>
</td>
<td class="num">(10,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of shares and warrants through placement from the controlling shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of shares and warrants through public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,846<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863<span></span>
</td>
<td class="nump">13,598<span></span>
</td>
<td class="nump">13,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</a></td>
<td class="nump">12,709<span></span>
</td>
<td class="nump">16,785<span></span>
</td>
<td class="nump">12,709<span></span>
</td>
<td class="nump">16,785<span></span>
</td>
<td class="nump">7,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash equivalents</a></td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">15,618<span></span>
</td>
<td class="nump">11,549<span></span>
</td>
<td class="nump">15,618<span></span>
</td>
<td class="nump">7,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</a></td>
<td class="nump">$ 12,709<span></span>
</td>
<td class="nump">$ 16,785<span></span>
</td>
<td class="nump">12,709<span></span>
</td>
<td class="nump">16,785<span></span>
</td>
<td class="nump">$ 7,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Recognition of new operating lease ROU and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in accrued liability for employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ChangesInFairValueOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from changes in fair value of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ChangesInFairValueOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_FinanceExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance expenses, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_FinanceExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_NetChangesInOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net changes in operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_NetChangesInOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ProceedsFromLongTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from long-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ProceedsFromLongTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ProceedsFromShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from short term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ProceedsFromShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount represents recognition ofoperating lease right of use assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603776526176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 1 - NATURE OF OPERATIONS</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo&#174;, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay&#174;, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo&#174; and Epsolay&#174; in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo&#174; is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay&#174; is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company&#8217;s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-&#8220;PellePharm&#8221;), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $6 million, and up to $64 million in commercial milestones which amount increases to $89 million when sales exceed $500 million as well as single digit royalties which increase to double digit royalties when sales exceed $500 million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $500 as clinical expenses.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&amp;D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S.</span></span><br/>&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border and launched a series of attacks against Israel. Following these attacks, Israel&#8217;s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee</span></span></div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt">&#160;</div>
            <div></div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk and Uncertainties</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since incorporation through June 30, 2024, the Company has an accumulated deficit of $224,671 and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.</span></span></div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603776504416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 2 &#8211; SIGNIFICANT ACCOUNTING POLICIES:<br/>&#160;</span></span></span></div>

          <div>
            <div style="line-height:1.25">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:18pt">&#160;</td>
                    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">Basis of Presentation</span></span></span></span></span><br/>&#160;</div>
                      <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="margin-left:36pt;line-height:1.25;text-align:justify">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:35.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.</span></span></span></span></div>
          </div>

        <div style="line-height:1.25">&#160;</div>

          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Earnings (Loss) per share</span></span></span></span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.</span></span></span></span></div>
          </div>

        <p style="margin:0pt">&#160;</p>
        <div style="line-height:1.25;font-weight:400;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">
          <div></div>
        </div>
        <div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif">
          <div>
            <div>
              <div style="line-height:1.25">

                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:18pt">&#160;</td>
                        <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div>
                            <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements, not yet adopted</span></span></div>&#160;<div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures&#8221;. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.</span></span></div>
                          </div>
                        </td>
                      </tr>

                  </table>

              </div>
            </div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603779006720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 3&#8201;-&#8201;MARKETABLE SECURITIES:</span></span></div>
        <div>
          <div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company&#8217;s marketable securities for the indicated periods:</span></span></div>
            <div style="margin-left:36pt;line-height:1.25">&#160;</div>

              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 securities:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S government and agency bonds</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,583</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,612</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other foreign government bonds</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,946</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,974</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate bonds*</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,942</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,326</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Investments in Corporate bonds rated A or higher.</span></span></div>
              </div>

            <div style="margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The table below sets forth a summary of the changes in the fair value of the Company&#8217;s marketable securities for the indicated periods:</span></span></div>
            <div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="margin-left:36pt">

                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ended June 30, 2024</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,678</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,164</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale or maturity</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,807</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,646</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value during the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">436</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                  <p style="margin:0pt">&#160;</p>
                </div>

            </div>
            <div></div>
            <div style="text-align:justify;text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2024, the Company&#8217;s debt securities had the following maturity dates:</span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt">

                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market value</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due within one year</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>

            </div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates. In addition, due to the short-term nature and/or low-risk nature of the Company's cash and cash equivalents, restricted cash equivalents, accounts receivable, accounts payable and other payables , their carrying amounts approximates their fair value</span></span></div>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603671229200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text">
      <div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 4&#8201;-&#8201; REVENUE:</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-right:35.45pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the Company&#8217;s revenues for the indicated periods:</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
        <div style="line-height:1.25;margin-left:36pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three months ended</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">514</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,056</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">214</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">612</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of IP and license revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Support services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">894</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,899</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">594</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,433</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>

        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603664946544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_CollaborationAgreementsTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 5 - COLLABORATION AGREEMENTS:<br/>&#160;</span></span></p>
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:20pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">a.</span></td>
              <td style="width:auto;vertical-align:top;text-align:justify">
                <div><span style="font-family:Times New Roman,Times,serif">In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material.</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:20pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">b.</span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">In 2016 through 2020, the Company entered into several collaboration agreements mainly with one third party (the "Partner") for the development, manufacturing and commercialization of several product candidates (including an agreement assumed by the Company in August 2018, following the transfer of an in-process research and development product candidate from a related party).</span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:20pt">&#160;</td>
              <td style="width:18pt;vertical-align:top"><span style="font-family:Times New Roman,Times,serif">c.</span></td>
              <td style="width:auto;vertical-align:top">
                <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">Under the agreements, the Partner is obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the products and prepare and file an abbreviated new drug application ("ANDA"), with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.</span></div>
                <div>&#160;</div>
                <div style="text-align:justify"><span style="font-family:Times New Roman,Times,serif">Upon FDA approval, the Partner has exclusive rights and is required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to a share of the Partner's gross profits related to the sale of the products, as such term is defined in each of the agreements.</span></div>
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <div></div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These Agreements are considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company recognizes collaboration revenues when the related sales occur.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In November 2021, the Company entered into a new agreement ("New Agreement") with the Partner, to sell its rights to the Partner in relation to ten generic collaborative agreements between the parties in consideration of $21,500 which was paid over 24 months. Under the New Agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, and is no longer entitled to receive its share in profit as detailed above.</span></span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In addition, the Company ceased paying any outstanding and future operational costs related to these collaborative agreements.</span></span></span></div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25">&#160;</div>
        <div style="text-align:justify;margin-left:38pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In August 15, 2024 the Company entered into a Termination Agreement with the Partner, For further details, see note 9.</span></span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_CollaborationAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_CollaborationAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603676437872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_LicenseAgreementsTextBlock', window );">AGREEMENTS</a></td>
<td class="text">
    <div>
      <div style="margin-left:0px">
        <div>
          <div>
            <div style="text-align:justify;line-height:1.25;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span>&#160;<span style="font-weight:bold">6 - AGREEMENTS:</span></span></span></div>
            <div>
              <div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:36pt">&#160;</td>
                      <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                      <td style="vertical-align:top;text-align:justify;width:auto">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of two of the Company's most advanced investigational drug products (Twyneo&#174; and Epsolay&#174;) in the United States. The Company was entitled to amounts of up to $7.5 million per product in upfront payments and regulatory approval milestone payments assuming 2021 approval of each respective product. The Company is also eligible to receive tiered double-digit royalties ranging from mid-teen to high-teen percentage of net sales as well as up to $9 million in sales milestone payments.</span></span></div>
                        <div style="line-height:1.25">&#160;</div>
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">According to the agreement, the Company has an option to regain commercialization rights five years following first commercialization.</span></span></div>
                        <div style="line-height:1.25">&#160;</div>
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 14, 2022, the Company announced that Twyneo&#174; is available for purchase by consumers who obtain a prescription from their physician, See note 1. On June 2, 2022, the Company announced that Epsolay&#174; is available for purchase by consumers who obtain a prescription from their physician, See also note 1.<span style="font-weight:bold">&#160;</span>The Company recognized $723 and $466 during the six-month periods ended June 30, 2024 and 2023, respectively, as royalty revenue in respect of the license agreement for both products.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:36pt">&#160;</td>
                      <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 6, 2023, the Company and Searchlight Pharma Inc. (&#8220;Searchlight&#8221;), a private Canadian specialty pharmaceutical company, signed on an exclusive license agreements for Twyneo&#174; and Epsolay&#174; for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada, with support from the Company.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div style="line-height:1.25">&#160;</div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the agreement, the Company will receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined. In addition, the Company will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.</span></span></div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt">&#160;</div>
                <div></div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2023, the Company received $500 as an upfront payment in connection with the license agreement and related support provided to Searchlight for obtaining the regulatory approval in the Canadian market. The Company is also required to support Searchlight during such period if needed based on agreed upon rates. The Company has identified two performance obligations in the license agreement as follows: (i) the license to market the products in Canada; and (ii) continuing support during the regulatory approval process.</span></span></div>
                <div style="text-align:justify;margin-left:56.7pt;line-height:1.25">&#160;</div>
                <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six-month period ended June 30, 2024, the Company recognized a total amount of $42 for continuing support. The remaining outstanding contract liability in respect of the support services, is, as of June 30, 2024 $78 .</span></span></div>
                <div style="line-height:1.25">&#160;</div>
                <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                    <tr>
                      <td style="width:36pt">&#160;</td>
                      <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
                      <td style="width:auto;vertical-align:top;text-align:justify">
                        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 15, 2024, the Company and Beimei, a private Chinese company, signed an agreement for the purchase and license by Beimei of certain rights in the intellectual property ("IP") related to Twyneo, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.</span></span></div>
                      </td>
                    </tr>

                </table>
                <div>
                  <div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the agreement, Beimei will purchase and license from the Company the IP in these territories. The Company is also required to support Beimei to a certain extent during the period until obtaining regulatory approval. The Company may provide further support services to Beimei, if needed, based on agreed upon rates. In return, Sol-Gel is to receive payments of up to $10 million (including amounts contingent on achieving certain milestones) and up to $5 million as royalty payments on net sales.</span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>
                    </div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has identified multiple performance obligations in the agreement. Revenue from sale and license of IP is recognized at a point in time, upon transfer of control over the license and the IP to Beimei. Support services are recognized over time as the services are performed.</span></span></div>
                    </div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six-month period ended June 30, 2024, the Company recognized revenue for a total amount of $4.8 million. This amount does not include variable consideration that was determined to be constrained (not probable that would not result in a significant reversal). In addition, the Company recorded $200 as a contract liability in respect of the support services.</span></span></div>
                    </div>
                    <div style="line-height:1.25">&#160;</div>
                    <div style="text-align:justify;line-height:1.25;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In July 2024, the Company received $2 million as the first payment in connection with the agreement.</span></span></div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license agreements information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603675625776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE BASED COMPENSATION</a></td>
<td class="text">
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE</span>&#160;<span style="font-weight:bold">7 - SHARE BASED COMPENSATION:</span></span></span></p>
      <div>
        <div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six months ended June 30, 2024, the Company granted 300,000 options to Directors as follows:</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2024, the board of directors approved and recommended the Company's shareholders to approve a grant of 300,000 options to the Company's Directors to purchase ordinary shares at an exercise price of $1.2 per share. The Company's shareholders approved the grant in February 28, 2024.</span></span></div>
          <div style="margin-left:35.45pt;line-height:1.25">&#160;</div>
          <div style="margin-left:35.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The options vest over a period of 3 years; one third of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following two years. The options expire on the tenth anniversary of their grant date.</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of options granted in 2024 was $207. The underlying data used for computing the fair value of the options are as follows:</span></span></div>
          <div style="line-height:1.25">&#160;</div>
          <div style="margin-left:36pt">

              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value of one ordinary share</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.2</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.8</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:center;text-indent:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4 years</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>

          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603778032368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text">
    <div>
      <div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 8 - RELATED PARTIES:<br/>&#160;</span></span></span></div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:18pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company.</span></span></div>
                  </td>
                </tr>

            </table>
            <div style="line-height:1.25">&#160;</div>
            <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                <tr>
                  <td style="width:18pt">&#160;</td>
                  <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                  <td style="width:auto;vertical-align:top;text-align:justify">
                    <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As to options granted to directors and executive officers, see note 7.</span></span></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603676467584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">
            <div>
              <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 9 <span style="font-weight:bold">&#8211;</span> SUBSEQUENT EVENT</span></span></div>
              <div style="line-height:1.25">&#160;</div>
              <div style="text-align:justify;margin-left:38pt;line-height:1.25;font-family:'Palatino Linotype', serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">In August 15, 2024, the Company entered into a </span><span>Termination Agreement </span><span style="color:rgb(0, 0, 0)">("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As </span><span>consideration </span><span style="color:rgb(0, 0, 0)">for the Agreement between the parties, the Partner will pay to the Company $4,250, which will paid </span><span>in quarterly installments </span><span style="color:rgb(0, 0, 0)">during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel 2% royalties of the Partner&#8217;s Gross Profits for that Product.</span></span></span></div>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603671267088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
          <div>
            <div style="line-height:1.25">
              <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                  <tr>
                    <td style="width:18pt">&#160;</td>
                    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
                    <td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
                      <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">Basis of Presentation</span></span></span></span></span><br/>&#160;</div>
                      <div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.</span></span></span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="margin-left:36pt;line-height:1.25;text-align:justify">&#160;</div>
            <div style="margin-left:36pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="margin-left:35.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.</span></span></span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per share</a></td>
<td class="text">
          <div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Earnings (Loss) per share</span></span></span></span></span></div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.</span></span></span></span></div>
            <div style="line-height:1.25">&#160;</div>
            <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.</span></span></span></span></div>
          </div>
        <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text">
                  <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

                      <tr>
                        <td style="width:18pt">&#160;</td>
                        <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
                        <td style="width:auto;vertical-align:top">
                          <div>
                            <div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently issued accounting pronouncements, not yet adopted</span></span></div>&#160;<div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures&#8221;. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.</span></span></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603675674080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text">
              <div>
                <div style="margin-left:36pt">
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June&#160;30,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 securities:</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S government and agency bonds</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,583</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,612</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other foreign government bonds</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,946</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,974</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate bonds*</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,942</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,326</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div style="line-height:1.25">&#160;</div>
                <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Investments in Corporate bonds rated A or higher.</span></span></div>
              </div>
            <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Summary of Changes in Fair Value of Marketable Securities</a></td>
<td class="text">
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketable securities</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the six months</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ended June 30, 2024</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:top;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,678</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23,164</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale or maturity</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,807</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,646</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                          <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                        </td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in fair value during the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">436</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of the period</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,471</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                  <p style="margin:0pt">&#160;</p>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Debt Securities</a></td>
<td class="text">
                <div>
                  <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Market value</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
                          <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30,</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                        <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>
                      <tr>
                        <td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Due within one year</span></span></div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                          <div style="line-height:1.25">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,912</span></span></div>
                          </div>
                        </td>
                        <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                      </tr>

                  </table>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603776515536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Components of Revenues</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">

                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six months ended</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three months ended</span></span></div>
                      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">514</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,056</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">214</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">612</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sale of IP and license revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">380</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,800</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Support services</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenue</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">894</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,899</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">594</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,433</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603667861120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value</a></td>
<td class="text">
              <div>
                <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">

                    <tr>
                      <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
                        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Value of one ordinary share</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.2</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
                      <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.8</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
                        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
                      <td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
                        <div style="text-align:center;text-indent:20pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4 years</span></span></div>
                      </td>
                      <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
                    </tr>

                </table>
              </div>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603673320752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (224,671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (224,671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (220,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,433<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 5,899<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=slgl_PellepharmMember', window );">PellePharm, Inc. [Member] | Asset Purchase Agreement [Member] | Development And Nda Acceptance Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=slgl_PellepharmMember', window );">PellePharm, Inc. [Member] | Asset Purchase Agreement [Member] | Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_DescriptionOfUpfrontPayment', window );">Description of upfront payment</a></td>
<td class="text">$4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million', window );">Increase in sales milestone amount due to sales exceed dollar 500 million</a></td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ClinicalExpenses', window );">Clinical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of clinical expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_DescriptionOfUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_DescriptionOfUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Increase in Sales Milestone amount due to sales exceed dollar 500 million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent of amount the sales milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=slgl_PellepharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=slgl_PellepharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=slgl_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=slgl_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_MilestonePaymentsAxis=slgl_DevelopmentAndNdaAcceptanceMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_MilestonePaymentsAxis=slgl_DevelopmentAndNdaAcceptanceMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_MilestonePaymentsAxis=slgl_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_MilestonePaymentsAxis=slgl_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603675689696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Options and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation</a></td>
<td class="nump">6,501,769<span></span>
</td>
<td class="nump">7,120,463<span></span>
</td>
<td class="nump">6,993,858<span></span>
</td>
<td class="nump">5,961,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603672187264">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,912<span></span>
</td>
<td class="nump">$ 20,471<span></span>
</td>
<td class="nump">$ 8,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S government and agency bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,612<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=slgl_OtherForeignGovernmentBondsMember', window );">Other foreign government bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 11,326<span></span>
</td>
<td class="nump">$ 15,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Investments in Corporate bonds rated A or higher.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=slgl_OtherForeignGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=slgl_OtherForeignGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603675735824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 20,471<span></span>
</td>
<td class="nump">$ 8,678<span></span>
</td>
<td class="nump">$ 8,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,114<span></span>
</td>
<td class="nump">23,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale or maturity</a></td>
<td class="num">(5,646)<span></span>
</td>
<td class="num">$ (7,995)<span></span>
</td>
<td class="num">(11,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTradingSecurities', window );">Changes in fair value during the period</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Balance at end of the period</a></td>
<td class="nump">$ 14,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603777288768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 14,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603667908016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 5,433<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 5,899<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Sale of IP and license revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Support services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603673485744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2007</div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>Agreement </div>
<div>Candidate </div>
<div>Program</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_NumberOfGenericCollaborativeAgreementsToSellRights', window );">Number of generic collaborative agreements to sell rights | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_NumberOfGenericProgramsRetainedForCollaborationRights', window );">Number of generic programs retained for collaboration rights | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_NumberOfGenericDrugCandidates', window );">Number of generic drug candidates | Candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ExpectedRevenueReceivableOverTwentyFourMonths', window );">Expected revenue receivable over twenty four months | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_RoyaltiesMaturity', window );">Royalties maturity</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_RoyaltiesMaturity', window );">Royalties maturity</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ExpectedRevenueReceivableOverTwentyFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of expected revenue receivable over twenty four months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ExpectedRevenueReceivableOverTwentyFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_NumberOfGenericCollaborativeAgreementsToSellRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of generic collaborative agreements to sell the rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_NumberOfGenericCollaborativeAgreementsToSellRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_NumberOfGenericDrugCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of generic drug candidates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_NumberOfGenericDrugCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_NumberOfGenericProgramsRetainedForCollaborationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of generic programs retained for collaboration rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_NumberOfGenericProgramsRetainedForCollaborationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_RoyaltiesMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_RoyaltiesMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603668151360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENTS (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=slgl_TwyneoMember', window );">Twyneo [Member] | License Agreements With Galderma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_RegulatoryApprovalMilestonePaymentsReceived', window );">Regulatory approval milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=slgl_TwyneoMember', window );">Twyneo [Member] | License Agreements With Beimei [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_UpfrontPaymentsReceived', window );">Upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Royalties revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ContractLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_EstimatedVariableConsiderationRevenue', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=slgl_TwyneoAndEpsolayMember', window );">Twyneo And Epsolay [Member] | License Agreements With Galderma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Royalties revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=slgl_TwyneoAndEpsolayMember', window );">Twyneo And Epsolay [Member] | License Agreements With Searchlight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_UpfrontPaymentsReceived', window );">Upfront payments received</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Royalties revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_ContractLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_ContractLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information about contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_ContractLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_EstimatedVariableConsiderationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of revenue that is estimated variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_EstimatedVariableConsiderationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_RegulatoryApprovalMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory approval milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_RegulatoryApprovalMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent of amount the sales milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_UpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_UpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=slgl_TwyneoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=slgl_TwyneoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithGaldermaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithGaldermaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithBeimeiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithBeimeiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=slgl_TwyneoAndEpsolayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=slgl_TwyneoAndEpsolayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithSearchlightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=slgl_LicenseAgreementsWithSearchlightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603668343888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option grants</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603770699488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one ordinary share</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140603671266032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Narrative) (Details) - Subsequent Event [Member] - Partner [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Consideration for agreement</a></td>
<td class="nump">$ 4,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_slgl_RoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_slgl_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The information about the royalties percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">slgl_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>slgl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_GeneralPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_GeneralPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(RPS$-]OHHB_W60_)Y0_'PW^!5!+ P04    "  T,!-9:B7&!:@"  !/!P
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V574_;,!2&_XH5) 02:]*D
M31FDD4I;!!.#BL!V,>W"34X;B\3.;*>%_?K93HA:EJ(.K1?UUWG?/.?$L8,U
MXT\B!9#H.<^H&%JIE,69;8LXA1R+#BN JI4%XSF6:LB7MB@XX,2(\LQV'<>W
M<TRH%09F;L;#@)4R(Q1F'(DRSS%_N8",K8=6UWJ=N"?+5.H).PP*O(0(Y&,Q
MXVID-RX)R8$*PBCBL!A:H^[9V-?Q)N ;@;78Z".=R9RQ)SVX3H:6HX$@@UAJ
M!ZR:%8PAR[21POA5>UK-([5PL__J?FER5[G,L8 QR[Z31*9#Z]1""2QPF<E[
MMKZ".I^^]HM9)LP_6E>Q@\\6BDLA65Z+%4%.:-7BY[H.&X)N;X? K07NO@*O
M%G@FT8K,I#7!$H<!9VO$=;1RTQU3&Z-6V1"JWV(DN5HE2B?#\=WM9'H;32=(
M]:*[F^O)Z$$-+D8WH]OQ%$57T^E#A(X>*2X3(B$Y1D<SS('*%"2)<7:,/J'#
M@U//=\^1C42JUD1@2T6F_>VXIKBH*-P=%%]*VD&><X)<Q^VUR,?ORR<0*WG7
MR+UMN:WJT13%;8KB&C]OAU\DL02U525B"W1)**8QP1F:,4',WOLQF@O)U0[\
MV99JY=UK]]9?Y9DH< Q#2WUV O@*K/#PH.L[YVV)_R>SK3)X31F\]]S#.YZH
MW/E+_5I/4($Y6N&LA+:T*Z^!\=)GQRIT.MW 7FUF\W[,%F2O@>S]&V35(ES*
ME''R&Y(VV,K3WP#I.]7O#?$>@5O8_0:[_R%L(D39CMS_B\0=G/8'OOL6>8_
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M-^0]/3-G[%=Z$CXAX"\G8V;*8V4'O?,M%_0&Z+OLD%RRRZ'GT_OA9+9<E-=
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M8ZMTJ"Q^C\AS?O0:E*D\4/JE?+@,SR9&.2(2DU510@3LSQ.9DS@ND=@XOAY
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MNN$I#B29U$MD 77A,E179O*4K/N'X*SX:'V04E]%P5PE@*A,Z@0Q9;VT)>C
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M^^9ASPSW4OW6!8 A;R47>N07QE2#(-!9 275U[("@3<;J4IJ4%3;0%<*:.Y
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M?"T-?FUW+'!&@[(&>+^1TAP$ZZ"=^N._4$L#!!0    ( #0P$UG8ZLC8, 8
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MA[DKDM8!_?XQ3V')#,4%TC41 !%7UL*"<#(G-^@9D):$-AX9Y<D"]7!GUK#
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M970Q,BYX;6RU6-MRX[@1??=7H+13&[M*ULV7<3RVJSRSWEDGF5W7V)L\I/(
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MQ&WIE!;CTR@<DVWOTA@4GVD7%C*(+7)QOI=2:<FY9E:7E<L E\1T#5<&Q22
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MT>#M62^= LV78,OXS@J#8[!%O%R01"UY 7Z?63R]U%_80?L2\^;?4$L#!!0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;(U5;6_;-A#^*P=U*UK
MLVS%2=/$-B G;M=AR;PXZ3X,^T!+)XLH12HD%=7]]3U2+[6+Q-@7B4?>/??<
M"X_36NDO)D>T\+40TLR"W-KR(@Q-DF/!S%"5*.DD4[I@ED2]#4VID:7>J!!A
M-!J=A07C,IA/_=Y*SZ>JLH)+7&DP55$PO5N@4/4L& ?=QAW?YM9MA/-IR;:X
M1OM0KC1)88^2\@*EX4J"QFP6Q..+Q<3I>X7/'&NSMP87R4:I+T[XE,Z"D2.$
M A/K$!C]GO *A7! 1..QQ0QZE\YP?]VA?_"Q4RP;9O!*B7]X:O-9<!Y BAFK
MA+U3]>_8QG/J\!(EC/]"W>A&[P-(*F-5T1H3@X++YL^^MGG8,S@?O6 0M0:1
MY]TX\BROF67SJ58U:*=-:&[A0_761(Y+5Y2UU73*R<[.UP^+]?+OA^7M/2P_
MTW<:6D)U9V'2(BP:A.@%A#.X4=+F!I8RQ?30/B0V/:6HH[2(C@+^4<DAG(P&
M$(VBR1&\DS[$$X]W\E*(U<;@8X72PO*)O@;^C3?&:FJ(_YX+MT&;/(_F+LF%
M*5F"LX!N@4']A,'\]:OQV>CR"-=)SW5R#/U_E>,XPNU?]TMX#Z]?G4?C\25\
MDA!76^HC&)\V&1V S1&N5%$RN0/*!VI,@4NK@,$]:FHRYB],O-6(A4O;F\"9
M]'+PEIK4YAYGQ;25J(=P3T)9Z5(9!)7!@0%P P1O6W#TI]?X1".A=.<#N&&R
MRJ@@E>9R"TRFCF"!.N%,\&\_\TD)(P7J$X3HW$=%W>*,R E=> &<BJS=?6S\
M_N!)<=(H$0T@'=VI3%0%%XP2E-!0*SS,_FZF6#&$V$"B:!*EJ!M;&H<_Q;A!
M6R-*OUN2-XYF<."ZYL2L9+N.4E>"7R:#Z)0"J'.>Y)T6=R6!QXIL48L="<8R
M(0K?OVF3IF@"A;]Z0U=FEJ;<41LX0X>/% E5 AFAMD">=D9C$';(M %FNEK]
MR2I)>M>N.F_<ALNQ.\RX=KGIJP&&B;["*ZW2*K&=1^H>S:W2.]CL#D(GKZXD
M<99QP0G8N%8Q%:.TM<F(;Z_CMX?Y,CEK$[96XK>/*"#Z%;3:,>%RVU-HM'V_
MO[LT\%$K8QRQS'ELRL1LQW3XW!T-]\8G1;GUCX0K>"5M,TG[W?X=BIOQ^T.]
M><1NF-Y2J4!@1J:CX;O3H&G$3K"J],-XHRR-=K_,Z2U%[13H/%/*=H)ST+_.
M\^]02P,$%     @ -# 3643D?[1@!P  $!0  !D   !X;"]W;W)K<VAE971S
M+W-H965T,38N>&ULG5A;<]NV$G[OK\"H,VTRH^IJRW9B>T9V+M69UO5$\>E#
MIP\0N1+1D  +@%;T[\^W $E+CJ2<Y,462>RW]V^7O%P;^\EE1%Y\+G+MKCJ9
M]^6K?M\E&172]4Q)&D^6QA;2X]*N^JZT)-,@5.3]T6 PZ1=2Z<[U9;AW;Z\O
M3>5SI>G>"E<5A;2;&\K-^JHS[#0W/JA5YOE&__JRE"N:DW\H[RVN^BU*J@K2
M3ADM+"VO.M/AJYL)GP\'_JMH[;9^"_9D8<PGOIBE5YT!&T0Y)9X1)/X]TBWE
M.0/!C']KS$ZKD@6W?S?H[X+O\&4A'=V:_$^5^NRJ<]X1*2UEE?L/9OTKU?Z<
M,EYB<A?^BG4\>WK1$4GEO"EJ85A0*!W_R\]U'+8$S@<'!$:UP"C8'14%*]](
M+Z\OK5D+RZ>!QC^"JT$:QBG-29E[BZ<*<OYZ/GM_-WLWNYW>?133V]L_'NX^
MSN[>B_L_?IO=SM[.Q8M[DZM$D7MYV??0QU+]I,:^B=BC ]@3\;O1/G/BK4XI
MW97OP\[6V%%C[,WH*.!_*MT3XT%7C :CDR-XX];Y<< ;'\";)HFIM%=Z)1HW
MQ5_3A?,6Q?+W/H<CWLE^/&Z@5ZZ4"5UUT"&.["-UKG_Z<3@9O#YB[4EK[<DQ
M].L;Z9039BGN&5M[R66]S\CC,++WPUXD\3$C46E9I<I3*A*#I&D7?SE$)Y5\
M>ZFTU(F2N7 0([2G=R*3CR061%K [5):G%/<<(FQ*4X3:MIGX;J.=FD50,H<
M\5Z1)BOS?,//J?11UL.6!QT,F;.>8.VT(*L2*5YT'GKSGG@_G=YW7@H0$R0\
M'A5[K>N):3 $>O--EY$W(C5"&P^Q)*]2$E#/^*Q4Z4AT@3%TRL>@W-*_E6*W
M%AO1Z@Z:I=85U.U7/(N.F%)IQH.*0FI0'3\.EKCOC3BHBWDM6"[3?\ 3X7Y7
MK#.59*UCFGW)<3JIK.7 [YS5E)!SH.+HB5A*99^4-!&Y-44I]>:G'\]'P[/7
M[I!QI7$J1BWD"JU*;:L&7W<%47C@S7 4 \:&@+L0<3ZZY2D.))G4*V0!=>$R
M5%=F\I2L^UEP5GRT/DBISZ)@QA% 5"9U@IAX=FT).O!C?$B9=)E88E:Y@[A'
M87NAC_;Z^FUXED*--DE2Z!"E4]0_C[$F.0VT-^@_09]+% 6GI=:T(6D9G5/_
M!D#%@JP8#Z.*8.EW5Z#+3)6GK)5W <X-9/ZI=!RVH>'9@@9Z+\9NA7UA-<2>
M&]V&%Q(V1F(A\\ Q<8>1_DL9\).+](2R@0BLL:;XNGG \AG^<!3$HL(/@RI\
M3ARI<DEN7&4/\43O"/>?MMQ_>I2TWTJKD40G7OQFG'O)A1-[81__?R>4X+&0
M"&J?Y\^>*Q<"7W' 3*2V13-)^$(C_L^EFYS6E9ZJ1Y7&^/#==5B:<(T!8D&,
M0E<A<\P*S-C,34$W=%0>J8FEG%:!S)YP>^*-RH-=1ZWG]2T555D;_PW:N;MQ
MN\0TP 1#F1PS;YUQJ;%!*+8>5HM#0DT9;0MCXTL^@1.?"'$MK95;Y!Z<B9)P
M!FT2(^S1AZC"38U0D,\0\&>VA.:1>5+E<<3!I_1YY-J0=;\L^$GW=##LGDTN
M]EK89MMGEBARW $2=G$0LR_POJD@2/#-2,R8<8:-P$_,)5HN>>"M&]:!/O7+
M_^48%\)6'>SQZ>)BW#T_/3_N4\O:A\?*:?=B,@3:1;@ZZPY'@^[)9/QUW&84
M?25NXRX3/G,\?.9E9D&)K!P%V>,!.L)!DY:#)D>)XP-X57L>0\Y5W#7;^YS1
M^)U0LUD@O!MFX]3P1K>/I([K6O1^^'YUO'?=F<<X!&+8.$#OIO.;!FPZ?PA/
M?AF<"=YL1H/7<UJ%M><#E<:RFE=B5D#38ST-,&+C([G(232GWSRQ?\ 9ON9:
M!->L*A5W7PQEI!<56"URIE>XX%4\C7U*N!IH>XQ@/2[BQ =/QID2:*\]PN7M
MU$JK)?8!"#<@O !@?KLXM[C:+:W0$A90[$K@7C@2UK%,4;M\,3HE*KQJ%_(3
MV5"2+<OP.,>$)PGZL2$(N%D$OHFVU/JA8ZG0S38T71<@0A:<M0"7DDNL*IO^
M5#[.DV9QY(8PW/<M'$9S$5#2=L/?#A,P9&U.R$DMUFZJN]8$&.D<\69^OYN,
M^@4%,<5+ NW!K&-93W=$L(YF/??6.W8%1=@,^-G>[2"2]G1^*T;G@\A=;;F@
M=&(G\V[#(5D" ;.#ER+>8E9*Z[#)+Q&0IUUG>-HPQ':TFCVXSM\W06%K#U&A
M4#VAM3A+@"R41_ZCW1+12>MUZ5F(F(/*,E=A _;6/!$7/^4 H<[A8&-D&5]&
MZY=''9/S]-ZQ_Q7KX];^R/L)WG,B:]"CS*M8V7ZG'Z$[)<]>Z)@^!>F$BPV5
MOXGOLO S5N?7MF .MJ4\'-A*]5ZZ[6]]I<&;["I\BV(EZ(_XP::]VW[NFL:O
M/$_'X[>RWZ5%\IS(:0G10>\,*Y^-WY_BA3=E^.:S,-Z;(OS,L*:3Y0-XOC18
M2NH+5M!^!+S^'U!+ P04    "  T,!-9:4MQ)Y8#  "'"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6R55E%OVS80?N>O.&C%D!1:9,FR[&:V 3MQ
MT6P-%L1)]S#L@9;.EA")=$G:3O[]CI2MJELB="\22=U]]]U]/%+C@U1/.D<T
M\%R50D^\W)CM91#H-,>*ZPNY14%?UE)5W-!4;0*]5<@SYU250=3K)4'%"^%-
MQV[M3DW'<F?*0N"= KVK*JY>YEC*P\0+O=/"?;')C5T(IN,MW^ 2S>/V3M$L
M:%"RHD*A"RE X7KBS<++>6+MG<&7 @^Z-0:;R4K*)SNYR29>SQ+"$E-C$3B]
M]GB%96F!B,;7(Z;7A+2.[?$)_:/+G7)9<8U7LORSR$P^\48>9+CFN]+<R\,G
M/.8SL'BI++5[PJ&V'?8\2'?:R.KH3 RJ0M1O_GRL0\MA])9#='2('.\ZD&-Y
MS0V?CI4\@++6A&8'+E7G3>0*8459&D5?"_(ST]O9_>^+A]G\\P*6BZO'^YN'
MF\42SA[XJD1]/@X,Q;"607K$F]=XT1MX"=Q*87(-"Y%A]KU_0-P:@M&)X#SJ
M!/QM)RZ@W_,AZD5Q!UZ_2;CO\/IOX-V(/6I#V\IH'ZYQ98"+#!9?=X5Y@26F
M.U68 C7\-5MIHVC3_/U:$>H8\>LQ;"-=ZBU/<>)1IVA4>_2F/_\4)KU?.S*(
MFPSB+O3IDAHSVY4(<@VW7#VAL6*UN+]&N!OR&E.L5JB@'_J,*HZVXHPJWK>/
MF'W&/980@6YB7++'BR5LY!Z5L,5T5:0N%ND+K*3(-(O\P:C/0C\)(_:'R0F<
MCA!J$M'VJDU#_T.<V.<P9E=2;:7B!NMO[UDXH*\1"T._'R7L01I>$BD_'H8L
MC/T/803OH24J% +^A0%VF,$,I(*<NA3518<,@T:&P0_+L*R/-#N\RKG8H*/Q
MD1<*OO!R]_^DZ@S[^MYJ87^3B-&Q!51X>$&N &T_-DNZ>(;*-2IK:P].<F<*
MIVW@&H_-><E%BL!),]P40A1B8[.R8%M4A<S8.S;RD^&(WD=Y9EE6V*.7]D+?
M#Y.8_<*6W!9,T0EF+,L7=D:ZCGI#=L[.!GY"N^"<M2JXMA7<NPIF9$\A6_'B
M?L)&PS8S(OX?3D<N[TZ;I4/YI%$^^6'EW0G2K6<G6)>>=>;?]6/,KJD6A\+D
M5!TI:FV[DPM:ET.%:N.N0 VIW E3WQ/-:G/+SNK+Y9MY?443+9)>0XEK<NU=
M#&FKJOK:JR=&;MU5LY*&+BXWS.E/ 94UH.]K*<UI8@,T_Q[3?P!02P,$%
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M?W$Y=HELQT.K:%';EMP)C?_/B@5.5)#& .]S(?11,0'Z&9W\!5!+ P04
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M/FAZ'=^)GFVC-\GM_>5-A7=^++K[8]&]=KD%?O7J^BTMV:^^AW[.ZW^#I_K
MB#ZRPOUDKCZ#9 6JKY9$6;UV?RO7P(E<TX3419_^4$QR)2$6GQLJ=%$48-!<
M #U6G8F4^G#>48.1 /X$G=FOOY@CX[<F8V'"+$R8C0ES,&$N)LQ#@M7,.JC,
M.FBCS^:^G\591"4$>KP._5 V&:X5<JCA,&%6 1OF,#W+>II]Z/4&H[$Y[3Z]
M]A)F4&?/H"YF4*\QJ-$W^E70F@.&E0.&K0ZXIQ$(0F.6)8U-WZH^M.DQ8=;P
MS0L9#OK]G79OR'0ZJ.=Q&O),3D]WVO)MILDNR$.J7JT=1U4[CEK;<:$F[[!8
M4QX?DZM$#6F?KB%^!/Z9_$OF0JC?,(N,^VLU22?S%8=B!'J5QX(G]3,DS9/G
M:J"Z"2A1O0.DDB8^D.M0V42R1'EE(VIR2VL9#W4+)LS"A-F8, <3YF+"/"18
MS<_CRL_CGSV-&F.:%1-F8<)L3)B#"7,Q81X2K&;62676R1Z#:+SI(TE*OVIK
M-OVPO9B\&4A&AF'41Y++UG"'N@D39F/"'$R8BPGSD& U-YU6;CK]7X?R2Q;'
MP/V01OL.VZWE.;0GQ(19F# ;$^9@PEQ,F(<$JWG7-+;+@<;/'KC+$B#Y%95F
MH=)L5)J#2G-1:1X6K>[:5XO8)MH(7J)J0_C@[1C>'O%@7V'2;%2:@TIS46D>
M%JWNJ][65[U67UD@?!ZF^2X;6Y(L77*FNK[27HWN:@<>#;1+(\V3C&RG"B?D
M80UZZ$]I\I6$@G#XDH4< IU-A5.]+Z%!$.J2J(E!L>"CBW1DG(PWR&,BLL>_
MP9=:I'IG(H''@E"1+PXF"A8F>?I\,3\FYI#$Q2Z(JE2<I_L1$V&R(@&5<-+8
MV;;6[N"/ I-FH](<5)J+2O.P:/6/8KM#8K:N:<_4I):#GKXJ-XF=CK<T9I"!
M]F#Q%%Y\T O4>I+ R= P-GYM_'[Z#2MU#;TSZKX'*LU&I3FH-!>5YF'1ZD;<
M[GZ8[=L?WUO\-M\NNBOW-9@)=4\#E6:CTAQ4FHM*\[!H=3-M-U+,]IV42Y40
M^FILA9<4$@'-<T?4_12S8>MBUYP6:D@;E>:@TEQ4FH=%*^S4?77")@:^RD];
M">+KKJ<X7%"E5B>ZYODYIIUTRSRSS89TQSQSB_-:6WQQ?.R:\E68"!+!4H52
MTSU5,5Z<R"IN)$OS\SV/3$H6YY=KH %PG4$]7S(F-S<Z0'4N;O8?4$L#!!0
M   ( #0P$UE_86ZV 0,  +L)   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;*U676_:,!3]*U8F3:VT-B$)M#! HH%U3"U%I5T?JCV8Y )6$SNS'>C^
M_6PG!&@#JC9>$MNYY]R/$]NWO6+\12P )'I-8BHZUD+*M&7;(EQ @L4Y2X&J
M+S/&$RS5E,]MD7+ D0$EL>TZ3L-.,*%6MVW6QKS;9IF,"84Q1R)+$LS_7$',
M5AVK9JT7[LE\(?6"W6VG> X3D(_IF*N97;)$) $J"*.(PZQC]6JM05W;&X.?
M!%9B:XQT)E/&7O1D&'4L1P<$,812,V#U6D( <:R)5!B_"TZK=*F!V^,U^S>3
MN\IEB@4$+'XBD5QTK$L+13##62SOV>H[%/F8 $,6"_-$J\+6L5"8"<F2 JPB
M2 C-W_BUJ,,60/%4 ]P"X+X%^'L 7@'P/NK!+P#^1SW4"X!)W<YS-X7K8XF[
M;<Y6B&MKQ:8'IOH&K>I%J/Y/)I*KKT3A9'<RO!X-OPV#WN@!]8+@[G'T,!Q=
MH_'=S3 8#B;H9(0YQUK,4W32!XE)+$[1&1(+S$&T;:EBT$QV6/B[ROVY>_QY
MZ)91N1!H0".(*O#]P_C& ;RM<B\+X*X+<.4>)/R1T7/D.5^0Z[A^13S!Q^%>
M53K_YWWPS]YWBN&5?X-G^/P]?'>IWKT"81JA)RT\E0(]WT(R!?ZK2NR#=/J,
M:XD4A]"QU"$F@"_!ZG[^5&LX7ZLJ?4RR_C')!D<BV]'$+S7Q#;NW1Y,>E20B
M<:;W()I F'$B":@-\!K&F=H#:,99@@*6I)G$YO!E,S3 G!(Z%V@,'$WT7D7/
M-XH8#24DHE)*_YA2'I.L?TRRP9'(=J2LEU+6#VXO+>59J:78: D[6H8;+:N$
MRGTTC _=!BR[C;I3NV@TV_9R6X/W=A<UU_$;WJY=OX*OV?0NZY>[=H/W=O5F
MH]9L;OSF1;&W;J,$^-RT 4)EE5&9'T7E:MEI],P%^V;]JM8*:A7K?=69Y(W$
MACYO:VXQGQ-U?L4P4ZZ<\PL5,\];A7PB66KNPBF3ZF8UPX7JKH!K _5]QIA<
M3[2#LE_K_@502P,$%     @ -# 367.[0QC  P  Y1$  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&ULK5C;;N,V$/T50EVT6:"UKK[6%I#8*IIV@P9Q
MTCXL^D!+8TN()*HD96_^OJ2DR)*M:)V +S8O<PYGCCGTD/,#H<\L!.#H6Q*G
M;*&%G&<S76=^" EF Y)!*F:VA":8BR[=Z2RC@(,"E,2Z91@C/<%1JKGS8NR>
MNG.2\SA*X9XBEB<)IB\W$)/#0C.UUX&':!=R.:"[\PSO8 W\*;NGHJ?7+$&4
M0,HBDB(*VX5V;<X\TY& PN+O" ZLT48RE TAS[)S&RPT0WH$,?A<4F#QM8<E
MQ+%D$G[\5Y%J]9H2V&R_LO]6!"^"V6 &2Q+_$P4\7&@3#06PQ7G,'\CA=Z@"
M&DH^G\2L^$2'RM;0D)\S3I(*+#Q(HK3\QM\J(1H TWX#8%4 ZQ3@O &P*X!]
M*<"I ,ZE@&$%*$+7R]@+X5:88W=.R0%1:2W89*-0OT +O:)4;I0UIV(V$CCN
MWET__.D]7M]\\=#:6SX]W#[>>FMTM18;,LAC0&2+EB3)</KR$T-WF#X#QQLQ
MO@8_IQ&/@'U&5RLQ&,6B]0MZ6J_0U:?/Z!.*4O08DISA-&!SG0M?Y8JZ7_FU
M+/VRWO#KCSP=(-OX&5F&Y73 5_WP%?@";A9PNP/N70ZWVG!="%RK;-4J6P6?
M_0;?%]A#C"S$:M5F79*4)$XWB3PR9BS#/BPT<28PH'O0W!]_,$?&KUT"J23S
M%)&UQ+-K\>P^=K>QZX[Z=<E7T@P+&GE [EW3F9KB]]LW=3FWL@QG;+:MO'.K
MR6@\J8U:@3AU($YO($^#-=J1/=!4G+0<B<1 XBQ._1>T(2))T-<[2#9 _^V*
MK9?YO5M#)9FGB*REZ+!6=*@BKX8JQ5-)YBDB:XDWJL4;J<FKDF;4S*O165J=
M&UG#B7V25;T.?3#<<1WNN#?<OW@(%(G22M0.:3,/OY]\O<3OW3\JR3Q%9"U!
M)[6@$Q7)-U$IGDHR3Q%92[QI+=Y43?)-SY-O.G9.DJ_+R!F=)%^O0Q\,US2.
M=:;1&_"2T(Q0S.&"?.NG>N^>4<KFJ6)KR]@HUTT525>QJ%)0)9NGBJVMX+$4
M-WN+U8LS[^8[/%_-[KUKG5>AIFV=)..JRVPX=4[^5;U^'SZJE:R\VR/'$M;L
MKV%%U+?I'AB7?YU,7O).$ULV W2-"$6AN*4#'72YHC>NK G07?%6P)!/\I27
M5X-ZM'Z/N"FN[6?C]FQEVITSCI@I[M7Z<8GR 41L@EV4,A3#5BQG#,;BAZ#E
MFT+9X20K+LT;PL45O&B&@ .@TD#,;PGAKQVY0/VRX_X/4$L#!!0    ( #0P
M$UE;BO8(<P,  *D*   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U6
M;6_;-A#^*X16;"G01*^6E,P6X+>BV18@B)/NP[ /M'2VB$BD2E)V\^]'2HIF
M2XK: OUB\^6>Y^XYDJ>;'AE_%BF 1%_SC(J9D4I9W)BFB%/(L;AB!5"ULV,\
MQU)-^=X4!0><5* \,QW+\LT<$VI$TVKMGD=35LJ,4+CG2)1YCOG+ C)VG!FV
M\;KP0/:IU MF-"WP'C8@GXI[KF9FRY*0'*@@C"(.NYDQMV]6H;:O##X3.(J3
M,=)*MHP]Z\EM,C,L'1!D$$O-@-7? 9:099I(A?&EX31:EQIX.GYE_UAI5UJV
M6,"297^31*8S(S10 CM<9O*!'3]!HV>B^6*6B>H7'1M;RT!Q*23+&["*(">T
M_L=?FSR< !3/,,!I $X7X+T!<!N VP7X;P"\!N!5F:FE5'E888FC*6='Q+6U
M8M.#*ID56LDG5!_[1G*U2Q1.1G?SAS_7C_/%7VNT62^?'FX?;]<;=+%1URLI
M,T!LAY8IIGL0B%#T$1../N.LK#=87F#Z\IM =Y@_@\1;!=A 7'(B"8CWZ&*E
M%DFF1I?H:;-"%^_>HW>:YS%EI< T$5-3*A$Z%#-N E[4 3MO!.RC.T9E*M":
M)I ,X%?C>-L9(3!5]MH4.J\I7#BCC'^4] JYU@?D6(XW$-#R^^'ND)YQ^ IB
M!;>'X&=JW/9"N!6?^P;?+3V D.IA2_$!K6 KD3HGM/Y2$OER<KCHG_E62*Z>
M[;]#9UC[\(9]Z%)V(PH<P\Q0M4H /X 1_?J+[5N_#^7O9Y*M?A+966Z]-K?>
M&'NTP!FF,2 LT1;VA%)"]_HAR110 9RPH?N\J#DG%:>NXH?(L;S GIJ'TR3U
MK4(_",^-5M\P.A,U:45-1D7-DX3H$C[XEFNH?^+0ZL3=M[ #V_8Z@?>M'-?V
MO>'(_39R?S3R#=8%CJMR*O6M?AD2X/<<7TY\S^^(\'MYO0RNKR<=$0-<MAU:
MP;"*H%41C*HX*<\[79X/57E.E")UN<9O5M +* PZRD9]_^C;Z_N[]%Q_6'[8
MR@^_]TV!*E3??$UA[ZAL[]IV.K)'??ZH[+[+\P=<ZS9//N(Y\'W5# D4LY+*
M^F/4KK;]UKQJ,SKK"_MF6;=-_]/439SZ3*NJ(U &.T5I704J)EXW1O5$LJ)J
M%;9,JL:C&J:JEP2N#=3^CC'Y.M$.VNXT^@]02P,$%     @ -# 36<)+L-@_
M @  9 0  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL?53O;YLP$/U7
M+%9MK5050MINZPA2?DW+MDI5:+</TSXX< E6C4WM(VG^^YT-09G4]@O<V??>
MO0=G)SMM'FT)@.RYDLJ.@A*QO@E#FY=0<7NA:U"TL]:FXDBIV82V-L +#ZID
M&$?1=5AQH8(T\6MW)DUT@U(HN#/,-E7%S7X"4N]&P2 X+"S%ID2W$*9)S3>0
M 3[4=X:RL&<I1 7*"JV8@?4H& ]N)D-7[PM^"=C9HY@Y)RNM'UVR*$9!Y 2!
MA!P= Z?7%J8@I2,B&4\=9]"W=,#C^,#^U7LG+RMN8:KE;U%@.0H^!:R -6\D
M+O7N&W1^KAQ?KJ7U3[;K:J. Y8U%775@4E )U;[Y<_<=C@!Q_ H@[@"QU]TV
M\BIG''F:&+UCQE43FPN\58\F<4*YGY*AH5U!.$QOQ\L?\_OQY.><9?/IPW)Q
MOYAG[#2CGU\T$IA>LZFN:J[V'RRY72$U-X^ ?$6;%O+&"!1@S]CIC!:%I.B$
M"<7N2]U8K@J;A$@R7;,P[R1-6DGQ*Y*^-^J"#:-S%D?Q)7O(9NSTY.Q_FI!<
M]E;CWFKL>8>O\"[4%BS20*$]9S-GA?2Q^5,C<,^RW@K[,UY9-#0N?U_2WO:X
M?+F'.T(WMN8YC (Z(Q;,%H+T_;O!=?3E#0?#WL'P+?9TU@"-!Y;T?;4"M@=N
M7I+8DEQY$G<HM^G@\O,@3L+M<>_P:&C<^;OE9B.491+6A(LN/A*!:6>Z35#7
M?HY6&FDJ?5C2-0#&%=#^6FL\)&XT^XLE_0=02P,$%     @ -# 367O&OPHP
M P  <0T  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULK5=;;]HP&/TK
M5E9-K;0U5\)E@%1(IG52)P1M]S#MP< '1$WBS':@_?>SDY!!$B(Z\D)BYYSS
M^=B'Q.[O"'UA&P".7@,_9 -EPWG44U6VV$" V2V)(!1/5H0&F(LF7:LLHH"7
M"2GP54/3;#7 7J@,^TG?A [[).:^%\*$(A8' :9O(_#);J#HRKYCZJTW7':H
MPWZ$US #_A1-J&BIN<K2"R!D'@D1A=5 N=-[;E?B$\"S!SMV<(^DDSDA+[)Q
MOQPHFAP0^+#@4@&+RQ;&X/M22 SC3Z:IY"4E\?!^K_XU\2Z\S#&#,?%_>DN^
M&2@=!2UAA6.?3\GN&V1^6E)O07R6_*)=BK5,!2UBQDF0D<4( B],K_@UFX<#
M@M"I)A@9P2@2K!,$,R.8YU:P,H)U;H561DBLJZGW9.(<S/&P3\D.48D6:O(F
MF?V$+>;+"V5.9IR*IY[@\>'4?79_/+GHV@&./9_=H,_H:>:@ZZL;=(6\$#UN
M2,QPN&1]E8MZDJ4N,NU1JFV<T#;1 PGYAB$W7,*R@N_4\^T:OBI\YF:-O=F1
M42OX/0YOD:E]0H9F6!7C&9]/-ZOL7%;=_>_J1Y-AYBMO)GK6";U'PK$O_NI;
M"&.H6MR4WDKH\G6S';8L4U3>'LY8!:AK'6.<"DRGVST&N650YT#HR*&5.[1J
M'4[)&_:Y!VSO$OUZ@& .]'>5W5HM^;KNL0@O8*"(]S$#N@5E^/&#;FM?JH+4
MI)C3I)C;D-C1@K3R!6E=%KF4;A^$P-:-0N+*&$,O)JZ,T;6674A<&=323R3.
MS@W:M09GV =$5NA^@L0K$_G>0GQ1X:SXU0J_-WY-BCE-BKD-B1VM3CM?G?9E
M\6N7$F%U-*V0OS+([!0PSCE";KW0D<-.[K!3G[\XB@CE2,Z<R!ZK35RMU'L3
MUZ28TZ28VY#8T7IT\_7H7I:X;NFK9^B%O)4AQ;25$5;A,^W6B:3.U(,]9 !T
MG6S>&5J0..3IIB+OS<\'=\FVN- _TGMCO:+?$>>)=/O_3SX]C#Q@NO9"AGQ8
MB5+:;5N,DZ8;_+3!293L8.>$B_UP<KL19R*@$B">KPCA^X8LD)^RAG\!4$L#
M!!0    ( #0P$UG4%/S.6 ,  &8+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;*V6;6_3,!#'O\HI3&B3T/+0IS':2EU78!+=IF[ "\0+-[FF%HD=
M;*?=)#X\YZ3-.DB#BO:FB1W?__R[N]K77TOU0R\1#3RDB= #9VE,=NZZ.EQB
MRO2IS%#0EX54*3,T5+&K,X4L*HS2Q T\K^NFC MGV"_F;M6P+W.3<(&W"G2>
MIDP]7F BUP/'=[83,QXOC9UPA_V,Q7B'YG-VJVCD5BH13U%H+@4H7 R<D7\^
M]CUK4*SXPG&M=][!HLRE_&$'5]' \>R.,,'06 E&CQ6.,4FL$NWCYT;4J7Q:
MP]WWK?K[ IY@YDSC6"9?>626 ^?,@0@7+$_,3*X_X@:H8_5"F>CB%];EVAYY
M#'-M9+HQIG'*1?ED#YM [!CXW3T&P<8@^,.@X^TQ:&T,6@5HN;,"ZY(9-NPK
MN09E5Y.:?2EB4U@3#1<VC7=&T5=.=F8XOOGT:71Q,QO=7]U<P^C#;#*93J[O
M[^#XFBG%;(Q/X/@2#>.)/H$CX +NES+73$2Z[QK:@A5RPXV[B])=L,>='\!4
M"K/4,!$11L\%7-I[!1!L 2Z"1L5+#$^AY;\!*MQ>S8;&S>;7<G4*7F$>^/#Y
M[A*.CTY@%"M$*E8#8^+D$3,(MTK&BJ4-6VY5,6\5/MO[?.;I'!7(!<0H4/$0
M*(L)F\LRWL"VWC48"53R"2A;C1I^/>VL+O:-;NV!<*XS%N+ H7^\1K5"9_CZ
ME=_UWM7%K13K%F+V,%@-?:_OKFJXVQ5W^T#NK(RII@.!"DQ@!'0P[4;#GA5;
M]-H$E."-?@\%;_\%'M1S=RKNSH'<D<IC"+>E9>&J.JO#:Y0_%*_S%UZ['J];
MX74;\28/&9W)E#N%*Q0YTC-$OF+S!$&N"-RLJ5X?*;6Y@K3\]_^"HSK01D>'
M@I9BG=T\^AUO3PWW*MA>(^R4"Y[F*7R;HDWJ]SJ*1H5#*5Y([!GL605[U@@[
MDX\L,9P*E.[+7''S6(?;K!%X?K>.J]'J/[G>5EQOFY/('OZ9Q$:%0Y/X0F+/
M8'WOZ8KW7B"-_Q"A^[%=A]9L=BB;N]/)I*CBHL'3="/DPI1-335;-9&CHG5R
MGY:7'>B4J9@+#0DNR-0[[=%)H,JFKAP8F15]T5P:ZK**UR4UPJCL OJ^D-)L
M!]9!U5H/?P-02P,$%     @ -# 360^'_17Y!   AB(  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&ULQ9IK;Z-&%(;_RHBNJD1JP\77I+:E)-#M5IMM
M%"?=#ZM^&-O'!BTP[,S87DO]\1TNX6*3D:F.M%]LP)SG,.^!,[R&R9[QK\('
MD.1[%,9B:OA2)C>F*98^1%1<L01B]<N:\8A*M<HWID@XT%46%(6F8UE#,Z)!
M;,PFV;9'/INPK0R#&!XY$=LHHOQP!R';3PW;>-WP%&Q\F6XP9Y.$;F .\B5Y
MY&K-+"FK(()8!"PF'-93X]:^\9PL(-OC[P#VHK9,TJ$L&/N:KGQ830TK/2((
M82E3!%5?.[B',$Q)ZCB^%5"CS)D&UI=?Z;]G@U>#65 !]RS\'*RD/S7&!EG!
MFFY#^<3V?T QH$'*6[)09)]D7^QK&62Y%9)%1; Z@BB(\V_ZO1"B%F#WWPAP
MB@#G.&#P1D"O".B=&] O OKG'M*@",B&;N9CSX1SJ:2S"6=[PM.]%2U=R-3/
MHI5>09R>*'/)U:^!BI.SV_=/GO?@?7J>DXM/E'.:UNV27+@@:1"*2_(K>9F[
MY.+=)7E'@I@\^VPK:+P2$U.J]"G$7!:I[O-4SANI;/+ 8ND+XL4K6+7$N_KX
MH2;>5,,NQ^Z\COW.T0+_W,97Q!K^0AS+Z;6-YXSPGI6%VVW#.3^\WQ+NG1_>
MTXC1*T^$7L;KO\%[WA]B8.3+ T0+X/^0?\G'8*D: I#;#0=0O4$*\CF0/GE/
MPQ6H:[3<M^7@[[3)TNYW(Q*ZA*FAVIL O@-C]O-/]M#ZK:T.F# 7$^8AP1H5
MZY<5ZV?TWAL54[TQI N67[+D5EV[\2:K$U'79V/]+^D#)]*G,6D&??FHF.2#
MA$BT5K&/645,F(L)\Y!@C2H.RBH.M-?=$VRV(96,'PA-$LYV-%1]/@35^55I
M$GK(KSP.2U 5:VN;=]H$7:N4PP89++W+V,U& \N:F+NZ^I@9/2180_UAJ?X0
MJ>O=@;H_"K0]3YNJ:QTP82XFS$."->HU*NLU^M$];X1914R8BPGSD&"-*H[+
M*HZU5]V<JO[6TN7:RJ$E=2T')LP=GW1*Y<Z..J6'E+$A\W4I\[56YI=DS=4=
M\WF3B!;556=,F)O#AC6=;>M4:*24#:%MJW)1EGX69P<:R@!2C7<0;Z'U7-9#
MNHJ,2G,+6EWFP:G*6#F;,M?,JJV5^5Z=SIPN)0D#N@C"0!Y:9=9".LN,27,+
MVK#9-8Y51DK95-FI5':T*GM"!A&5L"([RI70(9 EBT6@7!]-_]UIU5R+[*PY
M)LTM:'7-^^-3T9%R-D6O[+=]EO^^5;<Q7B)82 ]H7ER?N7-M4-TX*LW#HC5K
M6!ER^X<[<AO5DJ/27%2:AT5KUK*RY;;>EW>Y1]6C.A?EU()?G\S$+FI.#XO6
M%+MRX;;>AI]Y^X1JL%%I;D&KSS&C]'_9YA0S/*EL?S@L=VJ*5UEB6^O5_N?,
M,0?*EWZ8/D?13QZH?AB5YJ+2/"Q:LXR5)[;'/WSR0#73J#07E>9AT9JUK(RW
MC>B\"U:]*]CV2<._UZ?L+#<FS6L90OU/X^;3N<I4.QBF6@_I>E*CTESGU%3W
MG:-) 2MC4^3*4CL8EEH/Z2PRJJ4N:(U'%N-CD5$=M5E[WAX!WV0O.@AEDK>Q
MS!\_EUO+ERENLU<(CK:[]HV7OQ)18?(W-!XHWP2Q("&L%=*Z&JGA\?REAWQ%
MLB1[JK]@4K(H6_2!*C.8[J!^7S,F7U?2!.6K)[/_ %!+ P04    "  T,!-9
M1"T52"L#  "H"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6S%5EU/
MVS 4_2M7&9I  I*FM 761NH7@FF%BL+V@/;@)K>-16)GMMO2?S_;*5D[A0 3
MTOK0V,X]Q_<<.U>WO>+B4<:("I[2A,F.$RN5G;NN#&-,B3SF&3+]9L9%2I2>
MBKDK,X$DLJ T<7W/:[HIH<P)VG9M+((V7ZB$,AP+D(LT)6+=PX2O.D[->5ZX
MI?-8F04W:&=DCA-4]]E8Z)E;L$0T128I9R!PUG&ZM?/^F8FW =\IKN36&(R2
M*>>/9G(5=1S/)(0)ALHP$/U88A^3Q!#I-'YM.)UB2P/<'C^S7UCM6LN42.SS
MY >-5-QQ3AV(<$86B;KEJTO<Z&D8OI GTO[#:A/K.1 NI.+I!JPS2"G+G^1I
MX\,60/.4 _P-P'\KH+X!U*W0/#,K:T 4"=J"KT"8:,UF!M8;B]9J*#.G.%%"
MOZ4:IX+)9?=V"+WN9#B _LUH/+R>=.^N;JYA_YH(08S'![ _0$5H(@_@".XG
M ]C?.X ]<$'&1* $RN">424/]:(>W\5\(0F+9-M5.D.SCQMNLNGEV?@O9%.#
M$6<JEC!D$48E^'XUOEF!=[4SA3W^LST]OY+P*V''4*\=@N_Y)V7YO )?&+A7
M!M])IUZ<5MWRU5\Z+6/XD;FV$?1YJC]E2>S7T-5GQ>:H/R\%TS5LQXW)VBYW
M5T1$\/!-4\*5PE3^+#N??/^3\OU-23F7&0FQX^B:(5$LT0D^?ZHUO2]EYGP0
MV8Y5)X55)U7LP06A I8D62#P&?#,V"1AKFU2I3>K5TGW7N4Y6<.2F4*Z#'RO
MU7:7)8(:A:!&I: !%;KT<0$/(TRG*$J/KY+BO2(^B&Q';;-0V_S/-[WYD59]
M$-F.5:W"JE;EQ;BQ=SN_VJ4U-X<WMRYCW3._XC[F&EX-V\GNM,CNM#*[X1.*
MD$J$3- 0R]++\6=;^]:._;]RJ]SC'_T]*Q2<O<7?)4I%V1PR%)275I!JFCJL
MD8BR ^I7 M^KSMUJ!E(4<]LC20CY@JF\+RA6BS:L:[L/]T]XWL.-B)A37343
MG&FH=]S2%4'D?5$^43RSK<64*]VHV&&L6TD4)D"_GW&NGB=F@Z(Y#7X#4$L#
M!!0    ( #0P$UF]H/#UX (   8'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;(U5;6_:,!#^*Z=LFEII)2&\E'40B;>JG=86P=I]F/;!D .L.G%F
M.U#^_<X.9%0*:%\2O]P]SW-W]KF[E>I5KQ$-O"4BU3UO;4QVX_MZL<:$Z9K,
M,*6=I50),S15*U]G"EGLG!+AAT'0]A/&4R_JNK6)BKHR-X*G.%&@\R1A:C=
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M-:CF;)><[;.<X[>,.@45:B,%%5-PLZLB;E<0UZY/Q'M=<E^?Y9YR_7JU5(C
M4X-440.*KE85?P%4K[_C#YJ=:@&=4D#G_X(G]J2*]KQ[$W;(5.7-\H]Z4X)J
MY3JPAH7,4U.TJ7*U;/+]HK?],R]>B >F5IPZD, EN5+6Z1"HHNL6$R,SU^GF
MTE#?=,,U/52HK 'M+Z4TAXDE*)^^Z"]02P,$%     @ -# 36:XW>B)* @
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M<' N>&UL4$L! A0#%     @ -# 360=UJMKN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ -# 369E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  T,!-9 &E440\&  #O%0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ -# 36?##U?1)
M!@  2AH  !@              ("!4@X  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( #0P$UEJ)<8%J (  $\'   8              "
M@=$4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  T,!-9
MRL%GC%4$  "Z#P  &               @(&O%P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ -# 365OOG%XN!P  /2\  !@
M     ("!.AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M #0P$UEG-J=.4PH  -!%   8              " @9XC  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  T,!-9H@G_J^X)  "-%P  &
M            @($G+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ -# 364LJ]T5#!P  !!,  !@              ("!2S@  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #0P$UFK2/9K-P4  ,$+
M   8              " @<0_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  T,!-9R)%RK,("   !!@  &0              @($Q10
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #0P$UG8ZLC8
M, 8  *$.   9              " @2I(  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ -# 363>GWOL("   T!0  !D
M ("!D4X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  T
M,!-9!5G36M<#  "6"   &0              @('05@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #0P$UDR0KT8A (  (X%   9
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M970Q."YX;6Q02P$"% ,4    "  T,!-9%>S6P),"  !B!0  &0
M    @(&7;P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M #0P$UE2Y$DFG@4  ",G   9              " @6%R  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ -# 367]A;K8! P  NPD  !D
M             ("!-G@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  T,!-9<[M#&, #  #E$0  &0              @(%N>P  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #0P$UE;BO8(<P,
M *D*   9              " @65_  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ -# 36<)+L-@_ @  9 0  !D              ("!
M#X,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  T,!-9
M>\:_"C #  !Q#0  &0              @(&%A0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( #0P$UG4%/S.6 ,  &8+   9
M      " @>R(  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ -# 360^'_17Y!   AB(  !D              ("!>XP  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  T,!-91"T52"L#  "H"@
M&0              @(&KD0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( #0P$UF]H/#UX (   8'   9              " @0V5  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ -# 36:XW>B)*
M @  U@0  !D              ("!))@  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  T,!-94\" @D4#  !($P  #0
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:+GAM;%!+!08     )@ F $$*  "+I0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>81</ContextCount>
  <ElementCount>133</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/MarketableSecurities</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CollaborationAgreements</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/LicenseAgreements</Role>
      <ShortName>AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - SHARE BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/ShareCapital</Role>
      <ShortName>SHARE BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/MarketableSecuritiesTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/MarketableSecurities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/REVENUE</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - SHARE BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/ShareCapitalTables</Role>
      <ShortName>SHARE BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/ShareCapital</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/NatureOfOperationsDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/NatureOfOperations</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/MarketableSecuritiesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/MarketableSecuritiesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/MarketableSecuritiesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/REVENUEDetails</Role>
      <ShortName>REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/REVENUETables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - COLLABORATION AGREEMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/CollaborationAgreementsDetails</Role>
      <ShortName>COLLABORATION AGREEMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/CollaborationAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - AGREEMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/LicenseAgreementsDetails</Role>
      <ShortName>AGREEMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/LicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>SHARE BASED COMPENSATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/ShareCapitalTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails</Role>
      <ShortName>SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/ShareCapitalTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2431880.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sol-gel.co/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K/A" isDefinitelyFs="true" isUsgaap="true" original="exhibit_99-2.htm">exhibit_99-2.htm</File>
    <File doctype="6-K/A" isDefinitelyFs="true" isUsgaap="true" original="zk2431880.htm">zk2431880.htm</File>
    <File>slgl-20240630.xsd</File>
    <File>slgl-20240630_cal.xml</File>
    <File>slgl-20240630_def.xml</File>
    <File>slgl-20240630_lab.xml</File>
    <File>slgl-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="290">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exhibit_99-2.htm zk2431880.htm": {
   "nsprefix": "slgl",
   "nsuri": "http://www.sol-gel.co/20240630",
   "dts": {
    "inline": {
     "local": [
      "exhibit_99-2.htm",
      "zk2431880.htm"
     ]
    },
    "schema": {
     "local": [
      "slgl-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "slgl-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "slgl-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "slgl-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "slgl-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 105,
   "keyCustom": 28,
   "axisStandard": 10,
   "axisCustom": 1,
   "memberStandard": 14,
   "memberCustom": 10,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 81,
   "entityCount": 1,
   "segmentCount": 24,
   "elementCount": 236,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 290,
    "http://xbrl.sec.gov/dei/2024": 13
   },
   "report": {
    "R1": {
     "role": "http://www.sol-gel.co/role/DocumentAndEntityInformation",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "dei:DocumentFiscalYearFocus",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431880.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "dei:DocumentFiscalYearFocus",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zk2431880.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets",
     "longName": "0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:DepositsAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20240401to20240630",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240401to20240630",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity",
     "longName": "0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20240401to20240630",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sol-gel.co/role/NatureOfOperations",
     "longName": "0007 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sol-gel.co/role/SignificantAccountingPolicies",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sol-gel.co/role/MarketableSecurities",
     "longName": "0009 - Disclosure - MARKETABLE SECURITIES",
     "shortName": "MARKETABLE SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sol-gel.co/role/REVENUE",
     "longName": "0010 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sol-gel.co/role/CollaborationAgreements",
     "longName": "0011 - Disclosure - COLLABORATION AGREEMENTS",
     "shortName": "COLLABORATION AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "slgl:CollaborationAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "slgl:CollaborationAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sol-gel.co/role/LicenseAgreements",
     "longName": "0012 - Disclosure - AGREEMENTS",
     "shortName": "AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "slgl:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "slgl:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sol-gel.co/role/ShareCapital",
     "longName": "0013 - Disclosure - SHARE BASED COMPENSATION",
     "shortName": "SHARE BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sol-gel.co/role/RelatedParties",
     "longName": "0014 - Disclosure - RELATED PARTIES",
     "shortName": "RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.sol-gel.co/role/SUBSEQUENTEVENTS",
     "longName": "0015 - Disclosure - SUBSEQUENT EVENT",
     "shortName": "SUBSEQUENT EVENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies",
     "longName": "0016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sol-gel.co/role/MarketableSecuritiesTables",
     "longName": "0017 - Disclosure - MARKETABLE SECURITIES (Tables)",
     "shortName": "MARKETABLE SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sol-gel.co/role/REVENUETables",
     "longName": "0018 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sol-gel.co/role/ShareCapitalTables",
     "longName": "0019 - Disclosure - SHARE BASED COMPENSATION (Tables)",
     "shortName": "SHARE BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sol-gel.co/role/NatureOfOperationsDetails",
     "longName": "0020 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)",
     "shortName": "NATURE OF OPERATIONS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20230130to20230130_slglMilestonePaymentsAxis_slglDevelopmentAndNdaAcceptanceMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember",
      "name": "slgl:SalesMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails",
     "longName": "0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails",
     "longName": "0022 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails",
     "longName": "0023 - Disclosure - MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of Changes in Fair Value of Company's Marketable Securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20231231",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:IncreaseDecreaseInTradingSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails",
     "longName": "0024 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)",
     "shortName": "MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sol-gel.co/role/REVENUEDetails",
     "longName": "0025 - Disclosure - REVENUE (Details)",
     "shortName": "REVENUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20240401to20240630",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240401to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
     "longName": "0026 - Disclosure - COLLABORATION AGREEMENTS (Narrative) (Details)",
     "shortName": "COLLABORATION AGREEMENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20211101",
      "name": "slgl:NumberOfGenericCollaborativeAgreementsToSellRights",
      "unitRef": "Agreement",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "slgl:CollaborationAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20211101",
      "name": "slgl:NumberOfGenericCollaborativeAgreementsToSellRights",
      "unitRef": "Agreement",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "slgl:CollaborationAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sol-gel.co/role/LicenseAgreementsDetails",
     "longName": "0027 - Disclosure - AGREEMENTS (Narrative) (Details)",
     "shortName": "AGREEMENTS (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember",
      "name": "slgl:RegulatoryApprovalMilestonePaymentsReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "slgl:LicenseAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember",
      "name": "slgl:RegulatoryApprovalMilestonePaymentsReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "slgl:LicenseAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails",
     "longName": "0028 - Disclosure - SHARE BASED COMPENSATION (Narrative) (Details)",
     "shortName": "SHARE BASED COMPENSATION (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240101to20240630",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails",
     "longName": "0029 - Disclosure - SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)",
     "shortName": "SHARE BASED COMPENSATION (Schedule of Assumptions Used to Estimate Fair Value) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:SharePrice",
      "unitRef": "USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240630",
      "name": "us-gaap:SharePrice",
      "unitRef": "USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails",
     "longName": "0030 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details)",
     "shortName": "SUBSEQUENT EVENT (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exhibit_99-2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r399"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_AccountsReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Other long-term receivables",
        "verboseLabel": "Other long-term assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r435"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r425",
      "r426",
      "r427",
      "r428",
      "r449",
      "r498"
     ]
    },
    "slgl_AdditionalRevenueContingentOnAchievingCertainMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "AdditionalRevenueContingentOnAchievingCertainMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Revenue Contingent On Achieving Certain Milestones",
        "documentation": "Represents the amount of additional revenue contingent on achieving certain milestones.",
        "terseLabel": "Additional revenue contingent on achieving certain milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherCorporateBondsMember",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate bonds [Member]",
        "documentation": "Investments in corporate fixed maturity debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive shares",
        "terseLabel": "Anti-dilutive securities excluded from computation",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r448"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r448"
     ]
    },
    "slgl_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for Asset Purchase Agreement.",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Default Label]",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r50",
      "r60",
      "r74",
      "r99",
      "r101",
      "r105",
      "r106",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r206",
      "r210",
      "r225",
      "r258",
      "r319",
      "r383",
      "r384",
      "r399",
      "r415",
      "r443",
      "r444",
      "r454"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61",
      "r74",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r206",
      "r210",
      "r225",
      "r399",
      "r443",
      "r444",
      "r454"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r206",
      "r210",
      "r225",
      "r443",
      "r444",
      "r454"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in two fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "verboseLabel": "Between 1-2 years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due within one year",
        "terseLabel": "Due within one year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r256"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation",
        "verboseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash equivalents",
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r378"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS",
        "totalLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r71"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r33"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:",
        "terseLabel": "SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ChangesInAccruedLiabilityForEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in accrued liability for employee rights upon retirement.",
        "negatedLabel": "Changes in accrued liability for employee rights upon retirement, net",
        "label": "Changes In Accrued Liability For Employee Rights Upon Retirement"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_ChangesInFairValueOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ChangesInFairValueOfMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow from changes in fair value of marketable securities.",
        "negatedLabel": "Changes in fair value of marketable securities",
        "label": "Changes In Fair Value Of Marketable Securities",
        "terseLabel": "Change in fair value during the period"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_ClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ClinicalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Expenses",
        "documentation": "The amount of clinical expenses during the period.",
        "terseLabel": "Clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_CollaborationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "CollaborationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_CollaborationAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "CollaborationAgreementsTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreements [Text Block]",
        "documentation": "The entire disclosure of collaboration agreements.",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "slgl_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestones.",
        "label": "Commercial Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r43",
      "r259",
      "r306"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r425",
      "r426",
      "r428",
      "r449",
      "r496",
      "r498"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value",
        "verboseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r307"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "label": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r23",
      "r307",
      "r325",
      "r498",
      "r499"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares, NIS 0.1 par value - authorized: 50,000,000 as of December 31, 2021 and June 30, 2022; issued and outstanding: 23,000,782 and 23,029,951 as of December 31, 2021 and June 30, 2022, respectively.",
        "terseLabel": "Ordinary Shares, NIS 0.1 par value \u2013 authorized: 50,000,000 as of December 31, 2022 and June 30, 2023; issued and outstanding: 23,129,469 and 27,805,954 as of December 31, 2022 and June 30, 2023, respectively.",
        "verboseLabel": "Ordinary Shares, NIS 0.1 par value \u2013 authorized: 50,000,000 as of December 31, 2023 and June 30, 2024; issued and outstanding: 27,857,620 as of December 31, 2023 and June 30, 2024.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r260",
      "r399"
     ]
    },
    "slgl_ContractLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ContractLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about contract liability.",
        "label": "Contract Liability",
        "terseLabel": "Contract liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for employee rights upon retirement",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "slgl_DescriptionOfUpfrontPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "DescriptionOfUpfrontPayment",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of upfront payment.",
        "label": "Description Of Upfront Payment",
        "terseLabel": "Description of upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_DevelopmentAndNdaAcceptanceMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "DevelopmentAndNdaAcceptanceMilestonesMember",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Nda Acceptance Milestones.",
        "label": "Development And Nda Acceptance Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r497"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Components of Revenues",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "BASIC LOSS PER ORDINARY SHARE",
        "verboseLabel": "BASIC EARNINGS (LOSS) PER ORDINARY SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r89",
      "r91",
      "r93",
      "r94",
      "r95",
      "r98",
      "r200",
      "r203",
      "r220",
      "r221",
      "r254",
      "r267",
      "r380"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC AND DILUTED LOSS PER ORDINARY SHARE",
        "terseLabel": "DILUTED LOSS PER ORDINARY SHARE",
        "verboseLabel": "DILUTED EARNINGS (LOSS) PER ORDINARY SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r91",
      "r93",
      "r94",
      "r95",
      "r98",
      "r200",
      "r203",
      "r220",
      "r221",
      "r254",
      "r267",
      "r380"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share",
        "terseLabel": "Earnings (Loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r97"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sol-gel.co/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "slgl_EpsolayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "EpsolayMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epsolay",
        "label": "Epsolay [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r55",
      "r64",
      "r65",
      "r66",
      "r75",
      "r76",
      "r77",
      "r79",
      "r84",
      "r86",
      "r88",
      "r100",
      "r115",
      "r116",
      "r122",
      "r148",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r239",
      "r266",
      "r277",
      "r278",
      "r279",
      "r289",
      "r347"
     ]
    },
    "slgl_EstimatedVariableConsiderationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "EstimatedVariableConsiderationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Variable Consideration Revenue",
        "documentation": "Represents the amount of revenue that is estimated variable consideration.",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_ExpectedRevenueReceivableOverTwentyFourMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ExpectedRevenueReceivableOverTwentyFourMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of expected revenue receivable over twenty four months.",
        "label": "Expected Revenue Receivable Over Twenty Four Months",
        "terseLabel": "Expected revenue receivable over twenty four months"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_FinanceExpensesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "FinanceExpensesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance expenses, net.",
        "label": "Finance Expenses Net",
        "terseLabel": "Financial expenses (income), net"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_FinancialIncomeExpensesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "FinancialIncomeExpensesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial expenses (income), net.",
        "negatedLabel": "FINANCIAL INCOME, net",
        "label": "Financial Income Expenses Net",
        "terseLabel": "FINANCIAL INCOME, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignGovernmentDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignGovernmentDebtMember",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada government bonds [Member]",
        "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "label": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r329"
     ]
    },
    "us-gaap_GeneralPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralPartnerMember",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Partner [Member]",
        "terseLabel": "Partner [Member]",
        "documentation": "Party to a partnership business who has unlimited liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Accounts receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable, accrued expenses and other",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInLongTermReceivablesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivables from collaborative and licensing arrangements",
        "label": "Increase (Decrease) in Long-Term Receivables, Current",
        "documentation": "The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating asset and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInTradingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTradingSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair value of marketable securities",
        "label": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Changes in fair value during the period",
        "totalLabel": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI, Total",
        "documentation": "Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "slgl_IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Increase in Sales Milestone amount due to sales exceed dollar 500 million.",
        "label": "Increase In Sales Milestone Amount Due To Sales Exceed Dollar 500 Million",
        "terseLabel": "Increase in sales milestone amount due to sales exceed dollar 500 million"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_IntellectualPropertyRelatedToTwyneoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "IntellectualPropertyRelatedToTwyneoMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property Related To Twyneo [Member]",
        "documentation": "This member stands for Intellectual Property Related To Twyneo."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r354",
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r407"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r354",
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r407"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt Securities",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARKETABLE SECURITIES",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r54",
      "r111",
      "r112",
      "r223",
      "r224",
      "r463"
     ]
    },
    "slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of issuance of shares and warrants through private placement.",
        "label": "Issuance Of Shares And Warrants Through Private Placement From Controlling Shareholder",
        "terseLabel": "Issuance of shares and warrants through private placement from the controlling shareholder"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of issuance of shares and warrants through private placement, shares.",
        "label": "Issuance Of Shares And Warrants Through Private Placement From Controlling Shareholder Shares",
        "terseLabel": "Issuance of shares and warrants through private placement from the controlling shareholder Shares"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants through public offering, net of issuance costs.",
        "label": "Issuance Of Shares And Warrants Through Public Offering Net Of Issuance Costs",
        "terseLabel": "Issuance of shares and warrants through public offering, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants through public offering, net of issuance costs, shares",
        "label": "Issuance of shares and warrants through public offering, net of issuance costs, shares",
        "terseLabel": "Issuance of shares and warrants through public offering, net of issuance costs Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r74",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r207",
      "r210",
      "r211",
      "r225",
      "r305",
      "r381",
      "r415",
      "r443",
      "r454",
      "r455"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r44",
      "r262",
      "r399",
      "r424",
      "r439",
      "r451"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r58",
      "r74",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r207",
      "r210",
      "r211",
      "r225",
      "r399",
      "r443",
      "r454",
      "r455"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18",
      "r19",
      "r20",
      "r21",
      "r74",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r207",
      "r210",
      "r211",
      "r225",
      "r443",
      "r454",
      "r455"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM LIABILITIES -",
        "terseLabel": "LONG-TERM LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_LicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "LicenseAgreementsTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for license agreements information.",
        "label": "License Agreements Text Block",
        "verboseLabel": "AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_LicenseAgreementsWithBeimeiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "LicenseAgreementsWithBeimeiMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements With Beimei [Member]",
        "documentation": "This member stands for License Agreements with Beimei."
       }
      }
     },
     "auth_ref": []
    },
    "slgl_LicenseAgreementsWithGaldermaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "LicenseAgreementsWithGaldermaMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreements With Galderma",
        "label": "License Agreements With Galderma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_LicenseAgreementsWithSearchlightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "LicenseAgreementsWithSearchlightMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for License Agreements with Searchlight.",
        "label": "License Agreements With Searchlight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "terseLabel": "Sale of IP and license revenue [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets",
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails",
      "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of the period",
        "periodStartLabel": "Balance at beginning of the period",
        "label": "Marketable securities",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Marketable Securities",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r164",
      "r193",
      "r222",
      "r251",
      "r275",
      "r276",
      "r282",
      "r297",
      "r298",
      "r355",
      "r357",
      "r359",
      "r360",
      "r364",
      "r373",
      "r374",
      "r385",
      "r386",
      "r391",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r445",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "slgl_MilestonePaymentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "MilestonePaymentsAxis",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Axis",
        "label": "Milestone Payments [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_MilestonePaymentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "MilestonePaymentsDomain",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments domain",
        "label": "Milestone Payments [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r164",
      "r193",
      "r222",
      "r251",
      "r275",
      "r276",
      "r282",
      "r297",
      "r298",
      "r355",
      "r357",
      "r359",
      "r360",
      "r364",
      "r373",
      "r374",
      "r385",
      "r386",
      "r391",
      "r395",
      "r396",
      "r397",
      "r401",
      "r445",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NetChangesInOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NetChangesInOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net changes in operating leases.",
        "negatedLabel": "Net changes in operating leases",
        "label": "Net Changes In Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "label": "Loss",
        "terseLabel": "Loss for the period",
        "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r35",
      "r45",
      "r56",
      "r62",
      "r63",
      "r66",
      "r74",
      "r78",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r87",
      "r88",
      "r92",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r200",
      "r203",
      "r221",
      "r225",
      "r265",
      "r327",
      "r345",
      "r346",
      "r413",
      "r443"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Newly issued and recently adopted accounting pronouncements:",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NumberOfApprovedGenericDrugProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NumberOfApprovedGenericDrugProducts",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of approved generic drug products.",
        "label": "Number Of Approved Generic Drug Products",
        "terseLabel": "Number of approved generic drug products"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NumberOfEqualQuarterlyInstalments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NumberOfEqualQuarterlyInstalments",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal quarterly instalments.",
        "label": "Number Of Equal Quarterly Instalments",
        "terseLabel": "Number of equal quarterly instalments"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NumberOfGenericCollaborativeAgreementsToSellRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NumberOfGenericCollaborativeAgreementsToSellRights",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of generic collaborative agreements to sell the rights.",
        "label": "Number Of Generic Collaborative Agreements To Sell Rights",
        "terseLabel": "Number of generic collaborative agreements to sell rights"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NumberOfGenericDrugCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NumberOfGenericDrugCandidates",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of generic drug candidates.",
        "label": "Number Of Generic Drug Candidates",
        "terseLabel": "Number of generic drug candidates"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NumberOfGenericProgramsRetainedForCollaborationRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NumberOfGenericProgramsRetainedForCollaborationRights",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of generic programs retained for collaboration rights.",
        "label": "Number Of Generic Programs Retained For Collaboration Rights",
        "terseLabel": "Number of generic programs retained for collaboration rights"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_NumberOfUnapprovedGenericPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "NumberOfUnapprovedGenericPrograms",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of unapproved generic programs.",
        "label": "Number Of Unapproved Generic Programs",
        "terseLabel": "Number of unapproved generic programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "OPERATING INCOME (LOSS)",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r382",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturities of operating leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "slgl_OtherForeignGovernmentBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "OtherForeignGovernmentBondsMember",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other foreign government bonds [Member]",
        "label": "Other foreign government bonds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_OutstandingPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "OutstandingPrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of outstanding principal amount.",
        "label": "Outstanding Principal Amount",
        "terseLabel": "Outstanding principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_PaidUpfrontAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "PaidUpfrontAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent amount of upfront payment done.",
        "label": "Paid Upfront Amount",
        "terseLabel": "Upfront payment paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnerTypeOfPartnersCapitalAccountAxis",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partner Type [Axis]",
        "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r290"
     ]
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partner Type of Partners' Capital Account, Name [Domain]",
        "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r290"
     ]
    },
    "slgl_PaymentReceivableInInstalments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "PaymentReceivableInInstalments",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of payment receivable in instalments.",
        "label": "Payment Receivable In Instalments",
        "terseLabel": "Payment receivable in instalments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in marketable securities",
        "label": "Additions",
        "terseLabel": "Additions",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "slgl_PellepharmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "PellepharmMember",
     "presentation": [
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for Pellepharm.",
        "label": "Pellepharm [Member]",
        "terseLabel": "PellePharm, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest received",
        "documentation": "Interest received on loans and other debt instruments during the current period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of shares and warrants through public offering, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of shares and warrants through placement from the controlling shareholder",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "slgl_ProceedsFromLongTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ProceedsFromLongTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of proceeds from long-term deposits.",
        "label": "Proceeds From Long Term Deposits",
        "terseLabel": "Proceeds from long-term deposits",
        "verboseLabel": "Restricted long-term deposits",
        "positiveLabel": "Long-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.sol-gel.co/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale or maturity",
        "label": "Proceeds from sales and maturity of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "verboseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "slgl_ProceedsFromShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ProceedsFromShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of proceeds from short term deposits.",
        "label": "Proceeds From Short Term Deposits",
        "terseLabel": "Proceeds from short-term deposits",
        "verboseLabel": "Short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed from exercise of options",
        "terseLabel": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r252",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r377",
      "r387",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r441",
      "r442",
      "r446",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r252",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r377",
      "r387",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r441",
      "r442",
      "r446",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "LOSS FOR THE PERIOD",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss for the period",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r62",
      "r63",
      "r69",
      "r74",
      "r78",
      "r84",
      "r87",
      "r88",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r200",
      "r203",
      "r205",
      "r208",
      "r209",
      "r221",
      "r225",
      "r255",
      "r264",
      "r288",
      "r327",
      "r345",
      "r346",
      "r393",
      "r394",
      "r414",
      "r421",
      "r443"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r238",
      "r257",
      "r263",
      "r399"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r160",
      "r164",
      "r189",
      "r190",
      "r191",
      "r193",
      "r222",
      "r249",
      "r250",
      "r251",
      "r275",
      "r276",
      "r282",
      "r297",
      "r298",
      "r355",
      "r357",
      "r359",
      "r360",
      "r364",
      "r373",
      "r374",
      "r385",
      "r386",
      "r391",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r407",
      "r440",
      "r445",
      "r450",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r160",
      "r164",
      "r189",
      "r190",
      "r191",
      "r193",
      "r222",
      "r249",
      "r250",
      "r251",
      "r275",
      "r276",
      "r282",
      "r297",
      "r298",
      "r355",
      "r357",
      "r359",
      "r360",
      "r364",
      "r373",
      "r374",
      "r385",
      "r386",
      "r391",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r407",
      "r440",
      "r445",
      "r450",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "slgl_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents recognition ofoperating lease right of use assets and liabilities.",
        "label": "Recognition Of Operating Lease Right Of Use Assets And Liabilities",
        "terseLabel": "Recognition of new operating lease ROU and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_RegulatoryApprovalMilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "RegulatoryApprovalMilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory approval milestone payments received.",
        "label": "Regulatory Approval Milestone Payments Received",
        "terseLabel": "Regulatory approval milestone payments received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Consideration for agreement",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r243"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTIES:",
        "terseLabel": "RELATED PARTIES",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r285",
      "r286",
      "r287",
      "r330",
      "r331",
      "r332",
      "r351",
      "r353"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "label": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r375",
      "r383",
      "r462"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r423",
      "r464",
      "r466"
     ]
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted long-term deposits and cash",
        "verboseLabel": "Restricted long-term deposits and cash equivalents",
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r39",
      "r261",
      "r280",
      "r281",
      "r284",
      "r308",
      "r399"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "terseLabel": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r75",
      "r76",
      "r77",
      "r79",
      "r84",
      "r86",
      "r88",
      "r115",
      "r116",
      "r122",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r212",
      "r214",
      "r215",
      "r217",
      "r219",
      "r233",
      "r234",
      "r277",
      "r279",
      "r289",
      "r498"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/REVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ]
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "terseLabel": "Royalties revenues",
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r376",
      "r379"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails",
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Sales amount",
        "positiveLabel": "REVENUE",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r67",
      "r74",
      "r99",
      "r102",
      "r103",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r114",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r225",
      "r255",
      "r383",
      "r443"
     ]
    },
    "slgl_RoyaltiesMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "RoyaltiesMaturity",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Maturity.",
        "label": "Royalties Maturity",
        "terseLabel": "Royalties maturity"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalties Percentage",
        "documentation": "The information about the royalties percentage.",
        "terseLabel": "Royalties percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "terseLabel": "Royalties revenue [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "slgl_SalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "SalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent of amount the sales milestone payments",
        "label": "Sales Milestone Payments",
        "verboseLabel": "Sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Changes in Fair Value of Marketable Securities",
        "verboseLabel": "Schedule of Summary of Changes in Fair Value of Marketable Securities",
        "documentation": "Tabular disclosure of derivative assets at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails",
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions Used to Estimate Fair Value",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "terseLabel": "Support services [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "terseLabel": "Share-based compensation expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vesting period",
        "terseLabel": "Option vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails",
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option grants",
        "terseLabel": "Option grants",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "terseLabel": "Exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of one ordinary share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options granted",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "slgl_ShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "ShortTermDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term deposits.",
        "negatedLabel": "short-term deposits",
        "label": "Short Term Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES:",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r72"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r23",
      "r26",
      "r27",
      "r55",
      "r64",
      "r65",
      "r66",
      "r75",
      "r76",
      "r77",
      "r79",
      "r84",
      "r86",
      "r88",
      "r100",
      "r115",
      "r116",
      "r122",
      "r148",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r239",
      "r266",
      "r277",
      "r278",
      "r279",
      "r289",
      "r347"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails",
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r100",
      "r234",
      "r252",
      "r283",
      "r291",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347",
      "r408"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails",
      "http://www.sol-gel.co/role/REVENUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r100",
      "r110",
      "r234",
      "r252",
      "r283",
      "r291",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347",
      "r408"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r22",
      "r23",
      "r39",
      "r175"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r23",
      "r26",
      "r27",
      "r39"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets",
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26",
      "r27",
      "r37",
      "r309",
      "r325",
      "r348",
      "r349",
      "r399",
      "r415",
      "r424",
      "r439",
      "r451",
      "r498"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL:",
        "terseLabel": "SHARE BASED COMPENSATION",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r73",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r218",
      "r350",
      "r352",
      "r370"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.sol-gel.co/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r453"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.sol-gel.co/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_TwyneoAndEpsolayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "TwyneoAndEpsolayMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Twyneo and Epsolay.",
        "label": "Twyneo And Epsolay [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_TwyneoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "TwyneoMember",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twyneo",
        "label": "Twyneo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails",
      "http://www.sol-gel.co/role/NatureOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.sol-gel.co/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S government and agency bonds [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "slgl_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "UpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/CollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "slgl_UpfrontPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sol-gel.co/20240630",
     "localname": "UpfrontPaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.sol-gel.co/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments received.",
        "label": "Upfront Payments Received",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.sol-gel.co/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Options and Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r95"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.sol-gel.co/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r95"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001178913-24-002671-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-24-002671-xbrl.zip
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MF\ZX.X\=>/%#@)-O7P-/3+@-FMY5WK\;^M !-A],P,N90+ *E@.8?2@8G\W
M!*"T\&"I1;SAVU-V.#C#V^#^_)6[X O-6=U 3Z@-:QX-_P,N$[:6:CS =B'>
MY<Y6A63CD7&KV6AW:IU>G7=:HV%[V&CR9KO>:1QPJU-KE7'$$XE59O;_B8+0
M'LU_94!DL.S,R6T"]G=DTISQL2](  ,924!X,%,,?O7/?YVB)(!0#<XOST[Z
M_T*K,XA\;R;HZJ47P2_Z([ EG"Z C^6*L1>"/4+Q0_Y!(P0NF>[. BDGXW6"
MC[#^5,0_]D#(04R%[]LAB/YBGJ@@LI1'^MP4Y_U\P;N>/!U<7K)_'Y^=]@UV
M'/A<. ;K1V,8!*MW#9GQV\>]CP$['?SS\I_'%X/7K,)^F876+'(ES(F+WK*-
M8G@26E65DY;4V3_M7Q[U__Z&79Y\/GF-'GC*OP;Q(UUJL!DLN)".>XB[+9*W
M,'*-77MBM$  :T/("?H]O9X8@!+3P!#P,_@KQ$HK1,?[V($EQO80/!R@3>/5
MZW3$'*B(V2!NHS&$-Y[2W"@1W!^+"KA-P,&@\M.34XX3#$G*A/*74I(AKX"A
M\BP^AQNN%T%@8[%1G('5<3>.*"?6%JXEK#0A_AI!L-ZLR7658Y[)E"K8+B"-
M3JI&E%2MWAY"K&P5<L5@?=;/2173;LC?&Y)%<287,G67I(:/@!L<;T;,0EL@
M#QKT&C;MH-ZV6@<U83;;HU:OUQF"(>L.:[6#1JW>'0U;Q;1IZ1Q(UDCEV*-6
MM;&^17IT>Z127;'&:FO.CD,<:9@XF)";Q"Q)03WG%A_;0,B;B6VBD9HYW 12
MHR#-0(! 8RDO#H3$!@D#RCE\B+R%#F+2FI8^*^$WY35.P12AH-H_9> $BH6O
M%#9)_KL[=JK*A[Z!D/N+9CJ<D-E,S=F03\<9:_P"ST"_H%2T?N0.&'.TZC8-
M!!Y1J@0NS_A<F70BUXWM..C\SKAMR50AB.$4>'$B$^;@C#/<$ >9L>RQ#;ZX
M-^<.$E7F7L:^%P1(AA$&H'0IX(X@#WEYPDABSF9 *L_")T:X G/!?5@^4,..
M+2*\C$VU:Z\6J4%>-3XWBL((/N7U'<&<: !5=NS&7D8>U6CF)F:,D"9D2-PY
M [<E"&'B\KNEN\)] XBOA</5/@"MS)W\5&57P$Q\"MH^5!&&6A+*J2JVA3MC
M0=Z-M#KP$^'84S -FM/D"!9I$:=G\0-X3\N# \TDPJ7M"W<"-D? -'VYRS'S
M J(0#HG,W0\;3)L 1OF]PV#M'+A719WLC5W[)UGN"0_S_+\)Q]EG4F^)Y$ _
M(= $/X&3YQ&9P5S1?+]5+ZL&LR+R"_X:0==9X0?COL0)D0DB'HPB)_%: _L'
M\(9-?=SFP7X7<]()+L9E)K([19JPN,IWA4#1Q 5#'W/)CZW&0Y(D);'#WM/>
M;*K+N .<Y93_!SS7<(Y+FG%P4SVBSQ:$/B@:;I"I^#>XQ# *8W'^<E1_\T"H
M@$X@NQ ''X?<F<OM5<\/HS%WB .1"@X\9\6$2HTPRWQI:J$7#\K<GJ$%UM-4
MB27)D49VFP">43X(N!T@BTIY^F(< 5^BUP3<)((0/,!$!P$MHAG^]/=FM:O9
M36OR&]TZ/+!(  CN01L#'R/M^8S\P!R>5)MTJ4'XXK^1[8NX^Y HA"HV%5U4
MV4>.H"%/S1?H#,)""D ),"F;I6W#R/>UT4CX7?.;L<P]MT@2:2:'@T*?:))K
M[EFDPVTSP-^!%'6I7=RHT<$;C-Z92Y=Q%*=:5%^RI>R>J9]FA,PJZ]E(UL$$
MBQNA+TOV 0E]+=P(?-F0-#\H59]623Z>U31UO?3$"HWXFYQ$AT8+RA['NDB
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M"K=RYF<LS1\!1=SH_;$C\([-T*,2 UFDAIXE*6PKH[$/)[88I>K8SD80%X
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M;S8(39/%P"U"F04M7LSVZ>RS5/8?#P_O1"X;:/4T(+J:5QE/.\2!-\5<A8?
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M1[&E]+'C;)4'_!%2L;>L1\%S1%!5HF/,@HD7.9C9EW 78#/IX=\RTU2%NL'
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M>I36&'DJ02/1'%-#E:?]T6Y' DM+11&T'#I9J4C^ANW;KQ6@3OPWXF:,+4X
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M0NA6"D+*<#8V9!B:D LCP;@-BI'@!9 @+9MB?#XU(\&JDR!5.=QQME9&@A=
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ML.!"T28 OBYPWP6;Q-*8N&DN4%T*!0JQU15"->FN2R9Z5RB10%P7B,:CXCF
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MB2WTVX,8%#$H.N*B?/N"1.H8G Y%*9;0XEE)%5;)(+U*!M&D$5ID4MI GGH
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M3636T_7H&HF=NJY8-MHBT*9@+FTDC]@<@*\J7#C GKD;R 0LH.5]0SN#DC!
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MT.(>H0JU'W@;M<'4,N=X"73EV<0 ]P-ZT*9"PR9P9UD8!,.ECNG<\9B 1U6
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M8H8>,[&6+S98: N(W_,:! <R4VQR%_<.Z!IR\@UXJ_T&QC]7!C31)#?E]QQ
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MTXE]>8K$0@?GM"+DVC<\$HH^P0-"^'<-'G9>Y"-;\&+;03R.I,B-"/E3P;'
M&W&8O(R?B;R)0,5)C @85]X=YM"9H0D/CR7_S9A*0B>[FJ*K2WV=?S_9II\U
MX7#1G2A15@].[(GV^>X@2O"78[0VGO=<;^0$5QF\)2RFN,F7VWN!F_\3NP7(
MP2W CST_[VF?5O$W(!'I[A/^=(DS$H1.KK>#KJO^X.Y0\A57YP6NV8A)V(GC
MATWZ[LR"T'<.Q(JYMJLH8\Y!O.;C%;H"KGS%">F@)EYLMV@ G$ZQ0OK3%[O0
M\[0:8Z/$;(3!-QCM<1H'R0U)DO+C(*$"'-1N2URKWCJ2@];*XFXCP^&$&T$2
M<2<3(=)3/:L5VZHB7<H5JW/MAH!6+0;SCICU=H./9"-F-^MRZ6>]R0DBSR%X
M.8%/?$/;@5U'PCD"]L(OH\6A7415ECB%$5V;XO:26(4][*X^O%N%G%RR'Q^<
M4GCDMIJZ,^XZ"]_T\<XN%ON]COUNL=AO%OO-8K]9[#>+_2XF]OMX[3&K37+/
M*Z7))>>SWW'Q&<>%D<4$O9\[@$C0_(D&[*S6?8<58U^L_1&=!_;*G0?@[J#W
M8Y]@EZ 722)'C]QJ"!%'#QIQ(/X/P2HIB$G<8>E' ZZ'6X*P/OQG5R#3KO ^
M]^!)(7X[+RTLS.\Y(EX=-?8= 7T[X_7(3?9$CVW.."8G9]>.FWD>#,12 HYD
ML.TE]NX$([6"3,81D^0*.[(G)H[5B@-7CWA2>O?"ZM5OU965W""FN\[HDS]-
MG=$3.5+CF\ KY#F"+R1VZA%Z>=PWH#\GE5S7R>#N(0(I_MG=C8_>J_^)XP@T
M&[PL-3> #KXNL) (%LMG'7L<T>)@8X\7E(7@Q+U1T-F_L+2Y&Y_RO/(\_\03
MN#X%6Y^#J2+^3?R*(VYT 18_W=(-%KH5?A7BCO2*-*HS#4X#&0G87F1CLQO.
MB+>\?'_/\8:#+I#$BXNN>%G\.&^&N.#<L7C/1\^8XCPBB]C$N4 9(S>'95.S
MV,N$)R5$O>@S;'=RTUK\VR%Y<&YSWE#<,,'@-.$*"-YPO/P,<EFPE'%@-&Z-
M<5)=]1H\A!=C7;/<K<L5O:<WEX$ZD^YLKLOX!L=%'J3KY%AL#(?KQ^R,;H'8
MXMVXDS6Y(-)Q#6:D6@TN?*+AW"@2NH)C39 L8I!P0&Q%V$2D>*59I/!L^<%T
MWOH==2N9<V<%$NHAH(%7"=URKCEH_=UQHSW>F'A!+5M3]$S*1I-BM19$BM3&
M/HB/X@E"=([+77N#].H)>1&HAKLXF^#%^#C-K?*EI$@/P4/X0]&77B62$#_B
MJFH05RA%,.;&C;J%)Q"ES)65&Q"+C<_.SGC)8" /J0;D9=%MEOIPPM76;K/_
MA'T[8GR0(?X3'Y$8#39T#^RPI.X<'^WI16[WCR8OBLV&$/$7]$DI8[*&?:,+
MGW%]U:_K3*\>"4X-&.:-R:V;9#JV%"Q%NLWH-]B?<T)2@1U"),R/O/"^YOW[
MM?/X/[UQY]-]#XQZMT^/_3')+-J;1[1-.)G'1>;F,,9H--T4W_%V$->GXH2J
M@*]A+3Z_T/?!>/&I<.*CY.%\\B-G8?=L'E#U<"G7=KW1:$>R@C>,M&&A]/2Z
M>-E]WUOO4PU=F_M:*TR@);I:1ZO^Z_L8#\)IVN.6RIBRDIBXXZ7?Z)),7#NJ
M$1YN=GOB@]-ZCGC:<PXHBD?8]G/!85]0<Z='$KBCA(VLE^W(YLV,8G*@&.RJ
M]ZB%KP2U[!9Z4\%#;/J*@&%,&^"\\#'#1^]D #P'X<[8WD;G=<?>,XB$W)&H
M]77\I;0P%M8S\E/U,J*:?!";T3"@EH;E2Z7AC/>1N3:9Z/#T;O%GD&$&A'*/
M2Q !,:"F)BEN%IKLM,CBC!E-&5UR'$AFDY+/!D#%FA4P%MJ6+1_,<ZTDS<:O
M94"VI^L1>#'10(UU?37E!1KJ"CR;QN1P5<&MZ4V+,CS?_,XI3)T4<W]@0 8B
M72V]$;1+035[*B76A20VT5O76167=B"@_[Q4@(VK C=+">0(/(T^KVGV=E,#
M$GLK.IAZT1,VSTJQ<8K(U5O17 (ZF22?K8TQ:FD9-9'S8C>C!K/GJ&-4@6L(
M8K49-6]AIB*JW)"$V> <8#3"H.A#A[Q#DWA.Y:!VPW%%"'0?9$>".5*5K7#O
M.<(>=RYW;*#[$^:-5.&Y+4>;X):7^7*6M6CB1RH'=9D@X8>HB'Q3%(2F($B-
M>BM;*2]7R&A&FS9?'&3D+?4E]UW1Q!Z^J@%=J>Z_"R>3 CWH&U(-N0/1$#Q7
M8"A[@0*$/F.8V;LN"Q<!(U57,C"O=707U-=LE#J8UY$ >*9^GJ<O]F@^SED@
M9/#"X"4=>&GE8!3,'EX$3A+/U"^K""\%"X\R>IV*Z%]CTU%TVJ3*,^<WKZT!
M%_*9F$N<@A "79J&GG3_R.!=JKS);#+4FD00%>IM.5H8^P2)-AWO+L_),9WT
M2K=MG(4#Q4JN#,(8A)UV:5$0)@J"P$=Z^)T@-:<C^<I<^US']Z5"6%KIY >3
M-(_(1-V^M)C<WO\&@:1Q7*)@R[X*+)*GV\'U)F9H*-!*4@5@5\OF7;GXJ67W
M%CZ?H9ZXNMMEA_0YQ:VL</$&Z)6GQ14;_%HC;KT%U7PQT.-)C08MO"@3^.P$
M$ZECFIGANALML<Z!NW5%A[YA.];2*^E@AUK'N&V_;/(L7!5D:NJ:2<;A59B
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M/Y65C48VL_QS/ !WEX)'C!.9:8+J^,AFN8)S*$?6@)1?\@ 5VRC"+QUA3._
MU3O_#2+OD2#/.KRH$:+P!Q':E?8M9*BT%%Y*QS*-EW,(81>%C8;WM<^]>S#N
MW7X9#.^'G_N]$;@?=R.UX_PAG#(]X9G^N &9K:)9B:<D 1=N,"N7QV6P-#MO
M&2U%MG53=ZD&PS%:R_$0W X'W=Y@U.OB3VC!^]W.&'VYZP\Z@]M^YQZ,QNB'
MK[W!>+19YV?KW<>W3]>C:R12Z;IB>:7RS*6M&!,T,0BJX<(!]DSQ"EHNH.5]
MFRB.$O$<>_\L$E%0:+Y?XQA\!XV=S&$']KT,EO?MDZ$L)VBSGR3SLB<MO$J'
M_3%Z5:@,!:9-(.'BBKSPON;]^[7S^#^]<>?3?0^,>K=/C_TQ!B-O5MYBR5,S
MEGBZ]M\[4GIQ]ZP>/5.["RZ^"X@O!PHRQCR)_*09$T3^.1;,[-C8,!RJW,'%
M%K_<+H,Z4[PJMP@:S)]NA5(W/@@S/SRR^F61=2TE44"T%_44K<OQWJZKO7Y:
MW:*)Q6K)4M']>*@N>EU6X#+U I<TE/@I376AM.M=GF'-H*4FD6O#<&.GJ#4@
MT.Q0S;T83N%%=_8_YWAW;Z'T[^_I%U\4D08T9QM)>3>2HZO9L0TDZ4MX/0;]
MER!R?'OA>W=:K=B(HT(B=H+:64V\#A3G=ROV-Z^%K7K](G\MU?-2X[I+Z'>B
M, VWBC)M(3YG+EW!@9_,@5A^YS!;VA-\PY$R1)T?BJ9C(\2=:>',L(V'N N?
M'<\H@K[]2>!H:,#_(#!:=P)A[N.LH9*^?FFG^()3-@SFUWTHW$;H63&^(PI>
MF#9NNZ4L%I;YBFC5Z[6%SE05RUIAZRFYA .VAD-VT;$5>,:M$#0L^$+;P5&\
M%KE.U4T;XJY/))K7@I@= PVBR$G7H&\ Q2O,Q(')<GV!/3,MIX;;12&V=KQ.
M9.],"^CF3R3*V-_]G\,]D-Z@YRKVC'AYR ?XUU)#0\;F40[@ :*%Q;V/H@=Q
MU[(E[D=F015JI'55X,>%LB(&37QC$[<1]W^Q ;<]1<K<O29F&C>S?H#9MWX(
M?0U\B279!)$1WBU^"1IP]]F@9;XEU 6<J(0^1JHA/<(?T%A"G(/KVYTQJMXB
MF=1$-SO?WARV,A_I"LE'^R)N(GG+300>>W_T!D^]_4Z&$W#DP!10UNELXWOQ
M6P*MNYW%N7 LEYR.:%F&/<!9>0;7"W#84[=O(2/3'Q*N$O&>)+9;D93#KF8K
M+R\6?%$PA@ZG'B^FZN@YV9ESC LG,/,''#COUSZBB( :W>CCI853.I,E'_Y)
MJN&YYI0\A[>SPUFLK6Z'/A.QF^U0-T[24/:RXI&$&-@Z0O85(5E0W-&P,UHW
M"CJZPU297]MS!"1^VYV'CN2PJ/TV YX[7MG)#P]B&)%A 25,,9Y9$#(TR \-
M\MIOCT:$>,,'DV^R&%XJ+;/. N \T2]OUCZJZQO;Y:G8Y1E'9,P1R5WWC",8
M1UP"1[ ]@G$$XXAB]X@+T89<@W)=3%8@]6Q-Y""9AJ*X!/E:W';?2-?M9)EE
MF9#BH[E2=))=X[EJ$M)E*L1W5"U;FG3:? =^ A06&(R5R@2?5QJ[(C.^M^@@
M=B6*@B@WQ$9;CD1,>:[# R5*L;?PFVTY#Y8Y6:K.T!I!ZX>FPLZK9G];VOA.
M+CZLOI)&[^F4TQ9.;G!4.M[-6D)D %HB=F8 2B> 2I(LMH\ T*UPB]P!5.#X
M^LF%H$O'O0Q"J1@X'0S-()1*"&WAKN2[0DGC95"Y4!E49#)H27&HM .G@YT9
M@-()H$*C'FU!LE<&E0N501NGYSR5CG>I,6A?O+':;<\Z!?T'DKRC(RHW;%BH
MY9K*#8VF0>W>!"X)X)MB76@>)R$?8Z6]=SDA18"76CP= %\6Z9<FGJ-R4 P(
MB+51;K6E8]PUQUD;TP<"F6OQ# I*RW54#HI!@6LUJV=I-6,R 0,"V@?%@(
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M%A!I?2A )W%@8PH))LZA&PZ-"O0C@_0<HL.'<I7!% B$W#_B2#":@$?'LU#
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M_,F*/;COC(Y)4H-;_ 0_RF.6=DI8LFZI>DJ50$M&O%?EKV=8#3Z/D# J4M<
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M:S'=(D0_]V.[#<"UF";@ZL>>#+=QO!['!#[\59MG53*@Y5D:5;O8E6)#IKD
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MF!M^'Z7D*P.O3;@]Y79T4ES=2*NX,%4%T"[/5QR2;_,Y^'OJ8/X$H5EBFCT
M6%!C-VC+=F2RB71) EH%< C3:U;VLO2Z$J*%ZGWH"GN%/?3I?U!+ P04
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M>Q))]F 4E.>!$BJ_93L/5\J\!;FV93O72NV1*.%$"[EL#;7/;'L\1M+3 !X
M)+8JUV".., 9QLH2FI;8;]E.;D/(@0PK'4 C8;5,1/EX)A%3.)8!)T#E>S<=
ML=_:)+D,%MNF>=D #=)EQ,<=(#;?-EB/:+)X-DMF:R .9RE]2,E,@8*F2Y)R
M&+)&J/"'J[H@B)E@A,Q7+ZU>>X2RRKZJ>P<B4X;G8M%,,<HC$MD,PDP%]HY
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M=W8D.Y7;7O63F?H\W[H* /_TRZ,<U$;2]'%0L@7N8^S,0.Y#_?*-7M;G%2W
M3L=$L S?D =)% ;P'BS\DN I<6/5^("J0(272%ES36!RGP"P!7%!WW'@/,D=
MM)I8O*ZJ0V@"S4Q83' '7E6,XAZZ@BHTK:K.'<\L[4]SJE'0A?%92AGAL[K9
M4-E5*T"0,RU2%3QPT!QXY5#$/92]J0),CX!R?HO](CS\UGD':;W31QR,$D7L
M;K)<@>4<XM,F[#+J*09AB6(J @=#^NY<!T7JTW6XBN$P3/XP>'$@U;"97([?
MG9W1=A[?VZQAU%'/='#6IB^'WFJQ'WLL^)H>4N0@WA)5[SPZ-ZW6*7U8KT>N
MOZ1-D .\[#,>X?6\T6YT?MZ0T:4T $&SUBXRTC2A\1Y>^$,C7!(XI_D:N;61
M$R*\U:BS/&)"#)=C^N<8!-I;-9FG7<NRM>5AM_;PBHP4QEWUE8^O$+%@(RA;
M+2P]V.IT<$Z\Q#)B[^EO>-6/]T)^EXCL-RW&80DNA7*X54A;V8/L.O8RL!S2
MU"Q)>T]NN5&JQ?=+=)5IVZN6APDVJP>*36ZOEQWE9C]+8Q(-\$5L?K0TK-$
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M?U8TOW_;$3PHR,4NB$.\%_SH[(5$RU?P@?O;,(T^0PSTS-VFZ21D];.B.=\
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M>+1>(:KQ0<PO?;)Q^;.U3P!YR HPU7B.WF&JF>^9WWH@=N0\^WCU\ 2D#6X
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M%_0Q:N I^9TP-C7"FJT!D=/1N.O2W_05J*.Q.*C.9JBGL*?+Z8>RX<8F%N$
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M&H_F4S K@R&:M!+,*(TJ\7'T,+FQQK//>$>%/HI@K#NFM"#J#7WH-ENUT%5
M+']%?=*\Q7V1E\X8D%9T\7*64D:429]B\GN*(?1+>R1:$EN4VGQ >HA>=%;<
M@&[R /80=DL,?83<>/1\!+XM6:>!?@A9Z7PEF'/JX\<'<-#TUM\7^-\!-+L@
MQF]8NL%LEB/0>\'SQ W<A@N ,K"+,C/9Z$UF:*:[G4\7>[9?K-:GP3J,MG;[
M0O=Q/K^;X#77T>+OUO3^=K;X3*,((P%J5H.UMD?*M2$5"9+&#.[QX5/X0J(
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M\ ?B8*8FM/3DF^.GT!EXIP^S?=,D.WY:3^PH@#[!=#U:-Z<H-->L6ZCV W^
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M1&INH,Z%$E85B /'D;&8PO@@JUG;B*A"P71)=7R38]/,YE+97<4]MWJ_%>C
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MHDQ8G0]!+^O/0N_!MX*PHR@D/V8Q%5AW[>@.54CQV",#MO(.,<0\X%4 D^]
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M@&@1IG4A=Q!] ?$R\LL-_F2R5'TP[5+'W++MF6OT#KHO,!!$]!PUU*Y-S N
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M[P7-%=D<D5]-\2#@"QT3DN*6#%UD:CGY4Y4M&5 /4XOGPZJF+%.HE0\*#5E
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MZ)#'(0$7\(P7'AZPW*_$(IVS?F0<&V:]9ABU&G#F=W.)N,I<#7^2E#(R)-+
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M;O0X&1H@HM*PT3A49WTR/6X8!9\"<75,2-*1^RYQ9Y*:?7H *\@#Y00(<.B
M"M1LE@V9"4E,"0HY#0"W?,:()9"83?P1PQ,'%B;(E!CS&6_+:<1V,6"5==J[
MQB*^G7SWZ7RR<G*0Z/D,A!6N?K 6)H<U$-CZ*  ?+V'<P ;)P0(J^RSZ@9A1
M,8O+Z";*>8! 6&LY$3))%@X:$-=_/(P&3@Y&*MO#,,%DA"6I 5EC@)!I4:@A
M=GF]]WF:?T]+YK789!\X,E&Y.2.P6H+DL!#8DK8$;":@DIAG-?<12U@J]__L
MM(4<11;RA!87X>UW8OOV'%RCZ1/,L.+!:OT##R=Y#=V4HP.V2G\%0A%8!I'
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MEAK37_)(95+9XLARR6'-ASGRF!!=1!\NJ<B/",DO"HFQV_D_4$L! A0#%
M  @ -# 36:EK@_F#+P  I0," !               ( !     &5X:&EB:71?
M.3DM,2YH=&U02P$"% ,4    "  T,!-9B1$+F'^#  "$J@@ $
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@-#,Q.#@P+FAT;5!+!08     "  (  ("  #_;@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>zk2431880_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:slgl="http://www.sol-gel.co/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="slgl-20240630.xsd" xlink:type="simple"/>
    <context id="C_20240101to20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_srtTitleOfIndividualAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240131_srtTitleOfIndividualAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_20240131_srtTitleOfIndividualAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtProductOrServiceAxis_usgaapLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtProductOrServiceAxis_usgaapLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_srtProductOrServiceAxis_usgaapLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630_srtProductOrServiceAxis_usgaapLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630_srtProductOrServiceAxis_usgaapServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_srtProductOrServiceAxis_usgaapServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtProductOrServiceAxis_usgaapServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtProductOrServiceAxis_usgaapServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20070101to20071231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="C_20070101to20071231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="C_20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">slgl:PellepharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="slgl:MilestonePaymentsAxis">slgl:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="C_20230130to20230130_slglMilestonePaymentsAxis_slglDevelopmentAndNdaAcceptanceMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">slgl:PellepharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="slgl:MilestonePaymentsAxis">slgl:DevelopmentAndNdaAcceptanceMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="C_20240301to20240331_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">slgl:PellepharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="slgl:MilestonePaymentsAxis">slgl:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_20231231_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slgl:OtherForeignGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20231231_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20240630_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20240630_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slgl:OtherForeignGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20230601to20230606_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithSearchlightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithSearchlightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithSearchlightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoAndEpsolayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithGaldermaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slgl:TwyneoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slgl:LicenseAgreementsWithBeimeiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001684693</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:GeneralPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <unit id="Agreement">
        <measure>slgl:Agreement</measure>
    </unit>
    <unit id="Candidate">
        <measure>slgl:Candidate</measure>
    </unit>
    <unit id="ILSPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Program">
        <measure>slgl:Program</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20240101to20240630" id="FFact_322">0001684693</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_20240101to20240630" id="FFact_323">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="C_20240101to20240630" id="FFact_324">true</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="C_20240101to20240630" id="FFact_326">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20240101to20240630"
      id="Fdei_DocumentFiscalPeriodFocus20220718125411444">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="C_20240101to20240630" id="F20220718063032973_0">6-K/A</dei:DocumentType>
    <dei:DocumentFiscalYearFocus contextRef="C_20240101to20240630" id="F20220718063032973_1">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityRegistrantName contextRef="C_20240101to20240630" id="F20220718063032974_2">SOL-GEL TECHNOLOGIES LTD.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="C_20240101to20240630" id="F20220718063032974_3">7 Golda Meir Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_20240101to20240630" id="F20220718063032974_4">Ness Ziona</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="C_20240101to20240630" id="F20220718063032975_5">7403650</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="C_20240101to20240630" id="F20220718063032975_6">IL</dei:EntityAddressCountry>
    <dei:AmendmentDescription
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240819085853731">



                      Sol-Gel Technologies Ltd. (the &#x201c;Company&#x201d;) is amending its Report on Form 6-K furnished to the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;) on August 16, 2024 (the &#x201c;Original Form 6-K&#x201d;) solely to (i) revise Exhibit 99.1 of the Original 6-K to correct typographical errors; and&#160;

                    (ii) revise the incorporation by reference language included in the Explanatory Note of the Form 6-K. Other than as set forth below, the information contained in the Original Form 6-K remains unchanged.
                    &#160;

                      The press release attached hereto as Exhibit 99.1 was reissued on August 17, 2024 to correct typographical errors.

                    &#160;
                    The incorporation by reference paragraph in the Original Form 6-K is hereby amended and restated as follows:&#160;





                              Exhibit 99.1



                                Press release dated August 17, 2024 (reissued)






                    &#160;





                              Exhibit 99.2


                              Unaudited condensed consolidated financial statements as of June 30, 2024 and for the three and six months then ended.









                        Exhibit 99.1 (other than the paragraph immediately preceding the heading &#x201c;Financial Results for the Second Quarter 2024&#x201d;) and 99.2 are hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No 333-264190).




              </dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_1"
      unitRef="usd">7513000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_2"
      unitRef="usd">11549000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_3"
      unitRef="usd">10012000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_4"
      unitRef="usd">4012000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_5"
      unitRef="usd">20471000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_6"
      unitRef="usd">14912000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20240812183418752"
      unitRef="usd">377000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20240812183423585"
      unitRef="usd">6059000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_9"
      unitRef="usd">2794000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_10"
      unitRef="usd">1750000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_11"
      unitRef="usd">41167000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_12"
      unitRef="usd">38282000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_13"
      unitRef="usd">1284000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_14"
      unitRef="usd">1273000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_15"
      unitRef="usd">434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_16"
      unitRef="usd">305000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_17"
      unitRef="usd">1721000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_18"
      unitRef="usd">1507000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230731160858778_Fact_17"
      unitRef="usd">55000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230731160858778_Fact_18"
      unitRef="usd">34000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_19"
      unitRef="usd">626000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_20"
      unitRef="usd">604000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_21"
      unitRef="usd">4120000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_22"
      unitRef="usd">3723000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_23"
      unitRef="usd">45287000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_24"
      unitRef="usd">42005000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_25"
      unitRef="usd">154000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_26"
      unitRef="usd">679000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_27"
      unitRef="usd">3921000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_28"
      unitRef="usd">4147000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_29"
      unitRef="usd">447000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_30"
      unitRef="usd">376000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_31"
      unitRef="usd">4522000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_32"
      unitRef="usd">5202000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_33"
      unitRef="usd">1206000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_34"
      unitRef="usd">1018000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_35"
      unitRef="usd">915000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_36"
      unitRef="usd">883000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_37"
      unitRef="usd">2121000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_38"
      unitRef="usd">1901000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_39"
      unitRef="usd">6643000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_40"
      unitRef="usd">7103000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20220721225320013"
      unitRef="ILSPerShare">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20240630"
      decimals="INF"
      id="FFact_42"
      unitRef="ILSPerShare">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20220721225341350"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20240630"
      decimals="INF"
      id="FFact_44"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20240630"
      decimals="INF"
      id="Fxbrl_20240812183220415"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240630"
      decimals="INF"
      id="Fxbrl_20240812183204882"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20231231"
      decimals="INF"
      id="Fxbrl_20220721225424766"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231"
      decimals="INF"
      id="FFact_46"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_49"
      unitRef="usd">774000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_50"
      unitRef="usd">774000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_51"
      unitRef="usd">258173000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_52"
      unitRef="usd">258799000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_53"
      unitRef="usd">-220303000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_54"
      unitRef="usd">-224671000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_55"
      unitRef="usd">38644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_56"
      unitRef="usd">34902000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_57"
      unitRef="usd">45287000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_58"
      unitRef="usd">42005000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721161146624"
      unitRef="usd">894000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721161139299"
      unitRef="usd">5899000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20220721161133008"
      unitRef="usd">594000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="Fxbrl_20220721161123723"
      unitRef="usd">5433000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_63"
      unitRef="usd">14698000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_64"
      unitRef="usd">7783000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="FFact_65"
      unitRef="usd">5312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="FFact_66"
      unitRef="usd">2438000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_67"
      unitRef="usd">3786000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_68"
      unitRef="usd">3203000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="FFact_69"
      unitRef="usd">1809000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="FFact_70"
      unitRef="usd">1371000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_71"
      unitRef="usd">-17590000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_72"
      unitRef="usd">-5087000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="FFact_73"
      unitRef="usd">-6527000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="FFact_74"
      unitRef="usd">1624000</us-gaap:OperatingIncomeLoss>
    <slgl:FinancialIncomeExpensesNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_75"
      unitRef="usd">899000</slgl:FinancialIncomeExpensesNet>
    <slgl:FinancialIncomeExpensesNet
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_76"
      unitRef="usd">719000</slgl:FinancialIncomeExpensesNet>
    <slgl:FinancialIncomeExpensesNet
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="FFact_77"
      unitRef="usd">557000</slgl:FinancialIncomeExpensesNet>
    <slgl:FinancialIncomeExpensesNet
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="FFact_78"
      unitRef="usd">352000</slgl:FinancialIncomeExpensesNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_79"
      unitRef="usd">-16691000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_80"
      unitRef="usd">-4368000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="FFact_81"
      unitRef="usd">-5970000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="FFact_82"
      unitRef="usd">1976000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220721234223951"
      unitRef="USD_per_Share">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_83"
      unitRef="USD_per_Share">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220721234245557"
      unitRef="USD_per_Share">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="FFact_84"
      unitRef="USD_per_Share">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="Fxbrl_20220721234258686"
      unitRef="USD_per_Share">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="FFact_85"
      unitRef="USD_per_Share">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20240401to20240630"
      decimals="INF"
      id="Fxbrl_20220721234313495"
      unitRef="USD_per_Share">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20240401to20240630"
      decimals="INF"
      id="FFact_86"
      unitRef="USD_per_Share">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20220721234332813"
      unitRef="Shares">26306484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="FFact_87"
      unitRef="Shares">26306484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="Fxbrl_20220721234354066"
      unitRef="Shares">27857620</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240101to20240630"
      decimals="INF"
      id="FFact_88"
      unitRef="Shares">27857620</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="Fxbrl_20220721234405451"
      unitRef="Shares">27660326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="FFact_89"
      unitRef="Shares">27660326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20240401to20240630"
      decimals="INF"
      id="Fxbrl_20220721234419394"
      unitRef="Shares">27857620</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20240401to20240630"
      decimals="INF"
      id="FFact_90"
      unitRef="Shares">27857620</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220802203312766_Fact_121"
      unitRef="Shares">23129469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220802203312766_Fact_122"
      unitRef="usd">638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203312766_Fact_123"
      unitRef="usd">234640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220802203312766_Fact_124"
      unitRef="usd">-193065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220802203312766_Fact_125"
      unitRef="usd">42213000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220802203243985_Fact_126"
      unitRef="usd">-16691000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220802203243985_Fact_127"
      unitRef="usd">-16691000</us-gaap:ProfitLoss>
    <slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731165232354"
      unitRef="Shares">2560000</slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares>
    <slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731165255304"
      unitRef="usd">74000</slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts>
    <slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731165306136"
      unitRef="usd">11468000</slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts>
    <slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731165308803"
      unitRef="usd">11542000</slgl:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731165314251"
      unitRef="Shares">2000000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731165323696"
      unitRef="usd">56000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731165338826"
      unitRef="usd">9944000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731165341127"
      unitRef="usd">10000000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220802203243988_Fact_131"
      unitRef="Shares">116485</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220802203425221"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203243988_Fact_133"
      unitRef="usd">177000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220802203243988_Fact_134"
      unitRef="usd">180000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203243992_Fact_135"
      unitRef="usd">1052000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220802203243992_Fact_136"
      unitRef="usd">1052000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220802203243995_Fact_137"
      unitRef="Shares">27805954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220802203243995_Fact_138"
      unitRef="usd">771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203243995_Fact_139"
      unitRef="usd">257281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220802203243995_Fact_140"
      unitRef="usd">-209756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220802203243995_Fact_141"
      unitRef="usd">48296000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_121"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_122"
      unitRef="usd">774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_123"
      unitRef="usd">258173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_124"
      unitRef="usd">-220303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230731171644280_xbrl_20220802203312766_Fact_125"
      unitRef="usd">38644000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185624392"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185621393"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731162137076_xbrl_20220802203243985_Fact_126"
      unitRef="usd">-4368000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731162137076_xbrl_20220802203243985_Fact_127"
      unitRef="usd">-4368000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185640102"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185635670"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731162201964_xbrl_20220802203243992_Fact_135"
      unitRef="usd">626000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731162201964_xbrl_20220802203243992_Fact_136"
      unitRef="usd">626000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_137"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_138"
      unitRef="usd">774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_139"
      unitRef="usd">258799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_140"
      unitRef="usd">-224671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230731162213898_xbrl_20220802203243995_Fact_141"
      unitRef="usd">34902000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220802203522391_Fact_168"
      unitRef="Shares">25702237</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220802203522391_Fact_169"
      unitRef="usd">712000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203522391_Fact_170"
      unitRef="usd">246678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220802203522391_Fact_171"
      unitRef="usd">-203786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331"
      decimals="-3"
      id="Fxbrl_20220802203522391_Fact_172"
      unitRef="usd">43604000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220802203512165_Fact_173"
      unitRef="usd">-5970000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20220802203512165_Fact_174"
      unitRef="usd">-5970000</us-gaap:ProfitLoss>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731165403635"
      unitRef="Shares">2000000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731165351160"
      unitRef="usd">56000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731165357152"
      unitRef="usd">9944000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731165400531"
      unitRef="usd">10000000</slgl:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731163821363"
      unitRef="Shares">103717</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731163828939"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731163842514"
      unitRef="usd">161000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731163939372"
      unitRef="usd">164000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203512178_Fact_179"
      unitRef="usd">498000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20220802203512178_Fact_180"
      unitRef="usd">498000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220802203512181_Fact_181"
      unitRef="Shares">27805954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220802203512181_Fact_182"
      unitRef="usd">771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220802203512181_Fact_183"
      unitRef="usd">257281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220802203512181_Fact_184"
      unitRef="usd">-209756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220802203512181_Fact_185"
      unitRef="usd">48296000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_168"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_169"
      unitRef="usd">774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_170"
      unitRef="usd">258524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_171"
      unitRef="usd">-226647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240331"
      decimals="-3"
      id="Fxbrl_20230731163727635_xbrl_20220802203522391_Fact_172"
      unitRef="usd">32651000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185914982"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185910830"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731163734539_xbrl_20220802203512165_Fact_173"
      unitRef="usd">1976000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="Fxbrl_20230731163734539_xbrl_20220802203512165_Fact_174"
      unitRef="usd">1976000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185927735"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20240812185923525"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240401to20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731163954949_xbrl_20220802203512178_Fact_179"
      unitRef="usd">275000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="Fxbrl_20230731163954949_xbrl_20220802203512178_Fact_180"
      unitRef="usd">275000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_181"
      unitRef="Shares">27857620</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_182"
      unitRef="usd">774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_183"
      unitRef="usd">258799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_184"
      unitRef="usd">-224671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230731164006260_xbrl_20220802203512181_Fact_185"
      unitRef="usd">34902000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721165859137"
      unitRef="usd">-16691000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721165911882"
      unitRef="usd">-4368000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_188"
      unitRef="usd">185000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240812194344420"
      unitRef="usd">125000</us-gaap:Depreciation>
    <slgl:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_190"
      unitRef="usd">-9000</slgl:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement>
    <slgl:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_191"
      unitRef="usd">10000</slgl:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_192"
      unitRef="usd">1052000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_193"
      unitRef="usd">626000</us-gaap:ShareBasedCompensation>
    <slgl:FinanceExpensesNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731170354691"
      unitRef="usd">-1000</slgl:FinanceExpensesNet>
    <slgl:FinanceExpensesNet
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721165945170"
      unitRef="usd">-2000</slgl:FinanceExpensesNet>
    <slgl:NetChangesInOperatingLeases
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_196"
      unitRef="usd">36000</slgl:NetChangesInOperatingLeases>
    <slgl:NetChangesInOperatingLeases
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_197"
      unitRef="usd">45000</slgl:NetChangesInOperatingLeases>
    <slgl:ChangesInFairValueOfMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721165926561"
      unitRef="usd">66000</slgl:ChangesInFairValueOfMarketableSecurities>
    <slgl:ChangesInFairValueOfMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731170401785"
      unitRef="usd">87000</slgl:ChangesInFairValueOfMarketableSecurities>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_200"
      unitRef="usd">-5653000</us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_201"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240812194236884_Fact_200"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240812194236884_Fact_201"
      unitRef="usd">5682000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_202"
      unitRef="usd">1063000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_203"
      unitRef="usd">-1065000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721170010362"
      unitRef="usd">2623000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721170023162"
      unitRef="usd">751000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_206"
      unitRef="usd">-8335000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_207"
      unitRef="usd">-7627000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_208"
      unitRef="usd">94000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_209"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240812194936354_Fact_208"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240812194936354_Fact_209"
      unitRef="usd">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_210"
      unitRef="usd">17114000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_211"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_212"
      unitRef="usd">7995000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_213"
      unitRef="usd">5646000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <slgl:ProceedsFromShortTermDeposits
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721163559362"
      unitRef="usd">-1000000</slgl:ProceedsFromShortTermDeposits>
    <slgl:ProceedsFromShortTermDeposits
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731170423185"
      unitRef="usd">6000000</slgl:ProceedsFromShortTermDeposits>
    <slgl:ProceedsFromLongTermDeposits
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721163643329"
      unitRef="usd">12000</slgl:ProceedsFromLongTermDeposits>
    <slgl:ProceedsFromLongTermDeposits
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721163650650"
      unitRef="usd">821000</slgl:ProceedsFromLongTermDeposits>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731170434560"
      unitRef="usd">-10201000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721170501016"
      unitRef="usd">12471000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_220"
      unitRef="usd">180000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_221"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731170558344_Fact_220"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731170558344_Fact_221"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731170600336_Fact_220"
      unitRef="usd">11542000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731170600336_Fact_221"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_224"
      unitRef="usd">21722000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_225"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220721165808265"
      unitRef="usd">1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_227"
      unitRef="usd">2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731170445409"
      unitRef="usd">3187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721165838498"
      unitRef="usd">4846000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220721180304367"
      unitRef="usd">13598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_231"
      unitRef="usd">7863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_232"
      unitRef="usd">16785000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_233"
      unitRef="usd">12709000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_234"
      unitRef="usd">15618000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_235"
      unitRef="usd">11549000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_236"
      unitRef="usd">1167000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_237"
      unitRef="usd">1160000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="FFact_238"
      unitRef="usd">16785000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_239"
      unitRef="usd">12709000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <slgl:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731163016874"
      unitRef="usd">190000</slgl:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities>
    <slgl:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20230731163032579"
      unitRef="usd">0</slgl:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="FFact_240"
      unitRef="usd">590000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_241"
      unitRef="usd">1121000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:NatureOfOperations
      contextRef="C_20240101to20240630"
      id="Fxbrl_20230803164645178">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 1 - NATURE OF OPERATIONS&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sol-Gel Technologies Ltd. (collectively with its U.S. subsidiary, the Company) is an Israeli Company incorporated in 1997.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is an innovative dermatology company with a successful track record of two NDA approvals and advanced orphan drugs pipeline. The Company has two approved drugs: (i) Twyneo&#xae;, which was developed for the treatment of acne vulgaris and received marketing authorization by the U.S. Food and Durg Administration (the "FDA") on July 27, 2021 and (ii) Epsolay&#xae;, a treatment for subtype II rosacea that received marketing authorization by the FDA on April 25, 2022. In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of Twyneo&#xae; and Epsolay&#xae; in the United States, see Note 6a. On April 14, 2022, the Company announced that Twyneo&#xae; is available for purchase by consumers who obtain a prescription from their physician. On June 2, 2022, the Company announced that Epsolay&#xae; is available for purchase by consumers who obtain a prescription from their physician. In addition to the novel products, the Company&#x2019;s products included the approved generic products Acyclovir, Ivermectin and other generic product candidates. In November 2021, the Company entered into an agreement with Padagis, to sell its rights in relation to ten generic collaborative agreements between the parties, including the agreements for the two aforementioned approved generic drug products. Under the new agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, see note 5c.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 27, 2023 the Company entered into an asset purchase agreement ("APA") with PellePharm, Inc. (hereafter-&#x201c;PellePharm&#x201d;), pursuant to which the Company agreed to purchase all of the assets related to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome (such compound designated as investigational compound SGT-610). On January 30, 2023, upon closing of the transaction, the Company paid an upfront payment (hereafter- "upfront payment") of $4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date. In addition, the Company will be required to pay total development and NDA acceptance milestones of up to $6 million, and up to $64 million in commercial milestones which amount increases to $89 million when sales exceed $500 million as well as single digit royalties which increase to double digit royalties when sales exceed $500 million. During March 2024 the first developement milestone event has completed and the Company recorded an amount of $500 as clinical expenses.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The upfront payment and the additional development milestone payments under the APA represent payments for research and development in-process ("IPR&amp;amp;D") acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use. Accordingly, such payments were expensed as incurred and recognized as research and development expenses.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 15, 2024, the Company and Shenzhen Beimei Pharmaceutical Co. Ltd. ("Beimei"), entered into an asset purchase agreement, For further details, see Note 6c.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regards to marketing, regulatory affairs and business development relating to its products and technology in the U.S.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border and launched a series of attacks against Israel. Following these attacks, Israel&#x2019;s security cabinet declared war against Hamas and initiated a military campaign. As of the issuance date of this report, there was no material impact on the Company's ongoing operations in Israel. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employee&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Since incorporation through June 30, 2024, the Company has an accumulated deficit of $224,671 and its activities have been funded mainly by its shareholders, collaboration revenues and license agreements, see also Notes 5 and 6. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of June 30, 2024 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:NatureOfOperations>
    <slgl:DescriptionOfUpfrontPayment
      contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      id="Fxbrl_20230809125938262">$4 million to PellePharm. The Company is required to pay an additional amount of $0.7 million, subject to the terms as defined in the APA, 15 months from the closing date.</slgl:DescriptionOfUpfrontPayment>
    <slgl:SalesMilestonePayments
      contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglDevelopmentAndNdaAcceptanceMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      decimals="-6"
      id="Fxbrl_20230809125946725"
      unitRef="usd">6000000</slgl:SalesMilestonePayments>
    <slgl:SalesMilestonePayments
      contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      decimals="-6"
      id="Fxbrl_20230809125953294"
      unitRef="usd">64000000</slgl:SalesMilestonePayments>
    <slgl:IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million
      contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      decimals="-6"
      id="Fxbrl_20230809130002318"
      unitRef="usd">89000000</slgl:IncreaseInSalesMilestoneAmountDueToSalesExceedDollar500Million>
    <us-gaap:Revenues
      contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      decimals="-6"
      id="Fxbrl_20240812200107085"
      unitRef="usd">500000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230130to20230130_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      decimals="-6"
      id="Fxbrl_20240812200129542"
      unitRef="usd">500000000</us-gaap:Revenues>
    <slgl:ClinicalExpenses
      contextRef="C_20240301to20240331_slglMilestonePaymentsAxis_slglCommercialMilestonesMember_usgaapAssetAcquisitionAxis_slglPellepharmMember_usgaapTypeOfArrangementAxis_slglAssetPurchaseAgreementMember"
      decimals="-3"
      id="Fxbrl_20240812200141030"
      unitRef="usd">500000</slgl:ClinicalExpenses>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_242"
      unitRef="usd">-224671000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815124913284">
      &lt;div&gt;
        &lt;div style="text-align:justify;text-indent:-7.1pt;margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 2 &#x2013; SIGNIFICANT ACCOUNTING POLICIES:&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:18pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#x2019;s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:35.7pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Earnings (Loss) per share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;

        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
        &lt;div style="line-height:1.25;font-weight:400;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;div&gt;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-weight:400;font-family:'Times New Roman',Times,serif"&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="line-height:1.25"&gt;

                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="width:18pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="width:auto;vertical-align:top"&gt;
                          &lt;div&gt;
                            &lt;div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&#160;&lt;div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures&#x201d;. This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;

              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815124928826">
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;
              &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                  &lt;tr&gt;
                    &lt;td style="width:18pt"&gt;&#160;&lt;/td&gt;
                    &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt"&gt;
                      &lt;div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/div&gt;
                      &lt;div style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="margin-top:0pt;margin-bottom:0pt"&gt;The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#x2019;s consolidated financial position as of June 30, 2024, the consolidated results of operations and the statements of changes in shareholders' equity for the six month periods ended June 30, 2024 and 2023 and the statements of cash flows for the six month period ended June 30, 2024 and 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25;text-align:justify"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The consolidated results for the six month period ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:35.7pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2023. The comparative balance sheet at December 31, 2023 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815124937379">
          &lt;div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span style="font-weight:bold"&gt;Earnings (Loss) per share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Basic earnings (loss) per share is computed on the basis of the net earnings (loss) for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is based upon the weighted average number of ordinary shares and of potential ordinary shares outstanding when dilutive. Potential ordinary shares include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The calculation of diluted earnings per share, does not include 6,501,769 options and warrants for the three months ended June 30, 2024 as they are out of the money and therefore, their effect would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The calculation of diluted loss per share does not include 6,993,858 options and warrants for the six months ended June 30, 2024 and 5,961,999 and 7,120,463 options and warrants for the six and the three months ended June 30, 2023, respectively, because the effect would be anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240401to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230809130130036"
      unitRef="Shares">6501769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20240101to20240630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230809130146333"
      unitRef="Shares">6993858</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20240812132032517"
      unitRef="Shares">5961999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230401to20230630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20240812132039605"
      unitRef="Shares">7120463</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815124948619">
                  &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                      &lt;tr&gt;
                        &lt;td style="width:18pt"&gt;&#160;&lt;/td&gt;
                        &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                        &lt;td style="width:auto;vertical-align:top"&gt;
                          &lt;div&gt;
                            &lt;div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&#160;&lt;div style="text-align:justify;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures&#x201d;. This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20230803170227615">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 3&#x2009;-&#x2009;MARKETABLE SECURITIES:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the Company&#x2019;s marketable securities for the indicated periods:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

              &lt;div&gt;
                &lt;div style="margin-left:36pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2 securities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S government and agency bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other foreign government bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Corporate bonds*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* Investments in Corporate bonds rated A or higher.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;

            &lt;div style="margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The table below sets forth a summary of the changes in the fair value of the Company&#x2019;s marketable securities for the indicated periods:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="margin-right:35.45pt;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt"&gt;

                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketable securities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ended June 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,678&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sale or maturity&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value during the period&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at end of the period&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;&lt;/div&gt;
            &lt;div style="text-align:justify;text-indent:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2024, the Company&#x2019;s debt securities had the following maturity dates:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt"&gt;

                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Market value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Due within one year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates. In addition, due to the short-term nature and/or low-risk nature of the Company's cash and cash equivalents, restricted cash equivalents, accounts receivable, accounts payable and other payables , their carrying amounts approximates their fair value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240813000956692">
              &lt;div&gt;
                &lt;div style="margin-left:36pt"&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-left:9pt;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2 securities:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;U.S government and agency bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other foreign government bonds&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Corporate bonds*&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;* Investments in Corporate bonds rated A or higher.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/div&gt;
            </us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="FFact_251"
      unitRef="usd">2583000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630_usgaapInvestmentTypeAxis_usgaapUSGovernmentCorporationsAndAgenciesSecuritiesMember"
      decimals="-3"
      id="FFact_252"
      unitRef="usd">1612000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember"
      decimals="-3"
      id="FFact_255"
      unitRef="usd">1946000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630_usgaapInvestmentTypeAxis_slglOtherForeignGovernmentBondsMember"
      decimals="-3"
      id="Fxbrl_20220721171136582"
      unitRef="usd">1974000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember"
      decimals="-3"
      id="FFact_257"
      unitRef="usd">15942000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630_usgaapInvestmentTypeAxis_usgaapAllOtherCorporateBondsMember"
      decimals="-3"
      id="FFact_258"
      unitRef="usd">11326000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="Fxbrl_20230731231159479"
      unitRef="usd">20471000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="Fxbrl_20230731231211104"
      unitRef="usd">14912000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20230801011136317">
                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketable securities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ended June 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:top;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;8,678&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Additions&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sale or maturity&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                          &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Changes in fair value during the period&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at end of the period&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;20,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                  &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/div&gt;
              </us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_262"
      unitRef="usd">8678000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_263"
      unitRef="usd">20471000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_264"
      unitRef="usd">23164000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_265"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="FFact_266"
      unitRef="usd">11807000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="FFact_267"
      unitRef="usd">5646000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="C_20230101to20231231"
      decimals="-3"
      id="Fxbrl_20230731163411098"
      unitRef="usd">-436000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:IncreaseDecreaseInTradingSecurities
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20220721232906325"
      unitRef="usd">87000</us-gaap:IncreaseDecreaseInTradingSecurities>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20231231"
      decimals="-3"
      id="FFact_270"
      unitRef="usd">20471000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_271"
      unitRef="usd">14912000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20230801011321820">
                &lt;div&gt;
                  &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Market value&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;vertical-align:bottom"&gt;
                          &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="1" style="vertical-align:middle;padding-left:9pt;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="text-align:justify;text-indent:-2.5pt;margin-right:7.1pt;margin-left:20.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Due within one year&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                          &lt;div style="line-height:1.25"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                      &lt;/tr&gt;

                  &lt;/table&gt;
                &lt;/div&gt;
              </us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_20240630"
      decimals="-3"
      id="FFact_273"
      unitRef="usd">14912000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815130102404">
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 4&#x2009;-&#x2009; REVENUE:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-right:35.45pt;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the Company&#x2019;s revenues for the indicated periods:&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;margin-left:36pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Three months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Royalties revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sale of IP and license revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Support services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815130132988">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Six months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Three months ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman',Times,serif;text-align:center"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;font-weight:bold;text-indent:1pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Royalties revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sale of IP and license revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Support services&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;width:52%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="text-indent:-14.2pt;margin-left:33.9pt;line-height:1.25;color:rgb(0, 0, 0)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;894&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;font-family:'Times New Roman',Times,serif;vertical-align:bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember"
      decimals="-3"
      id="Fxbrl_20240812124626943"
      unitRef="usd">514000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember"
      decimals="-3"
      id="Fxbrl_20240812124633429"
      unitRef="usd">1056000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230401to20230630_srtProductOrServiceAxis_usgaapRoyaltyMember"
      decimals="-3"
      id="Fxbrl_20240812124802214"
      unitRef="usd">214000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240401to20240630_srtProductOrServiceAxis_usgaapRoyaltyMember"
      decimals="-3"
      id="Fxbrl_20240812124816598"
      unitRef="usd">612000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630_srtProductOrServiceAxis_usgaapLicenseMember"
      decimals="-3"
      id="Fxbrl_20240812124725174"
      unitRef="usd">380000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_usgaapLicenseMember"
      decimals="-3"
      id="Fxbrl_20240812124648933"
      unitRef="usd">4800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230401to20230630_srtProductOrServiceAxis_usgaapLicenseMember"
      decimals="-3"
      id="Fxbrl_20240812124805214"
      unitRef="usd">380000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240401to20240630_srtProductOrServiceAxis_usgaapLicenseMember"
      decimals="-3"
      id="Fxbrl_20240812124821702"
      unitRef="usd">4800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630_srtProductOrServiceAxis_usgaapServiceMember"
      decimals="-3"
      id="Fxbrl_20240815130928154_xbrl_20240812124725174"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_usgaapServiceMember"
      decimals="-3"
      id="Fxbrl_20240815130928154_xbrl_20240812124648933"
      unitRef="usd">43000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230401to20230630_srtProductOrServiceAxis_usgaapServiceMember"
      decimals="-3"
      id="Fxbrl_20240815130928154_xbrl_20240812124805214"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240401to20240630_srtProductOrServiceAxis_usgaapServiceMember"
      decimals="-3"
      id="Fxbrl_20240815130928154_xbrl_20240812124821702"
      unitRef="usd">21000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20240812124719390"
      unitRef="usd">894000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240812124705933"
      unitRef="usd">5899000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20240812124809576"
      unitRef="usd">594000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20240401to20240630"
      decimals="-3"
      id="Fxbrl_20240812124826302"
      unitRef="usd">5433000</us-gaap:Revenues>
    <slgl:CollaborationAgreementsTextBlock contextRef="C_20240101to20240630" id="FFact_281">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 5 - COLLABORATION AGREEMENTS:&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:20pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                &lt;div&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material.&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:20pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In 2016 through 2020, the Company entered into several collaboration agreements mainly with one third party (the "Partner") for the development, manufacturing and commercialization of several product candidates (including an agreement assumed by the Company in August 2018, following the transfer of an in-process research and development product candidate from a related party).&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:20pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top"&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the agreements, the Partner is obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the products and prepare and file an abbreviated new drug application ("ANDA"), with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Upon FDA approval, the Partner has exclusive rights and is required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to a share of the Partner's gross profits related to the sale of the products, as such term is defined in each of the agreements.&lt;/span&gt;&lt;/div&gt;
                &lt;div&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:38pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;These Agreements are considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company recognizes collaboration revenues when the related sales occur.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:38pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In November 2021, the Company entered into a new agreement ("New Agreement") with the Partner, to sell its rights to the Partner in relation to ten generic collaborative agreements between the parties in consideration of $21,500 which was paid over 24 months. Under the New Agreement, the Company has retained collaboration rights to two generic programs related to four generic drug candidates, and is no longer entitled to receive its share in profit as detailed above.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:38pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In addition, the Company ceased paying any outstanding and future operational costs related to these collaborative agreements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:38pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:38pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In August 15, 2024 the Company entered into a Termination Agreement with the Partner, For further details, see note 9.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </slgl:CollaborationAgreementsTextBlock>
    <slgl:RoyaltiesMaturity
      contextRef="C_20070101to20071231_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20220721155340132">2016</slgl:RoyaltiesMaturity>
    <slgl:RoyaltiesMaturity
      contextRef="C_20070101to20071231_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20220721155348640">2024</slgl:RoyaltiesMaturity>
    <slgl:NumberOfGenericCollaborativeAgreementsToSellRights
      contextRef="C_20211101"
      decimals="0"
      id="Fxbrl_20230809130555941"
      unitRef="Agreement">10</slgl:NumberOfGenericCollaborativeAgreementsToSellRights>
    <slgl:ExpectedRevenueReceivableOverTwentyFourMonths
      contextRef="C_20211101"
      decimals="-3"
      id="Fxbrl_20220721163242015"
      unitRef="usd">21500000</slgl:ExpectedRevenueReceivableOverTwentyFourMonths>
    <slgl:NumberOfGenericProgramsRetainedForCollaborationRights
      contextRef="C_20211101"
      decimals="0"
      id="Fxbrl_20230809130607525"
      unitRef="Program">2</slgl:NumberOfGenericProgramsRetainedForCollaborationRights>
    <slgl:NumberOfGenericDrugCandidates
      contextRef="C_20211101"
      decimals="0"
      id="Fxbrl_20230809130616870"
      unitRef="Candidate">4</slgl:NumberOfGenericDrugCandidates>
    <slgl:LicenseAgreementsTextBlock contextRef="C_20240101to20240630" id="FFact_285">
    &lt;div&gt;
      &lt;div style="margin-left:0px"&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="text-align:justify;line-height:1.25;margin-top:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE&lt;/span&gt;&#160;&lt;span style="font-weight:bold"&gt;6 - AGREEMENTS:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="vertical-align:top;width:18pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In June 2021, the Company entered into two exclusive license agreements with Galderma for the commercialization of two of the Company's most advanced investigational drug products (Twyneo&#xae; and Epsolay&#xae;) in the United States. The Company was entitled to amounts of up to $7.5 million per product in upfront payments and regulatory approval milestone payments assuming 2021 approval of each respective product. The Company is also eligible to receive tiered double-digit royalties ranging from mid-teen to high-teen percentage of net sales as well as up to $9 million in sales milestone payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;According to the agreement, the Company has an option to regain commercialization rights five years following first commercialization.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 14, 2022, the Company announced that Twyneo&#xae; is available for purchase by consumers who obtain a prescription from their physician, See note 1. On June 2, 2022, the Company announced that Epsolay&#xae; is available for purchase by consumers who obtain a prescription from their physician, See also note 1.&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;The Company recognized $723 and $466 during the six-month periods ended June 30, 2024 and 2023, respectively, as royalty revenue in respect of the license agreement for both products.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On June 6, 2023, the Company and Searchlight Pharma Inc. (&#x201c;Searchlight&#x201d;), a private Canadian specialty pharmaceutical company, signed on an exclusive license agreements for Twyneo&#xae; and Epsolay&#xae; for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada, with support from the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the agreement, the Company will receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined. In addition, the Company will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt"&gt;&#160;&lt;/div&gt;
                &lt;div&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In June 2023, the Company received $500 as an upfront payment in connection with the license agreement and related support provided to Searchlight for obtaining the regulatory approval in the Canadian market. The Company is also required to support Searchlight during such period if needed based on agreed upon rates. The Company has identified two performance obligations in the license agreement as follows: (i) the license to market the products in Canada; and (ii) continuing support during the regulatory approval process.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six-month period ended June 30, 2024, the Company recognized a total amount of $42 for continuing support. The remaining outstanding contract liability in respect of the support services, is, as of June 30, 2024 $78 .&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                    &lt;tr&gt;
                      &lt;td style="width:36pt"&gt;&#160;&lt;/td&gt;
                      &lt;td style="width:18pt;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                      &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 15, 2024, the Company and Beimei, a private Chinese company, signed an agreement for the purchase and license by Beimei of certain rights in the intellectual property ("IP") related to Twyneo, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the agreement, Beimei will purchase and license from the Company the IP in these territories. The Company is also required to support Beimei to a certain extent during the period until obtaining regulatory approval. The Company may provide further support services to Beimei, if needed, based on agreed upon rates. In return, Sol-Gel is to receive payments of up to $10 million (including amounts contingent on achieving certain milestones) and up to $5 million as royalty payments on net sales.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has identified multiple performance obligations in the agreement. Revenue from sale and license of IP is recognized at a point in time, upon transfer of control over the license and the IP to Beimei. Support services are recognized over time as the services are performed.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt;font-family:'Times New Roman',Times,serif"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the six-month period ended June 30, 2024, the Company recognized revenue for a total amount of $4.8 million. This amount does not include variable consideration that was determined to be constrained (not probable that would not result in a significant reversal). In addition, the Company recorded $200 as a contract liability in respect of the support services.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                    &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;div style="text-align:justify;line-height:1.25;margin-left:54pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In July 2024, the Company received $2 million as the first payment in connection with the agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </slgl:LicenseAgreementsTextBlock>
    <slgl:RegulatoryApprovalMilestonePaymentsReceived
      contextRef="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"
      decimals="-5"
      id="Fxbrl_20230803181242436"
      unitRef="usd">7500000</slgl:RegulatoryApprovalMilestonePaymentsReceived>
    <slgl:SalesMilestonePayments
      contextRef="C_20210601to20210630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"
      decimals="-6"
      id="Fxbrl_20230803181903246"
      unitRef="usd">9000000</slgl:SalesMilestonePayments>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"
      decimals="-3"
      id="Fxbrl_20230803181330296"
      unitRef="usd">723000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithGaldermaMember"
      decimals="-3"
      id="Fxbrl_20240812112622375"
      unitRef="usd">466000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <slgl:UpfrontPaymentsReceived
      contextRef="C_20230601to20230606_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"
      decimals="-6"
      id="Fxbrl_20230803181302644"
      unitRef="usd">11000000</slgl:UpfrontPaymentsReceived>
    <slgl:UpfrontPaymentsReceived
      contextRef="C_20230101to20230630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"
      decimals="-3"
      id="Fxbrl_20230808134752021"
      unitRef="usd">500000</slgl:UpfrontPaymentsReceived>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"
      decimals="-3"
      id="Fxbrl_20230808134758188"
      unitRef="usd">42000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <slgl:ContractLiability
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoAndEpsolayMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithSearchlightMember"
      decimals="-3"
      id="Fxbrl_20230808134805084"
      unitRef="usd">78000</slgl:ContractLiability>
    <slgl:UpfrontPaymentsReceived
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember"
      decimals="-6"
      id="Fxbrl_20240812113218328"
      unitRef="usd">10000000</slgl:UpfrontPaymentsReceived>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember"
      decimals="-6"
      id="Fxbrl_20240812113426144"
      unitRef="usd">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <slgl:EstimatedVariableConsiderationRevenue
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember"
      decimals="-5"
      id="Fxbrl_20240812113646895"
      unitRef="usd">4800000</slgl:EstimatedVariableConsiderationRevenue>
    <slgl:ContractLiability
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember"
      decimals="-3"
      id="Fxbrl_20240812113656167"
      unitRef="usd">200000</slgl:ContractLiability>
    <slgl:SalesMilestonePayments
      contextRef="C_20240101to20240630_srtProductOrServiceAxis_slglTwyneoMember_usgaapTypeOfArrangementAxis_slglLicenseAgreementsWithBeimeiMember"
      decimals="-6"
      id="Fxbrl_20240812113617559"
      unitRef="usd">2000000</slgl:SalesMilestonePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20230731205816709">
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE&lt;/span&gt;&#160;&lt;span style="font-weight:bold"&gt;7 - SHARE BASED COMPENSATION:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:35.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six months ended June 30, 2024, the Company granted 300,000 options to Directors as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:35.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2024, the board of directors approved and recommended the Company's shareholders to approve a grant of 300,000 options to the Company's Directors to purchase ordinary shares at an exercise price of $1.2 per share. The Company's shareholders approved the grant in February 28, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="margin-left:35.45pt;line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:35.45pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The options vest over a period of 3 years; one third of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following two years. The options expire on the tenth anniversary of their grant date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="text-align:justify;margin-left:36pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of options granted in 2024 was $207. The underlying data used for computing the fair value of the options are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
          &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:36pt"&gt;

              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Value of one ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;text-indent:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20240101to20240630_srtTitleOfIndividualAxis_srtDirectorMember"
      decimals="INF"
      id="Fxbrl_20230803174227564"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20240101to20240131_srtTitleOfIndividualAxis_srtDirectorMember"
      decimals="INF"
      id="Fxbrl_20230803174236536"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20240131_srtTitleOfIndividualAxis_srtDirectorMember"
      decimals="1"
      id="Fxbrl_20230803174245540"
      unitRef="USD_per_Share">1.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20240101to20240131_srtTitleOfIndividualAxis_srtDirectorMember"
      id="Fxbrl_20230803174304312">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20240101to20240630"
      decimals="-3"
      id="Fxbrl_20240815132733772"
      unitRef="usd">207000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20230803174142717">
              &lt;div&gt;
                &lt;table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"&gt;

                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Value of one ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;width:88%;padding-bottom:4px;vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"&gt;
                        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                    &lt;/tr&gt;
                    &lt;tr&gt;
                      &lt;td style="vertical-align:top;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                      &lt;td colspan="2" style="vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"&gt;
                        &lt;div style="text-align:center;text-indent:20pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                      &lt;/td&gt;
                      &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                    &lt;/tr&gt;

                &lt;/table&gt;
              &lt;/div&gt;
            </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_20240630"
      decimals="1"
      id="Fxbrl_20230803174055527_xbrl_20230731204457117"
      unitRef="USD_per_Share">1.2</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20240101to20240630"
      decimals="2"
      id="Fxbrl_20230803174055529_xbrl_20230731204503117"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20240101to20240630"
      decimals="2"
      id="Fxbrl_20230803174055532_xbrl_20230731204509677"
      unitRef="pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20240101to20240630"
      decimals="3"
      id="Fxbrl_20230803174055534_xbrl_20230731204516412"
      unitRef="pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240812212059837">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20240101to20240630" id="FFact_318">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 8 - RELATED PARTIES:&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:18pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="width:18pt"&gt;&#160;&lt;/td&gt;
                  &lt;td style="width:18pt;vertical-align:top;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="width:auto;vertical-align:top;text-align:justify"&gt;
                    &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As to options granted to directors and executive officers, see note 7.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20240101to20240630"
      id="Fxbrl_20240815133358684">
            &lt;div&gt;
              &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE 9 &lt;span style="font-weight:bold"&gt;&#x2013;&lt;/span&gt; SUBSEQUENT EVENT&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
              &lt;div style="text-align:justify;margin-left:38pt;line-height:1.25;font-family:'Palatino Linotype', serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;In August 15, 2024, the Company entered into a &lt;/span&gt;&lt;span&gt;Termination Agreement &lt;/span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;("the Agreement") with the Partner. The purpose of the Agreement is to terminate the Development, Manufacturing and Commercialization Agreement dated June 28, 2020, and to sell its rights to the Partner in relation to Roflumilast cream and Roflumilast foam. As &lt;/span&gt;&lt;span&gt;consideration &lt;/span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;for the Agreement between the parties, the Partner will pay to the Company $4,250, which will paid &lt;/span&gt;&lt;span&gt;in quarterly installments &lt;/span&gt;&lt;span style="color:rgb(0, 0, 0)"&gt;during 24 months. In addition, in the end of each quarter for five years as of the Launch Date (the date of first commercial sale of the Product in the Territory by the Partner or its Affiliates pursuant to the ANDA), the Partner shall pay Sol-Gel 2% royalties of the Partner&#x2019;s Gross Profits for that Product.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="-3"
      id="Fxbrl_20240815134553794"
      unitRef="usd">4250000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <slgl:RoyaltiesPercentage
      contextRef="C_20240815to20240815_usgaapPartnerTypeOfPartnersCapitalAccountAxis_usgaapGeneralPartnerMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="2"
      id="Fxbrl_20240815134600435"
      unitRef="pure">0.02</slgl:RoyaltiesPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
